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Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
ABSTRACT
Erythrina cristagalli lectin is a galactose-specific legume lectin that specifically 
recognises dorsal root ganglia (neurons involved in the sensation of pain). Botulinum 
neurotoxin A, the causative agent of botulism, induces flaccid paralysis by inhibiting the 
release of acetylcholine at the neuromuscular junction. Erythrina cristagalli lectin can 
be used to retarget the potent activity of fragments of botulinum neurotoxin A to dorsal 
root ganglia. Conjugates composed of Erythrina cristagalli lectin chemically coupled to 
non-toxic fragments of botulinum neurotoxin A have potential therapeutic utility in the 
treatment of chronic pain syndromes. It was anticipated that structural analysis of the 
protein components would shed light on their biological function and possibly allow 
rational improvement of the design of the conjugate.
The structure of natively-sourced Erythrina cristagalli lectin was reported in 
2002 in complex with lactose and fucosyllactose (Svensson et al 2002). When this 
report was published, the structure of Erythrina cristagalli lectin was also being 
analysed as part of this investigation. Data had been collected on the crystal structures 
of native and recombinant forms of the lectin, both unliganded and in complex with 
lactose. There are some differences between the published structure and the structure 
of the native lectin determined in this investigation at the amino acid sequence level. 
The tertiary structure of Erythrina cristagalli lectin was confirmed as being homologous 
to the known structures of other legume lectins, although protomers dimerise in a 
noncanonical fashion. Lactose is recognised via the galactose ring and forms a 
network of hydrogen bonds and hydrophobic interactions with combining site residues 
Leu86, Asp89, Tyr106, Gly107, Phe131, Asn133, Ala218 and Gin219. Except for the absence of 
glycosylation from recombinant ECL, there are no differences between the structures of 
native and recombinant forms of the lectin.Since glycosylation has no role in 
dimerisation or carbohydrate recognition, native and recombinant forms of Erythrina 
cristagalli lectin can be considered equivalent.
Two non-toxic fragments of botulinum neurotoxin A were studied -  one active 
and one catalytically inactive. The three-dimensional structures of the toxin fragments 
could not be determined because crystallisation was unsuccessful, so their secondary 
structures were analysed using circular dichroism spectroscopy. The fragments were 
highly similar, in terms of their secondary structures, comprising approximately 33% a- 
helix, 18% p-strand and 31% random coil.
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CHAPTER ONE 
INTRODUCTION
Non-toxic fragments of botulinum toxin A conjugated to Erythrina cristagalli 
lectin are of potential therapeutic use in the treatment of chronic pain syndromes 
(Duggan et al. 2002). In addition to information on the biological activity of these 
conjugates in vitro and in vivo, the structures of the components are of interest as they 
can provide insight into the mechanism of action and might allow the conjugates to be 
specifically redesigned to improve their function.
1.1 SENSATION AND TRANSMISSION OF PAINFUL STIMULI
Nociception, the sensation of pain, is triggered by the stimulation of peripheral 
nerves and is normally associated with tissue damage. Peripheral sensory neurons 
transmit painful stimuli from the site of injury to the central nervous system (CNS). 
These primary sensory neurons (known as nociceptors) can be stimulated by noxious 
stimuli (for example, intense heat or pressure) but not by innocuous stimuli, such as 
gentle warming or light touch (Julius and Basbaum 2001).
There are three main groups of sensory neurons, Ap-, A8- and C-fibres. Ap- 
fibres are myelinated, rapidly conducting neurons with large cell bodies that detect 
innocuous stimuli. A8-fibres are thinly myelinated, rapidly conducting neurons that 
mediate the sensation of rapid, acute, sharp pain. C-fibres are unmyelinated, slow- 
conducting fibres that signal the delayed, more diffuse, dull painful stimuli. In all 
nociceptors, glutamate is the predominant excitatory neurotransmitter (Julius and 
Basbaum 2001), although the peptide neurotransmitters substance P and calcitonin 
gene-related peptide (CGRP) are also involved.
Dorsal root ganglia (DRG) are nociceptive afferents that transmit peripheral 
noxious stimuli to spinal cord neurons at the dorsal horn. Noxious signals, transmitted 
from the DRG by the release of glutamate, substance P and CGRP, are integrated in 
the spinal cord and transferred on to the thalamus before reaching the somatosensory 
cortex where they are recognised as painful stimuli (Riedel and Neeck 2001).
1.1.1 Chronic Pain
Pain is an unpleasant sensation that is normally associated with tissue 
damage. Chronic pain is caused by the continual stimulation of nociceptors in areas of 
tissue damage but persists long after the injury has healed (Ashburn and Staats 1999).
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Common syndromes of chronic pain include myofascial pain, phantom limb pain and 
chronic low back pain. Chronic pain is thought to affect up to 45% of the population and 
is one of the most common reasons why people seek medical attention (Elliott et al. 
1999). Effective treatment involves a number of therapies because the patient’s 
general health is affected: people with chronic pain commonly also suffer depression, 
sleep disturbance and fatigue (Ashburn and Staats 1999). In terms of financial burden, 
chronic pain is an expensive public health problem because of the number of working 
days lost each year and the cost of long-term pharmaceutical treatments.
Several pharmaceuticals are available for the treatment of chronic pain 
although some induce unpleasant side effects and none are entirely effective. Non­
steroidal anti-inflammatory drugs, for example, can cause gastrointestinal irritation and 
ulceration (Allison et al. 1992) as well as renal dysfunction (Clive and Stoff 1984). 
Opioid analgesics, such as morphine, can effectively control chronic pain but their use 
is associated with constipation, sedation, tolerance and addiction (Ashburn and Staats 
1999).
1.2 ERYTHRINA CRISTAGALLI LECTIN
Erythrina cristagalli lectin (ECL) is a galactose-specific lectin isolated from 
seeds of the leguminous coral tree E.cristagalli. ECL is biologically active as a 
heterodimer of approximately 56.8kDa molecular weight, comprising two glycosylated 
subunits of 28kDa and 26kDa (Iglesias et al. 1982). Its biological function in the legume 
is currently unknown, although, in vitro, ECL has been demonstrated to agglutinate 
rabbit and human erythrocytes (Iglesias et al. 1982). ECL is also mitogenic for human 
peripheral blood T lymphocytes and can potentially be used to differentiate between 
cell types according to the oligosaccharides expressed on the cell surfaces. The crystal 
structure of ECL was first reported in 2002 (Svensson et al 2002). This published 
structure (herein referred to as SvenECL) differs from the crystal structures of native 
and recombinant ECL determined in the current investigation, as described and 
discussed in Chapter 3.
1.3 BOTULINUM NEUROTOXIN A
Botulinum neurotoxin A (BoNT/A) is one member of a family of toxins 
produced and secreted by bacteria of the genus Clostridium. The botulinum 
neurotoxins are the most poisonous proteins known to Man. They cause the disease 
botulism, which is characterised by a descending flaccid paralysis resulting from the 
blockade of acetylcholine release at the neuromuscular junction.
15
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BoNT/A is a di-chain molecule in which the light and heavy chains are linked 
by a disulphide bond. The toxin contains three functional domains, each of which is 
involved in the mechanism of action. The binding domain enables the toxin to 
recognise cholinergic neurons and to be internalised into an endosome. The 
translocation domain forms an ion-conducting channel spanning the endosomal 
membrane through which the catalytic domain translocates to the cytosol. The catalytic 
domain has zinc-dependent endopeptidase activity and acts upon the SNARE protein 
SNAP-25, thus preventing the release of neurotransmitter molecules into the synapse.
BoNT/A has been licensed as a biopharmaceutical since 1989 and is currently 
available in two preparations: Botox (Allergan Inc, USA) and Dysport (Speywood 
Pharmaceuticals Ltd, UK). Due to its action in cholinergic neurons, BoNT/A can be 
used to relieve a variety of muscle spasm disorders as well as complaints of the 
autonomic nervous system. In conjunction with relief of spasticity, the use of BoNT/A is 
associated with antinociception, which has led to its proposed utility as a therapeutic 
agent for the treatment of chronic pain syndromes, such as migraine and tension 
headaches (Aoki 2003; Wheeler 1998). In particular, BoNT/A is noted for its longevity 
of action (the induced paralysis lasts for up to 6 months) although there are side effects 
associated with its use and the possibility of developing immunity to the toxin. More 
recently, fragments of BoNT/A and other clostridial neurotoxins have been utilised as 
delivery vehicles for specifically targeting ligands to cholinergic neurons. In addition, 
the cell-binding domains of these toxins has been replaced with cell-binding moieties of 
alternative specificity, enabling the potent activity of the toxin to be selectively 
retargeted to non-native targets and increasing the number of potential therapeutic 
applications of these proteins.
1.4 RETARGETING THE ACTIVITY OF BOTULINUM NEUROTOXIN A
A non-toxic derivative of BoNT/A that lacks the cell-binding domain has been 
prepared (Chaddock et al. 2002). This fragment, known as LHN/A, is unable to bind 
neurons but retains the full endopeptidase activity of the native toxin. Chemically 
coupling LHN/A to non-native cell-binding moieties provides a means of specifically 
retargeting the catalytic activity of BoNT/A to cells other than cholinergic neurons. For 
example, when applied to a variety of cell lines (including those normally resistant to 
the effects of BoNT/A) a conjugate of LHN/A and wheat germ agglutinin was found to 
inhibit secretory responses (Chaddock et al. 2000b). More recently, LHN/A has been 
coupled to ECL, forming the LHN/A-ECL conjugate, which specifically targets DRG 
(Duggan et al. 2002). Unlike other neurons, DRG express galactose-containing
16
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oligosaccharides on their surfaces (Streit et al. 1985; Streit et al. 1986), which can be 
recognised by ECL (Duggan et al. 2002).
The action of LHN/A-ECL on DRG inhibits the release of glutamate, substance 
P and CGRP, thereby preventing the transmission of painful stimuli to the spinal cord 
(Duggan et al. 2002). The longevity of action of the conjugate is equivalent to that of 
the native toxin and its action does not affect non-noxious activity. Application of the 
conjugate to rats has provided evidence that it could become a useful therapeutic 
agent in the treatment of chronic pain (Duggan et al. 2002). Moreover, the side effects 
associated with conventional analgesics are not predicted for LHN/A-ECL.
1.5 AIMS OF THE INVESTIGATION
This investigation has formed part of collaboration between the University of 
Bath and the Health Protection Agency, where the LHN/A-ECL conjugate has been 
prepared and tested. The ultimate aims of the project were to determine and analyse 
the three-dimensional structures of LHN/A and ECL. It was anticipated that structural 
knowledge of the protein components of the LHN/A-ECL conjugate would provide 
insight into its biological function and possibly allow rational improvement of the design 
of the conjugate. The method of choice was X-ray crystallography, which is routinely 
used to accurately determine the structures of biological macromolecules to high 
resolution. Protein structures have been determined crystallographically since the 
1950s and there are now more than 22,400* protein structures deposited in the Protein 
Data Bank, PDB (Berman et al. 2000; www.rcsb.org/pdb/).
1.5.1 Structural Studies on Fragments of Botulinum Neurotoxin A
The effects of LHN/A on dorsal root ganglia were compared with those of a 
catalytically inactive fragment, known as LHN/A(H227Y) in which His227, a key residue in 
the catalytic mechanism of the toxin, was mutated to tyrosine (Duggan et al. 2002). 
Mutating His227 to Tyr abolishes the catalytic activity of BoNT/A (Zhou et al. 1995), 
making LHm/A ^ 22^ )  a useful control agent for assessing the non-catalytic effects of 
the conjugate on target cells. Therefore, the initial focus of the investigation was to 
crystallise both LHN/A and LHN/A(H227Y) and then to determine and compare their 
crystal structures.
Since the crystal structure of BoNT/A is known (Lacy et al. 1998), atomic 
coordinates for the catalytic and translocation domains were to be used as a search 
model in molecular replacement to determine initial phases for the toxin fragments.
* 22 ,448 protein structures deposited by 9 September 2003
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There is only one amino acid different between the primary structures of the two 
fragments, but as this mutation abolishes the catalytic activity of LHn^ H 22^ ) ,  any 
structural rearrangements in the active site were to be analysed. The final structural 
models for each fragments were then to be compared with the known crystal structure 
of the BoNT/A holotoxin (PDB code 3BTA) to assess any structural changes brought 
about by removal of the binding domain.
The BoNT/A translocation domain undergoes structural rearrangement at low 
pH, forming a membrane-spanning channel that facilitates release of its light chain into 
the neuron cytosol. In order for the catalytic light chain to be activated, the disulphide 
bond linking it to the translocation domain must be reduced. Currently, it is not known 
at what point during the mechanism of action this takes place, but it is known that the 
structure of the light chain after translocation is different to its structure when joined to 
the toxin heavy chain (Li and Singh 2000b). Therefore, the nature of any structural 
changes resulting from reduction of the disulphide bond were to be investigated by co- 
crystallising LHN/A with dithiothreitol, or by adding dithiothreitol to pre-formed crystals 
prior to data collection. It was hoped that these studies would provide insight into the 
location of the translocation belt following reduction of the interchain disulphide bond.
Furthermore, co-crystallisation of LHN/A and LHm/A ^ 22^ )  with substrates or 
substrate analogues was to be attempted in order to fully understand the effects of 
mutating His227 to Tyr on the catalytic site. Of particular interest, were the mode of zinc 
coordination in LHn/A ^ 22^ )  compared to LHn/A and BoNT/A and chemical details of 
the substrate-enzyme interface. Potential inhibitors of the metallopeptidase activity of 
BoNT/B (Adler et al. 1998; Eswaramoorthy et al. 2002) and substrate analogues for 
BoNT/A, based on truncated versions of SNAP-25, have recently been described 
(Hallis et al. 1996; Schmidt et al. 1998). Co-crystallisation of the toxin fragments with 
these compounds might shed light on the catalytic mechanism of BoNT/A.
1.5.2 Structural Studies on Erythrina cristagalli Lectin
The ECL-LHn/A conjugate is prepared using a recombinantly over-expressed 
form of ECL. It is, therefore, necessary to ensure that recombinant ECL (recECL) is 
identical in structure and activity to native ECL (r?ECL) so that it may be expected to 
behave in the same way in biological systems. The main structural difference between 
recombinant and native forms of ECL is the absence of glycosylation from the 
recombinant form, since the expression host (Escherichia coli) does not contain the 
cellular machinery required to glycosylate proteins in the same way as eukaryotic cells. 
Therefore, the aim was to determine and compare the crystal structures of both native
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and recombinant forms of ECL to demonstrate that the structure of the recombinant 
form does not differ significantly from that of native ECL. The crystal structure of the 
closely related Erythrina corallodendron lectin was available as a search model for 
molecular replacement.
The crystal structure of nECL was also to be compared with the known 
structures of other legume lectins to analyse the mode of dimerisation and assess the 
potential role of glycosylation in the observed mode of quarternary association. 
Additionally, the quarternary association of recECL protomers was of interest. Erythrina 
corallodendron lectin, which is closely related to ECL, has an unusual dimer structure 
that is postulated to be caused by the presence of a bound oligosaccharide. Therefore, 
it was of interest to determine whether or not ECL adopts the canonical mode of 
dimerisation and, if not, whether or not the variation could be attributed to the presence 
of carbohydrate by comparing the quarternary association of native and recombinant 
(i.e. glycosylated and non-glycosylated) forms.
Half-way through the current investigation, the crystal structures of natively- 
sourced ECL in complex with lactose and fucosyllactose (PDB codes 1GZ9 nd 1GZC) 
were reported (Svensson et al 2002). These data showed that SvenECL protomers 
adopt the jelly-roll fold and dimerise back-to-back in a non-canonical fashion. N-linked 
glycosylation was observed at two positions in SvenECL, Asn17 and Asn113, and the 
side-chains of Asp89, Gly107 and Asn133 were shown to create a strong hydrogen- 
bonding network for carbohydrate binding.
In addition, co-crystallisation of both nECL and recECL with a variety of 
galactose-containing saccharides was to be attempted in order to glean information on 
the architecture of the combining site and the mode of carbohydrate binding. Analysis 
of the combining site was of interest because the activity of ECL in retargeting LHN/A to 
DRG is based upon its carbohydrate specificity. Although DRG are the only neurons 
expressing galactose-containing carbohydrates on their surfaces, the specificity of the 
interaction might be enhanced by site-directed mutagenesis if we understand the 
architecture of the combining site and have knowledge of the residues involved in 
carbohydrate binding. Furthermore, despite high sequence similarity, slight differences 
have been noted in the carbohydrate-binding properties of ECL compared with other 
Erythrina lectins. The basis of these differences is also of interest, as it will provide 
insight into the variation in carbohydrate specificity observed among lectins with similar 
tertiary and quarternary structures.
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CHAPTER TWO 
PROTEIN CRYSTALLOGRAPHY
Crystallography, the science of crystal structures, properties and forms, can 
be utilised to determine the three-dimensional structures of biological macromolecules. 
Determination of protein structures by this method involves collecting and analysing the 
diffraction patterns produced when protein crystals scatter X-rays. Due to their short 
wavelengths, X-rays allow resolution down to the atomic level. A beam of X-rays 
incident on a protein crystal will be scattered and the resultant diffraction pattern can be 
recorded. No physical X-ray lens exists, so recombination of the scattered X-rays must 
be simulated using information on the intensity and phase of each diffracted X-ray. 
However, only the intensities of the X-rays can be recorded in the diffraction pattern, 
creating a “phase problem”, which must be overcome in order to elucidate structural 
information.
The crystallographic determination of protein structures involves a series of 
experimental steps: The protein must be isolated, purified and crystallised before X-ray 
diffraction data can be collected. The recorded data must then be processed and initial 
phases determined in order to calculate electron density maps of the protein structure. 
A model is then fitted to the electron density and repeated cycles of refinement and 
model building are performed until the model cannot be further improved.
2.1 OBTAINING PURE PROTEIN
Before crystallisation trials can commence, the protein of interest must be 
isolated and purified. Proteins can either be obtained directly from a wild type source 
(referred to as “native”) or recombinantly over-expressed in a host organism. Milligram 
quantities of protein are required for crystallisation and the protein should be soluble 
and in the authentic conformation as well as being of the highest purity.
2.1.1 Hosts for the Recombinant Expression of Proteins
It can be expensive and impractical to isolate protein from wild type sources, 
particularly if the protein of interest is mammalian, so the gene coding for the protein is 
often introduced into a host cell system for over-expression. Several systems can be 
used for the preparation of recombinant proteins -  bacteria, yeasts, insect cells and 
mammalian cells. Each expression system has its own relative merits and associated 
disadvantages and no one system is suitable for all practical applications.
20
Structural Studies on Erythrina cristagafii Lectin and Botulinum Neurotoxin A
Escherichia coli, the most common initial choice for protein over-expression, 
has several advantages over other hosts. The bacterium has been well characterised 
in terms of its genetics, molecular biology and physiology and is easy to culture with a 
high growth rate. It is easy to extract protein from E.coli, but the cells have limited post- 
translational machinery and the fine structure of genes is different to that in higher 
eukaryotes. Many proteins form insoluble aggregates (inclusion bodies) when over­
expressed in E.coli because they are incorrectly folded (Georgiou and Valax 1996) but 
this can be avoided by slowing the rate of protein synthesis; expressing the protein of 
interest as a fusion with a highly soluble protein; or by co-expressing molecular 
chaperones. If the protein is toxic to E.coli and expression as a fusion or targeting to 
the periplasm does not reduce the toxicity, another expression host should be 
considered.
Yeasts, such as Pichia pastoris and Saccharomyces cerevisiae, are as cheap 
and easy to use as bacterial expression systems with the added advantage of having 
post-translational processing machinery similar to mammalian cells (Sudbery 1996). 
The protein of interest can be directed into the yeast secretory pathway, where protein 
folding, disulphide bond formation and glycosylation occur, although the nature of the 
glycosylation can differ from that of the native protein. Insect cells (for example, from 
Drosophila melanogaster and Spodoptera frugiperda) can be used as expression 
systems in conjunction with baculovirus or plasmid vectors (McCarroll and King 1997). 
Insect cells are cheap to maintain and can perform the same types of post-translational 
modification as mammalian cells. Mammalian cells (e.g. Chinese hamster ovary cells) 
provide the most native environment for the over-expression of mammalian proteins 
and can produce recombinant proteins that have near-native glycosylation profiles and 
post-translational modifications.
2.1.2 Methods of Protein Purification
The protein of interest must be purified, whether it has been isolated from a 
wild-type source or recombinantly over-expressed in a host system, to remove other 
protein species and biomacromolecules. Purity is important for crystallographic studies 
and great care must be taken to prepare material that is at least 99% pure protein for 
crystallisation trials. Affinity purification typically provides a protein sample that is 80- 
90% pure, with further purification steps normally including ion-exchange and size- 
exclusion chromatography (Lesley 2001). Incorporation of foreign molecules is likely to 
introduce lattice defects, inhibiting crystal growth. The solution should also be 
monodisperse (i.e. the protein should exist as a single, oligomeric species) and
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conformationally pure because differences in the charge or glycosylation of protein 
molecules, for example, can hinder crystallisation.
Ion-exchange chromatography separates proteins according to differences in 
charge of the protein species. The impure protein sample is loaded onto a column that 
is oppositely charged to the protein of interest. Conditions (e.g. salt concentration) are 
then altered stepwise to elute the bound protein species. Affinity chromatography 
separates proteins using reversible affinity for a specific ligand that is attached to the 
column. The rationale is that only the protein of interest will bind to the ligand and once 
all unbound protein has been removed, the protein can be released from the column by 
applying another ligand for which the protein has higher affinity or by altering the pH, 
ionic strength or polarity of the column. Gel filtration chromatography is used to 
separate proteins on the basis of their molecular size. This is typically the last step in 
the purification procedure.
It is vital to ensure that the protein is folded and active after purification and to 
use fresh stocks for crystallisation so that the protein molecules have not degraded.
2.2 CRYSTALLISATION
The first step in protein crystallography is crystallisation of the protein of 
interest. Good-quality, large, single crystals are sought for diffraction experiments 
because the accuracy of the final structural model depends upon recording good- 
quality diffraction data. Crystals of proteins differ from those of small molecules in their 
physical properties. In addition, the crystallisation of proteins is different to that of small 
molecules because proteins have different physicochemical properties and a larger 
number of parameters are involved (Drenth 1999). Protein crystals tend to be smaller 
(less than 10mm3) and more fragile with high solvent contents and large unit cells 
(Ducruix and Giege 1999). Protein crystals are also sensitive to external conditions and 
are weakly birefringent under polarised light.
2.2.1 Crystals and Symmetry
A crystal is a three-dimensional structure in which molecules are repeated at 
regular intervals in each dimension. During crystallisation, molecules aggregate 
together in symmetric patterns. This is because the crystallisation conditions favour a 
small number of intermolecular contacts, which are repeated to form a symmetric 
pattern. The “unit cell” is the smallest repeating unit that can make up the crystal (by 
translation operations only) and the information it contains is the structure of all the 
component molecules. “Crystallographic symmetry” describes the arrangement of 
molecules within the unit cell. The “asymmetric unit” is defined as the smallest unit that
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can be rotated and translated by the crystallographic symmetry to generate one unit 
cell. The molecules within one asymmetric unit are related by “non-crystallographic 
symmetry” because they do not have identical environments (Drenth 1999).
Cartoon Representation of the Crystal Lattice
The crystal lattice describes the regular arrangement of component molecules. The unit cell, the smallest 
repeatable building block of the crystal lattice, is defined by dimensions a,b,c and angles a,(3,y. The unit 
cell contains all the information required to describe the structure of the component molecules, although 
they do not always exist in the centre of the unit cell. W here there is more than one molecule per unit cell, 
the asymmetric unit is defined as the smallest unit that can generate one unit cell.
The crystal lattice, defined by three axes (a,b,c) and three angles (ot,(3,y) 
(Figure 1), describes the regular spacing of the component molecules (Ducruix and 
Giege 1999). The symmetry of the intermolecular interactions defines the symmetry of 
the crystal lattice and the symmetric constraints imposed on the crystal lattice allow all 
crystals to be classified into seven crystal systems (Table 1) (Giacovazzo 1994). The 
symmetry operators that define the arrangement of molecules in crystals include 
rotations, translations, mirror planes and inversion centres, and different combinations 
of these operators give rise to 230 space groups. However, because of the 
enantiomeric nature of amino acids, mirror planes, glide planes and inversion centres 
cannot be applied to protein crystals, so their symmetries are restricted to only 65 
space groups. Protein crystals can have 2-, 3-, 4- or 6-fold axes of symmetry (along 
with the corresponding screw axes) and can include centring symmetry (McRee 1993).
Figure 1 - The Arrangement of Unit Cells in the Crystal Lattice
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A space lattice is an arrangement of points where each point occurs in exactly 
the same environment and orientation as every other point (Blundell and Johnson 
1976). If the points are located at each corner of the unit cell, the space lattice is 
described as primitive (P), but if a point is also placed at the centre of each face, the 
lattice is face-centred (F). If a point is placed in the centre of the unit cell and at each 
corner, the lattice is known as body-centred (I), whilst the prefix ‘C’ identifies monoclinic 
and orthorhombic lattices in which a point is located at each corner of the unit cell and 
in the centre of the C face. The fourteen lattices that may be generated from the crystal 
classes using these criteria are known as Bravais lattices.
Table 1 -  The Seven Crystal Systems and 65 Protein Space Groups
Triclinic None P1
Monoclinic a = y = 90° (b is unique axis) 
a = p = 90° (c is unique axis)
P2; P 2 i;C 2
Orthorhombic 53 II TO II -i II CD O o P222; P222i; P2i2i2; P2i2 i2 i; C222; C222i; 
F222; I222; I2 i2 i2 i
Tetragonal a = b; a = p = y = 90° P4; P4-i; P43; P42; 14; I4i;
P422; P42i2; P4i22; P4322; P4i2i2; P432 i 2; 
P4222; P422 i 2; I422; I4i22
Trigonal a = b; a = P = 90°; y = 120° P3; P 3 i; P32; R3;
(Rhombohedral) (a = b = c; a = P = y) P312; P321; P3i21; P3221; P3i12; P3212; 
R32
Hexagonal a = b; a = p = 90°; y = 120° P6 ; P61; P62; P63; P64; P65;
P622; P6i22; P6522; P6222; P6422; P6322
Cubic a = b = c;a = p = y = 90° P23; F23; I23; P2i3; I2i3
P432; P4i32; P4332; P4232; F432; F4i32;
I432; I4i32
All crystals can be classified into one of the seven crystal systems. These crystal systems are defined by 
the symmetry constraints they impose on the crystal lattice. Different combinations of symmetry operators 
can be applied to the molecules within a crystal, giving rise to 230 space groups, but the stereochemistry 
of amino acids limits protein crystals to only 65 of these space groups.
2.2.2 Crystallogenesis
Crystallisation is a multi-step process in which nucleation is followed by crystal 
growth. Nucleation and growth depend upon supersaturation of the protein solution 
(Weber 1997). Supersaturation is a function of protein concentration and factors such 
as pH, temperature and ionic strength that affect protein solubility. Protein solutions
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can become supersaturated by the alteration of some internal parameters and/or by the 
addition of precipitation agents (Zanotti 1994). In order to grow large, single crystals for 
diffraction experiments, supersaturation should be achieved slowly. The methods 
available for protein crystallisation bring the protein solution into a supersaturated state 
that favours nucleation and growth.
Crystallogenesis proceeds by the spontaneous association of aggregates in a 
process known as nucleation (Weber 1997). Formation of nuclei reduces the level of 
supersaturation of the protein solution, which in turn lowers the probability that further 
nuclei will form. The degree of supersaturation required for crystal growth is lower than 
that needed for nucleation and too many nuclei would form if the level of 
supersaturation remained high (Drenth 1999). Once the nuclei have reached a critical 
size, crystal growth continues by the addition of protein molecules to the crystalline 
lattice (Weber 1997). Crystal growth does not continue indefinitely and cessation of 
growth has several causes, including depletion of protein molecules from the 
crystallising solution; poisoning of the crystal faces; ageing of the constituent protein 
molecules; and the presence of growth defects in the crystal lattice.
2.2.3 Crystallisation Methods
The search for crystallisation conditions is a somewhat trial-and-error process. 
Parameters commonly varied include the buffer, pH, precipitant, protein and precipitant 
concentrations and incubation temperature (Drenth 1999). The presence of additives in 
low concentrations can also aid crystallisation. With a large number of precipitants, 
buffers and additives to sample, “sparse matrix” screens are often used to identify initial 
crystallisation conditions from a wide range of solutions. Subsequent optimisation of 
conditions that produce initial crystals may then lead to the growth of crystals suitable 
for diffraction experiments.
Vapour diffusion methods manipulate the concentration of the protein solution 
remotely, by diffusion through air (Weber 1997). A droplet containing both protein and 
precipitant, commonly in a 1:1 ratio, is sealed over a reservoir containing the precipitant 
or crystallisation buffer (also called the “mother liquor”). Hanging drops are dispensed 
onto a coverslip that is then inverted and sealed over the precipitant. Sitting drops are 
placed in microbridges that elevate the drop above the level of precipitant in the well. In 
either case, equilibration leads to the movement of water molecules between the drop 
and the reservoir, reducing the volume of the drop. The concentration of the protein 
increases, supersaturating the drop and leading to nucleation and growth.
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Crystallisation by dialysis involves containing the protein solution within a 
“dialysis button” such that it is separated from the mother liquor by a semi-permeable 
membrane (Ducruix and Giege 1999). Small molecules are free to cross the membrane 
but protein molecules are not, so the pH and ionic strength of the protein solution can 
be manipulated directly. Dialysis is a versatile technique because the mother liquor can 
easily be changed several times, or the concentration of a precipitant increased in 
incremental stages.
Batch methods involve mixing protein with precipitant at a concentration that 
will instantly reach supersaturation (Ducruix and Giege 1999). The mixture is sealed 
and incubated to allow crystal growth. This process has been automated and can 
handle very small drops, known as “microbatch” crystallisation. In microbatch, the 
protein and precipitant solutions are mixed and incubated under paraffin oil to prevent 
evaporation of the precipitant (Chayen 1997). However, the microbatch technique is 
not suitable for use with organic solvents that are soluble in paraffin oil.
2.3 X-RAY DIFFRACTION
A beam of X-rays incident on a protein crystal will be scattered (diffracted) due 
to interactions with electrons in the crystal lattice. An electron excited by an X-ray will 
oscillate at the same frequency as the incident wave. This oscillation deflects the X-ray, 
producing a diffracted beam with the same wavelength as the incident radiation, but 
differing in phase by 180° (Blundell and Johnson 1976). A crystal contains a large 
number of electrons, each of which will deflect the incident radiation, and the scattered 
X-rays will be prone to interference.
The distance between evenly spaced parallel planes of atoms in the crystal is 
known as the crystal spacing (d). X-rays incident on a plane of atoms at an angle 0 will 
be diffracted through 20. However, X-rays diffracted by successive planes of atoms are 
subject to interference. If the difference in path length between two waves diffracted by 
successive planes is equal to a whole number of wavelengths, they will interfere 
constructively and a diffraction spot will be recorded (Figure 2). This is described by 
Bragg’s law:
nX = 2d sin0
where: X is the wavelength of the incident radiation 
d is the crystal spacing 
0 is the angle of diffraction
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This diagram represents a crystal lattice in which planes of atoms are separated by a regular distance, d. 
A beam of X-rays incident on a plane of atoms at an angle 0 will be reflected and emerge at an angle of 
the same value. The difference in path length between X-rays 1 and 2 as they travel through the crystal is 
equal to AB+BC. If this path difference is equal to a whole number of wavelengths, Bragg’s law is satisfied 
and the emergent X-rays will interfere constructively, giving rise to a reflection in the diffraction pattern.
In crystallography, the term “resolution” refers to the crystal spacing. It is 
related to the scattering angle, 0, as determined by rearranging Bragg’s law:
sin(0)/A
2.3.1 The Ewald Construction
The Ewald construction (Figure 3) is a three-dimensional representation of 
Bragg’s law based on the reciprocal lattice which has dimensions inversely proportional 
to those of the crystal lattice. The incident X-radiation is depicted as a sphere of radius 
MX positioned centrally on the beam (Dauter 1999). The reciprocal lattice is oriented 
with its origin at the point where the X-ray beam passes through the sphere. When a 
reciprocal lattice point lies on the surface of the Ewald sphere, Bragg’s law is satisfied, 
giving rise to a diffracted beam. This is because each reciprocal lattice point lies at the 
end of a vector of length 1/d, perpendicular to the corresponding family of crystal 
planes. Thus, if a reciprocal lattice point lies on the Ewald sphere, 1/2d = (1/X)sin0, 
which takes the form of Bragg’s law when rearranged.
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Figure 3 - The Ewald Construction
The Ewald construction represents Bragg’s law in three dimensions. The incident radiation is shown as a 
sphere of radius M X  (the Ewald sphere) that is positioned centrally on the beam. The reciprocal lattice is 
oriented with its origin at the point where the X-ray beam passes through the sphere. When a reciprocal 
lattice point lies on the surface of the Ewald sphere, Bragg’s law is satisfied and a reflection will be 
observed.
Each reciprocal lattice point (i.e. each spot in the diffraction pattern) arises 
from one diffracted X-ray beam (Drenth 1999).
The diffraction pattern (Figure 4) contains information on the structure of the 
crystal and its component molecules, which in the present case are protein. The 
spacing between reflections is inversely related to the crystal spacing because the 
dimensions of the reciprocal lattice are inversely proportional to those of the crystal 
lattice. Thus, the smaller the crystal spacing, the greater the distance between lines of 
reflections in the diffraction pattern. The circular arrangements of spots in the diffraction 
pattern are known as “lunes”. The reflections within each lune arise from diffraction by 
one plane of the reciprocal lattice. Each reflection corresponds to the molecular 
transform at a given reciprocal lattice point and its intensity is related to the strength of 
the molecular transform at that point (Blundell and Johnson 1976).
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Figure 4 - A Typical X-ray Diffraction Pattern Collected from a Protein Crystal
This X-ray diffraction pattern was recorded from a crystal of E ry th r in a  c r is ta g a l l i lectin. Data were collected 
to 2 .0 A  resolution using the Synchrotron Radiation Source at Daresbury (UK) in December 2 001 . The 
diffraction pattern consists of a series of spots (reflections) whose positions contain information on the 
dimensions of the crystal lattice, and whose intensities are related to the arrangement of the atoms within 
that lattice.
2.3.2 Diffraction by a Crystal
Individual reflections correspond to reciprocal lattice points and are identified 
by Miller indices (h,k,l)- Each diffracted X-ray giving rise to a reflection in the diffraction 
pattern can be described as the sum of the contributions of all electrons in the unit cell 
(Rhodes 2000). The value of this sum is known as a structure factor, F(hkl). The 
structure factor equation thus represents the molecular transform sampled at reciprocal 
lattice point hkl (Blundell and Johnson 1976):
F (hkt) = ^  f j exp 2 mQixj + kyj + Izj)
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A crystal will therefore produce a discontinuous diffraction pattern, observed as a 
series of spots (known as “reflections”).
Each reflection has a magnitude |F| and a phase angle a. This can be 
represented as a vector (comprising real and imaginary parts) of length F at an angle a 
to the real axis (Figure 5). The structure factor equation for a given reflection can be 
expressed in terms of its amplitude and phase:
F (hki) -  F(hkt)exp i a(hkt)
where: F(hkl) is the amplitude 
a(hkl) is the phase
The amplitude of the reflection is related to its intensity (I) by the equation:
R
Vector diagram representing the magnitude (F) and phase angle (a) of a recorded reflection.
Mathematically, the recorded diffraction pattern is related to the structure of 
the protein by a Fourier transform. The Fourier transform of a protein crystal is the 
product of the Fourier transform of one protein molecule and the Fourier transform of 
the crystal lattice. In the same way, a Fourier transform of the diffraction pattern will 
give the electron density of the protein molecule, which can be considered to be an 
image of its structure. If the structure of the crystal is known, the diffraction pattern can 
be calculated using the structure factor equation (Blundell and Johnson 1976). In order 
to compute the structure of the protein from the diffraction pattern, the structure factor 
equation is rewritten in terms of a continuous summation over the volume of the unit 
cell:
I(hkl) -  F (hk(f
Figure 5 -  Vector Representation of a Diffracted Wave
1 00 00 00
p(xyz) =  —  X X X F (M /)e x p - Im Qix +  k y + lz )
*  ^  L   ^  / _
where: p(xyz) is the electron density at point xyz in the unit cell
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V is the volume of the unit cell 
This is known as the electron density equation and it can be seen that if the structure 
factors for all reflections are known, the electron density at each point in the unit cell 
may be calculated (Blundell and Johnson 1976).
2.4 X-RAY DIFFRACTION DATA COLLECTION
The protein crystal is merely a tool that enables the crystallographer to glean 
structural information about its component molecules. The crystal lattice acts as a 
diffraction grating, scattering electromagnetic radiation of appropriate wavelengths (i.e. 
X-rays) and analysis of the resultant diffraction patterns allows the three-dimensional 
structures of the molecules that make up the crystal to be determined. It is important to 
collect good quality diffraction data in order to generate high quality electron density 
maps and precise atomic models (Dauter 1997).
2.4.1 Crystal Handling
The ability of a crystal to diffract cannot be assessed without placing it in an X- 
ray beam. Some crystals diffract strongly, some weakly and others not at all. This is 
even true of protein crystals grown in the same drop or under the same conditions in 
different drops. It may also be difficult to determine the nature of a crystal without 
recording a diffraction pattern. Mother liquors used to crystallise proteins may contain 
high concentrations of salt, which can crystallise. Salt crystals are not easy to 
distinguish from protein crystals by eye, but they produce markedly different diffraction 
patterns characterised by very few, intense spots.
To collect diffraction data, the crystal must be mounted and centred in an X- 
ray beam. Protein crystals are sensitive to external conditions and a large proportion of 
the crystal volume is solvent, so it is important that the crystal does not dry out during 
the experiment. To collect data at room temperature, crystals are mounted in quartz 
capillaries with a small volume of mother liquor. Data can also be collected at cryo- 
temperatures (100-120K) with the crystals mounted in wire loops and positioned under 
a stream of cold nitrogen gas during the experiment. Cryo-cooled crystals tend to have 
increased lifetimes in the X-ray beam and produce better diffraction data because cryo- 
cooling provides some protection against radiation damage (Garman 1999). The most 
important factor when preparing crystals for cryo-temperatures is to cool them quickly 
so that ice crystals do not form. A cryoprotectant solution is normally required to act as 
an antifreeze agent. Crystals can either be crystallised in cryoprotectant mother liquor 
or immersed in cryoprotectant solution prior to cooling.
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Radiation damage is caused by the action of the X-ray beam on the crystal. 
Energy absorbed by the crystal is dissipated through the crystal in the form of heat and 
as covalent bond breakage (Sliz et al. 2003). This is “primary” radiation damage and is 
largely dependent upon the X-ray dose. “Secondary” radiation damage is caused by 
the action of reactive radical species generated by primary radiation damage within the 
crystal. This is temperature and time dependent but can be reduced or eliminated by 
cooling crystals to cryo-temperatures.
2.4.2 X-ray Sources and Detectors
Diffraction data can be collected in the “home” laboratory or at a synchrotron 
radiation source (SRS). The basic requirements are an X-ray source and a detector 
upon which to record the diffracted X-rays (known as “reflections”). In addition, the 
experimental set-up will normally include a monochromator, to select a single X-ray 
wavelength; a mirror, to focus the beam onto the sample; and a positioning device (a 
goniostat), to allow rotation of the crystal in the X-ray beam.
X-rays of fixed wavelength may be generated in house using a sealed tube or 
a rotating anode (Drenth 1999). Both produce X-rays by accelerating electrons at high 
voltage (40-50kV) against a metal target (McRee 1993). The composition of the metal 
target determines the wavelength at which X-rays are emitted. However, the target 
becomes very hot and the power of both sources is limited by the rate at which this 
heat can be dissipated. Rotating anodes are preferred for protein crystallography 
because the X-rays produced are of higher intensity (i.e. “brighter”), causing less 
radiation damage to crystals and improving the quality of the recorded data (Nave 
1999).
The alternative is a synchrotron radiation source in which electrically charged 
particles are circulated close to the speed of light using magnetic devices (Drenth 
1999). Electrons accelerate as they move in a circle and emit a continuous spectrum of 
electromagnetic radiation. The X-rays produced by a SRS are up to two orders of 
magnitude brighter than the best rotating anodes (McRee 1993). Tight 
monochromation of the X-ray beam reduces the level of background radiation and 
increases the signal-to-noise ratio. The X-rays are of high intensity, allowing data to be 
collected from small or weakly diffracting crystals and reducing exposure times. 
However, if the intensity of the radiation is too high, the level of radiation damage in the 
crystal will increase (Nave 1999). The X-ray beam is also highly parallel with low 
divergence, giving rise to sharp diffraction spots. The maximum achievable resolution 
using a SRS is often better than that in house because there are more diffracted
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beams at high diffraction angles. The wavelength of the X-rays may also be varied (i.e. 
it is tunable), which affords synchrotron radiation sources two additional advantages 
over rotating anodes and sealed tubes: Shorter wavelength X-rays are absorbed to a 
lesser extent by crystals, causing less radiation damage (Helliwell 1997) and the 
tunability enables multi-wavelength anomalous dispersion experiments to be performed 
(Walsh et al. 1999).
Diffraction experiments generally require X-rays of a single wavelength, so a 
narrow band of radiation is selected from the spectrum output by the source (Drenth 
1999). The most commonly used radiation from an in-house source, CuKa, has a 
characteristic wavelength of 1.5418A. This wavelength is selected from the spectrum 
produced by a copper anode using a nickel filter or a graphite monochromator (Drenth 
1999). Monochromators at synchrotron radiation sources are generally composed of 
silicum or germanium, which allow selection of a narrower wavelength band. The X-ray 
beam can be focussed using a pair of curved mirrors, one mirror in the horizontal plane 
and one in the vertical plane (McRee 1993). Focussing increases the brilliance of the 
radiation incident on the crystal and allows resolution of large unit cells. The direct 
beam is extremely powerful and is blocked by a piece of metal (the beamstop) placed 
just between the crystal and the detector. It prevents excessive amounts of radiation 
reaching the centre of the detector.
The detector records the positions and intensities of the X-rays diffracted by 
the crystal. It must therefore be uniformly sensitive and record a large proportion of the 
incident X-rays with high efficiency (Amemiya 1997). The diffraction pattern may be 
distorted if the detector has a flat surface because X-rays are emitted from the crystal 
in a sphere. Distortion can be recognised by the presence of elongated spots at the 
edges of the diffraction pattern and must be corrected. Diffraction data were originally 
recorded using photographic film, which has a high resolution and can be bent to form 
a curved surface (McRee 1993). However, film records a high level of background 
radiation, has low efficiency (a small number of the incident waves are recorded) and a 
low dynamic range (i.e. the reflections are easily saturated). The level of background 
radiation is not negligible because there is significant scattering of X-rays by air (Drenth 
1999). Exposed X-ray film must then be developed and scanned in order to analyse the 
recorded data but, in order to retain the high resolution, a fine pixel scanner must be 
used. Most beamlines now employ image plates and charge-coupled device area 
detectors in place of X-ray film.
Image plates comprise a thin layer of an inorganic phosphor deposited on a 
flat base (Drenth 1999). X-rays incident on the image plate excite electrons in the
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phosphor to higher energy levels. Most of the energy Is stored in the phosphor, but 
some is emitted as fluorescent light. The stored energy is released by illuminating the 
plate with a red laser and the amount of blue light emitted is proportional to the number 
of incident photons. The diffraction pattern is read spirally but the read-out time is too 
slow for image plates to be used with synchrotrons. Once an image has been recorded 
and read, it can be erased by exposure to intense white light and the image plate used 
to record another diffraction pattern. Image plates are extremely sensitive at shorter 
wavelengths and are much more sensitive than X-ray film (Drenth 1999). The main 
problem is with “overloaded” reflections. If a pixel becomes overloaded, the statistical 
error will be artificially low and such reflections should be removed from the data. 
Charge-coupled device (CCD) area detectors utilise inorganic phosphors that emit 
visible light in response to X-radiation. The CCD accumulates charge in direct 
proportion to the number of photons incident upon it and the charges are read out 
serially (Rhodes 2000). CCDs are suitable for use with synchrotrons because they 
have better spatial resolution and shorter read-out times than image plates (Muchmore 
1999). Other advantages include high dynamic range with low noise and high 
maximum count rate, although they have lower sensitivity at shorter wavelengths.
2.4.3 Data Collection Strategy
The success of subsequent steps in protein structure determination depends 
largely upon the quality of the diffraction data recorded from the crystal (Dauter 1999). 
The detector records the positions and intensities of X-rays diffracted by the crystal and 
it is important that these reflections are recorded completely and do not overlap. As 
they form the only experimentally observed parameter, the quality of the intensities is 
important. The whole area of the detector face should be used to record the diffraction 
pattern so the crystal-to-detector distance should be as large as possible to collect data 
to the resolution limit of the crystal (Dauter 1997). A large crystal-to-detector distance 
also increases the signal to noise ratio. As the resolution increases, so does the 
quantity of data. The exposure time per image should also be carefully chosen -  if it is 
too long, the detector will be overloaded with strong, low-angle reflections and the level 
of radiation damage to the crystal will increase (Evans 1999).
Reducing the level of background radiation recorded by the detector increases 
the signal to noise ratio and improves the quality of the data. This can be achieved by 
matching the width of the X-ray beam to the size of the crystal (Evans 1999). A large 
beam incident on a small crystal will produce a high level of background radiation 
because X-rays are scattered by air. The path length of the direct X-ray beam through
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air should therefore be minimised by positioning the beamstop close to the crystal 
(McRee 1993).
In order to collect a complete dataset, it is necessary to rotate the reciprocal 
lattice so that all reciprocal lattice points will, at some time, lie on the Ewald sphere. 
This is achieved by rotating the crystal during data collection (because the reciprocal 
lattice rotates with the crystal lattice). A dataset therefore comprises a set of X-ray 
diffraction images recorded across a rotation range in a series of small oscillations. The 
oscillation angle should be as large as possible to minimise the number of images that 
must be recorded while avoiding overlapping reflections. The number of images 
required for a complete dataset and high redundancy depends on both crystal 
symmetry and the angular range which each image covers. High redundancy is 
important because it improves the accuracy of the data (Evans 1999).
The recorded reflections will be small and sharp for a highly ordered crystal 
(McRee 1993). However, most crystals contain imperfections and, in some cases, the 
reflecting planes diverge increasing the size of the reciprocal lattice points and hence 
the angular range over which they diffract. This “mosaicity” can be recognised in the 
diffraction pattern by wide lunes and overlapping reflections. High mosaicity produces 
lower-resolution diffraction and a lower signal-to-noise ratio. Overlaps occur when two 
reciprocal lattice points meet the Ewald sphere at the same point and within one 
oscillation of the crystal, giving rise to reflections in the same place in the diffraction 
pattern, making it difficult to deduce from which reflective plane the diffracted beams 
originate.
There is a “blind region” in the part of reciprocal space close to the axis of 
rotation where the reciprocal lattice points will never meet the surface of the Ewald 
sphere (Dauter 1997). For higher symmetry space groups, it can be possible to orient 
the crystal so that reflections equivalent to those in the blind region can be measured.
2.5 DATA PROCESSING
In order to reconstruct the three-dimensional structure of a protein from a set 
of diffraction patterns, the amplitudes and phases of the reflections must be known. 
The amplitude of each reflection can easily be determined because it is related to the 
recorded intensity. Therefore, the diffraction data must be carefully processed. Data 
processing, the analysis and reduction of diffraction data, comprises several steps 
(Otwinowski and Minor 1997): Firstly, the recorded diffraction images are visualised 
and the reflections indexed. The crystal and detector parameters must then be refined. 
The intensities of the reflections are integrated and the relative scale factor between
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measurements is determined. Crystal parameters are precisely refined using the whole 
dataset and measurements related by space group symmetry are merged and 
statistically analysed.
2.5.1 Indexing
The first step in data processing is to give each reflection an index that can be 
used to identify each point in reciprocal space (McRee 1993). Indexing begins with the 
identification of intense spots on the diffraction pattern -  a process known as “peak 
picking” (Rossmann and van Beek 1999). The positions of these peaks are analysed in 
order to elucidate the unit cell dimensions and Bravais lattice of the crystal. The 
symmetry of the crystal is then selected from a list that ranks each Bravais lattice with a 
“penalty”. In general, the correct lattice is that with the highest symmetry and lowest 
penalty ranking. It is worthwhile to note that any unit cell dimensions will fit a triclinic 
lattice, but that a higher symmetry lattice should be sought before a P1 space group is 
assigned. The orientation of the crystal with respect to the direction of the X-ray beam 
must also be determined, requiring accurate knowledge of the main beam position.
Once the crystal orientation is known and the space group has been chosen, 
Miller indices (hkl) are assigned to each reflection. The positions of all the reflections in 
the diffraction pattern can then be predicted for each image and differences between 
the positions of the observed and calculated reflections are minimised by refinement 
(Pflugrath 1997). Weak reflections can only be located by prediction based on the 
positional information provided by stronger reflections. The orientation of the crystal 
and detector are refined for each image, and this is important for refining the positions 
of the reflections. Accurate prediction of reflection positions is essential for precise 
integration of intensities. Errors in the prediction of spot positions affects the statistical 
error in the intensity measurements (Otwinowski and Minor 1997).
2.5.2 Integration
Integration of the intensity (I) of a spot in the diffraction pattern separates the 
background counts from those in the reflection (McRee 1993). However, in order to 
accurately integrate the intensities of the reflections, the spots in the diffraction images 
must be non-overlapping and the index and position of each reflection must be known 
(Otwinowski and Minor 1997).
Two methods are available for the integration of reflection intensities, 
summation and profile fitting, and there should be good agreement between the results 
that each method produces for any given dataset. Summation involves summing the
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intensities of all the pixels in a peak, then subtracting the intensity of the background 
radiation (Leslie 1999). The intensity of the background radiation is determined using 
the pixels adjacent to a peak and a background-corrected intensity is calculated for 
each reflection. Profile fitting involves fitting a smooth profile to the data and taking the 
area beneath the curve as the intensity (McRee 1993). This has two advantages over 
summation -  an improved signal-to-noise ratio for weak reflections and estimation of 
overloaded reflections (Leslie 1999). Firstly, a standard profile accurately representing 
the true reflection profile is derived, with the optimum profile being that which provides 
the best fit to all the reflections. From this standard profile, the intensities for fully 
recorded reflections can be evaluated by determining a scale factor and background- 
plane constants. For both methods, it is important to accurately estimate the level of 
background radiation recorded by the detector in order to reduce the error in the 
measured intensity of each reflection.
Integrated intensities are merged in order to group together reflections with 
common indices (McRee 1993). Merged multiple measurements of several reflections 
are weighted by the estimated error (a). Reflections are often rejected during data 
processing by the ratio of intensity to the error -  I/a(I) -  which, for a good dataset, 
should have a value greater than 2. The error (a) estimated for each reflection 
combines the height and variance of the background intensity and the number of times 
each reflection was measured. Errors in intensity measurement arise from several 
sources, including counting statistics; instability of the detector; profile fitting; local 
variations in the level of background radiation; saturated pixels; overlapped profiles; 
and errors in background models (McRee 1993). For example, the diffraction pattern 
may include features (such as white radiation streaks and cosmic rays) that do not 
arise from Bragg diffraction and the effects of these on the estimation of the 
background intensity must be reduced (Leslie 1999).
2.5.3 Scaling
Scaling corrects for absorption differences, variation in the intensity of the X- 
ray beam and, if more than one crystal is used, variability in the diffracting power of 
crystals during data collection (Drenth 1999). If diffraction data are collected from more 
than one crystal, the separate datasets must be normalised by the application of a 
scale factor before they can be merged (Monaco 1994). The dataset is then reduced to 
a unique list of reflections (i.e. “merged”).
Scaling generates statistics that evaluate the quality of the data and should be 
performed several times to improve these statistics as outliers are rejected. An R factor
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(Rsymm) compares symmetry-related reflections that should be of identical intensity and, 
thus, provides an internal measure of the accuracy of a dataset (McRee 1993).
Eft- I )
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2-l*h
If Rsymm has a value of 0.10 or less, the data are considered good enough for structure 
determination. A %2 test performed on the scaled data indicates the accuracy of the 
error model. A good error model will give a %2 value close to 1.0. A high value of %2 
may indicate that the crystal suffered radiation damage, which cannot be corrected by 
scaling. The completeness of the data is given as a percentage and is the number of 
measured unique reflections compared with the number of possible unique reflections. 
Generally, data that are >80% complete through all resolution bins are considered 
sufficient for accurate structure determination.
Scaling programs can also be used to determine the space group of a crystal. 
The Bravais lattice is determined during indexing but some lattices include several 
spacegroups. Scaling is performed on each possible space group, starting with that of 
lowest symmetry. If the value of %2 increases with higher symmetry, then the previous 
choice of space group was correct. Scaling produces a list of systematic absences -  if 
the correct space group is chosen, these reflections should be absent and their values 
very small. Correspondence of absences observed in the experimental data with the 
systematic absences characteristic of certain space group, identifies the correct space 
group for the experimental data.
2.6 THE PHASE PROBLEM
As described previously, the electron density in a crystal can be determined by 
performing a Fourier summation:
p(xyz)  = — y^| F (h k t) | exp [-2  m(hx + ky +  /z )+  ia (h k f^
V hkl
where: \F(hkl) is the structure factor amplitude of reflection hkl 
a(hkl) is the phase angle 
x,y,z are coordinates in the unit cell 
The amplitude of each reflection can easily be determined from the measured intensity,
because I (h k f )= F Q ik if , but the phase angles cannot be measured experimentally. 
This creates a problem, known as the “phase problem”, because the phases contain 
most of the structural information. It follows that accurate phase information is essential 
for the generation of good quality electron density maps.
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Initial phases, to be used for the generation of an initial electron density map, 
must therefore be derived indirectly and there are three main methods are available for 
this. Isomorphous replacement uses differences in intensity between the diffraction 
patterns of a native protein crystal and at least one heavy atom protein derivative. 
Multi-wavelength anomalous dispersion derives initial phases from the anomalous 
scattering of X-rays by heavy atoms present in the crystal at wavelengths close to their 
absorption edges. Molecular replacement utilises phase information from a previously 
determined, homologous protein structure.
2.6.1 Isomorphous Replacement
The isomorphous replacement method (Green et al. 1954) involves the 
preparation of heavy atom derivatives either by soaking protein crystals in a buffer 
containing a heavy metal compound or by co-crystallising a protein with a heavy metal 
compound (Ke 1997). The presence of the heavy atoms (such as Hg or Pt) alters the 
intensities of reflections in the diffraction patterns. These differences can be used to 
locate the positions of the heavy atoms in the crystal and determine the relative phase 
angles.
Figure 6 - Phase Determination by Isomorphous Replacement
The magnitudes of |Fph| and |Fr| are measured experimentally using the derivative and native crystals. 
Values for |Fh| and the phase of the heavy atom are determined from the heavy atom model. This gives 
two possible solutions for the structure factor of the native protein. A unique solution can only be obtained 
by collecting data from a second heavy-atom derivative because this produces another pair of vectors that 
resolve the phase ambiguity.
The structure factors of the native crystal (FP), the heavy atom (FH) and the 
heavy atom derivative (FPH) are related as follows:
Fp =  F Ph -  F h
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The magnitudes of |FP| and |FPH| are measured experimentally and values for |FH| and 
aH are obtained from the heavy atom model. Representing the structure factors as 
vectors reveals two possible phase angles for FP (Figure 6), one of which is correct. A 
unique solution can only be obtained by collecting data from a second heavy-atom 
derivative as this produces another pair of equations that resolve the ambiguity.
The use of only one heavy atom derivative is known as single isomorphous 
replacement (SIR) but will not solve the phase ambiguity for the native protein. The use 
of two or more derivatives (multiple isomorphous replacement, MIR) will solve the 
phase ambiguity.
2.6.2 Multiwavelength Anomalous Dispersion
The multiwavelength anomalous dispersion (MAD) method (Hendrickson and 
Ogata 1997) requires tunability of the X-ray wavelength, so the experiments can only 
be performed using a SRS. This is because the technique relies upon the anomalous 
scattering produced when a bound electron is promoted to a higher energy level. The 
energy required comes from photon absorption at the “absorption edge” of the element. 
The energy, E, imparted to the electron is related to the X-ray wavelength, X, as 
follows:
E = h —
X
where: h is Planck’s constant
c is the speed of the incident radiation
X-rays used in standard diffraction experiments do not cause electronic 
transitions in the “light” elements that make up proteins (i.e. C, H, N and O). 
Anomalous scattering is only observed when heavy atoms are present in the protein 
and the wavelength of the radiation is varied to bring the energy close to that required 
for an electronic transition. Heavy atoms, such as zinc and iron, are intrinsic to some 
proteins. Other proteins can be recombinantly expressed such that all methionines are 
replaced with selenomethionines, which are no larger than the native amino acid and 
do not affect the structure of the protein.
As the energy of the X-rays incident on a crystal approaches that required for 
an electronic transition, the oscillation of the electron is increased and a resonance 
condition is established (Hendrickson and Ogata 1997). Remote from the resonant 
energy of the electron, scattering is largely independent of wavelength and produces a 
primary wave 180° out of phase with the incident radiation. Close to resonant energies 
resonance effects cause anomalous scattering. The effect of anomalous dispersion can
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be expressed in terms of the atomic scattering factor, / ,  which may be defined as 
follows (Karle 1989):
/  = / 0 + A
where: f 0 is the normal or non-anomalous scattering factor 
A /  is the real part of the correction to f 0 
i f "  if the imaginary part of the correction to f 0 
This is explained in Figure 7. When the value of / ” is not negligible, Friedel’s law 
(which states that Fhw = F-h-k-i) does not hold true. The difference between the structure 
factors of two Friedel mates, the Bijvoet difference, is used to determine phase 
information (Blundell and Johnson 1976).
Figure 7 - The Anomalous Scattering Factor
i
The atomic scattering factor for a completely free electron is represented as /o. The anomalous scattering 
factor for a heavy atom ( / )  consists of two additional components, a real part A/  and an imaginary part f ' .
The X-ray wavelengths used in a MAD experiment must be carefully chosen to 
maximise the Bijvoet difference (Drenth 1999). Data are typically recorded at three 
different wavelengths -  where / ’ is small, where / ’ is large and negative and where the 
Bijvoet difference is maximum. Locating the anomalous scatterers in the structure can 
be achieved in a manner analogous to that used in isomorphous replacement, enabling 
the structure factor amplitudes of the protein to be estimated.
2.6.3 Molecular Replacement
Proteins that are homologous in their amino acid sequences often have similar 
tertiary structures. Therefore, if the protein under investigation is similar in primary 
structure to another protein whose crystal structure has previously been determined, 
the phases of the known structure can be used as initial phases for the unknown 
protein. This is known as molecular replacement (Rossmann and Blow 1967). 
However, if a low homology model is used, the phases will poorly represent the true 
phase of the unknown protein and the resultant structure will be biased towards the
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model and consequently difficult to refine correctly (McRee 1993). The bias introduced 
by the model phases is the main disadvantage of the molecular replacement method. 
For this reason, there should be high structural homology betweenthe known and 
unknown proteins. Suitable model proteins can be identified by comparing the 
sequence of the unknown protein with the sequences of proteins whose structures 
have been deposited in the PDB.
Two identical molecules (X<| and X2) with different positions and orientations 
can be brought to coincidence by defined rotation and translation functions (Blundell 
and Johnson 1976) as follows:
x2 = [C]X1 + d
where: [C] is the rotation matrix 
d is the translation vector 
Thus, molecular replacement identifies the rotation and translation that allow a known 
structure (the “search model”) to be precisely positioned in the unit cell of the unknown 
structure (the “target”). It is a six-dimensional search problem because three rotational 
and three translational parameters are involved. If the asymmetric unit contains more 
than one protein molecule or subunit, molecular replacement can also determine their 
relative positions (i.e. non-crystallographic symmetry) (Drenth 1999).
Figure 8 is a flowchart of the steps involved in molecular replacement. First, a 
model structure must be identified and modified, if necessary, to improve the success 
of the rotation search. The number of molecules per asymmetric unit is estimated and 
the rotational and translational parameters required to superimpose the search model 
on the target are ascertained. The solution is checked to ensure that no molecules are 
overlapping in the unit cell and the model structure is then refined.
Solving the rotation and translation functions is not always clear-cut (Drenth 
1999). It can be necessary to vary the parameters of the search or modify the search 
model. For example, if the model is an oligomer it may be better to perform the search 
with only one monomer. It may also be beneficial to remove the first and last few amino 
acids from the termini; to delete non-conserved loops; and/or to replace non-conserved 
residues with alanines. These alterations reduce the difference between the search 
and target structures and improve the success of the rotation and translation functions.
Before molecular replacement is undertaken, the number of protein molecules 
per asymmetric unit should be estimated by calculating the Matthews coefficient, Vm 
(Matthews 1968). This provides an estimate of the crystal solvent content from the unit 
cell volume and molecular weight of one molecule. Most protein crystals are 30-75%
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protein, corresponding to Vm values of 4.00 to 1.66. If the value of Vm falls outside this 
range, the assumed number of molecules per asymmetric unit is likely to be incorrect.
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Figure 8 - Flowchart of Steps Involved in Molecular Replacement
Refine the model
Calculate the Matthews coefficient and estimate the 
number of protein molecules per asymmetric unit
Perform a rotation search to orient the search model 
correctly
Perform a translation search to superimpose the rotated 
search model onto the target
Check the positions of the molecules to make sure 
there are no steric clashes
Find a homologous model whose three-dimensional 
structure has been solved
Perform subsequent translation searches to find the 
locations of other protein molecules within the 
asymmetric unit
Prepare the search model (use only one monomer, 
remove non-conserved side chains, remove the first 
and last few residues, remove non-conserved loops)
The molecular replacement method involves two main steps, a rotation search and a translation search, 
that allow the search model to be precisely positioned in the target unit cell. It is actually a six-dimensional 
problem because it involves three rotational and three translational parameters. It is important to choose a 
highly structurally homologous model because the initial phases will be biased towards the search model.
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2.6.3.1 The Patterson Function
The basic principle of molecular replacement can be explained in terms of the 
Patterson function, P(uvw). This is a Fourier summation involving the measured 
intensities, with all phase angles set to zero (Drenth 1999):
P(uvw) = —X I  F (hkl)  12 cos[2;t(Ak + kv + /w)]
y  hkl
The Patterson cell has the same dimensions as the real unit cell of the crystal, but the 
coordinates u,v,w are used to avoid confusion with the coordinates of the real cell 
(x,y,z).
The Patterson synthesis produces a map of the vectors between atoms in the 
unit cell by placing each atom in turn at the origin (Figure 9). If the unit cell contains N 
atoms, the Patterson map will have N2 peaks, of which N will be located at the origin 
(Drenth 1999). This explains why the highest peak is the map is located at the origin. 
The number of unique peaks in the map is therefore N(N-1). The Patterson map will 
always be centrosymmetric.
Figure 9 - Vectors in a Patterson Map
[0,0,0)
The Patterson synthesis of a three-atom molecule (shown on the left) is shown on the right. The Patterson 
map shows the vectors between the atoms and is derived by taking each atom in the molecule in turn and 
placing it at the origin (0,0,0).
Patterson vectors relate pairs of atoms in the unit cell and the peaks in the 
Patterson map correspond to these interatomic vectors (Grosse-Kunstleve and Adams 
2001). Self-Patterson vectors are relatively short and exist between atoms from the 
same protein molecule, whereas cross-Patterson vectors relate atoms from different 
protein molecules. If more than one identical molecule exists in the asymmetric unit, 
the distribution of self-vectors will be the same for all of the molecules except for a
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rotation that is equal to the non-crystallographic symmetry. In molecular replacement, 
both self- and cross-Patterson vectors are used to superimpose the search model onto 
the target in the target unit cell.
Self-Patterson peaks are located around the origin of the Patterson map in a 
volume of radius equal to the dimension of one molecule (Drenth 1999). The self­
vectors for homologous molecules are very similar, but not equal, and can reveal the 
rotation that relates them. Cross-vectors can then be used to determine the translation 
required to move the rotated search model to its correct position in the target unit cell. 
An observed Patterson map, calculated from the measured reflection intensities, and a 
model Patterson map, derived from the search model after rotation and translation, can 
be compared by superposition (Grosse-Kunstleve and Adams 2001). The observed 
and model Patterson maps will overlap maximally if the search model has been 
correctly oriented.
2.6.3.2 Rotation Function
The rotation function determines a rotation matrix, [C], that transforms the 
coordinates representing the search model without altering its dimensions. The search 
model, which is assumed to be spherical, is placed at the centre of an artificial unit cell 
with no crystallographic symmetry (i.e. space group P1) (Drenth 1999). Calculated 
structure factors for the search model in this artificial lattice can then be used instead of 
X-ray data from the known crystal structure in the rotation search. The rotation search 
determines the spatial orientation of the search model with respect to the target and is 
performed over the unique volume of the space group of the unknown structure. The 
search model is rotated through all possible angles and, at each point, the observed 
and model Patterson maps are compared (McRee 1993). If the search model is 
correctly oriented, there will be maximum overlap between the two maps.
Only intramolecular vectors, which are relatively short, should be considered 
during the rotation search, so the dimensions of the unit cell are limited to eliminate the 
longer cross-vectors. Typically, the cell will be no more than 30A larger than the search 
model in each dimension. The resolution of the data is another important consideration. 
Very low-resolution data are excluded because they only supply information on the 
gross features of the structure. Very high-resolution data should also be removed, as 
they will be too-heavily biased towards the search model. Therefore, the resolution 
range used for a rotation search is usually limited to 10-3.5A (McRee 1993).
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2.6.3.3 Translation Function
After the rotation angles have been determined, the translation required to 
superimpose the search model onto the target must be ascertained (Drenth 1999). This 
is achieved by moving the search model through the asymmetric unit. Observed and 
calculated structure factors (F0bS and Fcaic) are then compared at each position by 
calculating an R-factor or correlation coefficient. The correlation coefficient is a more 
reliable indication of correct placement of the search model because it is insensitive to 
scaling. If there is more than one molecule or subunit per asymmetric unit, then the 
translation function must be performed repeatedly until all of the molecules have been 
located. Possible locations of the search model are limited by knowledge of the crystal 
packing because the protein molecules cannot penetrate each other. However, the 
translation vector cannot be successfully assigned if the rotation matrix has not been 
precisely determined (Blundell and Johnson 1976).
2.7 REFINEMENT AND MODEL BUILDING
Unfortunately, the methods used for phase determination are not free of error 
and, consequently, interpretation of the resultant electron density maps is not always 
straightforward. The level of detail observed in the electron density map depends upon 
the quality of the diffraction data, so it is vital that a complete dataset with a high signal- 
to-noise ratio and high redundancy is used (Jones and Kjeldgaard 1997). The initial 
molecular model must be built into the calculated electron density. The ultimate aim of 
model building and refinement procedures is to generate a model of the protein that 
accurately represents the experimental data and makes sense physically, chemically 
and biologically (Kleywegt and Jones 1997). The processes involved in model building 
and refinement are repeated until no further improvements can be made to the model. 
The structure of the protein can then be analysed to extract information on its function 
or mechanism of action, for example.
2.7.1 Refinement
Refinement is achieved by modifying the initial molecular model to improve the 
agreement between the observed and calculated structure factor amplitudes (Kleywegt 
and Jones 1997). The agreement between Fobs and Fcaic is represented by the R-factor, 
Rcryst (Drenth 1999):
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A high R-factor indicates that the model is incorrect (McRee 1993) but, because 
refinement is not a fully automated process, it is possible to over-fit the model, giving 
rise to an artificially low R-factor. So, the value of Rcyst alone is not a good indication of 
the accuracy of the model. Refinement can be monitored using another R-factor known 
as Rfree, which is calculated in the same way as Royst from a small subset of the data 
(the “test set”) that are excluded from the refinement. Comparison of R^ yst and Rfree 
provides a more reliable indication that the model is being improved -  if the model 
forms an accurate representation of the experimental data, both R-factors will have 
similar values (Kleywegt and Jones 1997). Once the R-factors have reached a 
minimum value and are in agreement, one last round of refinement is performed before 
the accuracy of the final model is assessed.
Refinement is concerned with the coordinates (x.y.z) and B-factors of all the 
atoms within the model. The B-factor measures the displacement of an atom due to 
thermal motion, conformational disorder and static lattice disorder (McRee 1993). This 
displacement causes the electron density to spread, making the maps more difficult to 
interpret. The number of measured reflections in the dataset is far outweighed by the 
number of parameters to be refined. Therefore, additional information is included in the 
refinement process. This includes information on ideal bond lengths and bond angles, 
the amino acid sequence of the protein and “solvent flattening”. Refinement is 
described as “restrained” if the stereochemical parameters are allowed to vary around 
a set standard or, “constrained” if the stereochemistry of bond lengths and angles is 
kept rigid and only dihedral angles can be varied (Drenth 1999). Solvent flattening 
prevents ordering of the bulk solvent so it is observed as a flat region in the electron 
density map.
2.7.2 Calculation of Electron Density Maps and Model Building
As has been described previously, just as the diffraction pattern is a Fourier 
transform of the protein and the crystal lattice, a Fourier transform of the diffraction 
pattern with phase information will provide an electron density map of the protein.
The classic Fourier synthesis involves the observed amplitudes (F0) and the 
most current phase angles (otcaic) but is subject to model bias (McRee 1993). A 
difference Fourier map (F0-Fc), calculated using observed amplitudes, calculated 
amplitudes (Fc) and current phases, shows peaks where electron density is not 
accounted for in the model. Thus, it is used for identifying corrections that should be 
made to the model. The 2F0-FC map (the sum of the sum of the F0 map and the F0-Fc
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map) looks like protein density, but its quality is dependent upon the quality of the 
phases.
2F0-FC and F0-Fc electron density maps are compared to aid model building. 
The original maps should be retained in order that they may be reinterpreted after each 
round of refinement (Kleywegt and Jones 1997). As well as protein molecules, the 
model may also contain metal ions, ligands, substrates and water molecules, which 
must be modelled into the F0-Fc electron density. If molecular replacement was used to 
determine the initial phases, it may also be necessary to replace non-identical side- 
chains that were converted to alanine in the search model back to the native side-chain 
in the structural model. Such residues will need to have their native side-chains rebuilt 
in accordance with the F0-Fc electron density map. After an amino acid residue has 
been built or modified, or an additional molecule added to the model, the model should 
be refined. New electron density maps should be generated and the R-factors analysed 
to determine that the change led to an improvement in the model.
Towards the end of refinement and model building, F0-Fc electron density can 
often be explained by the addition of water molecules to the molecular model (McRee 
1993). The structure of the solvent surrounding the protein molecules is an important 
aspect of the protein structure and should be modelled carefully. Water molecules 
should not be added until all other changes have been implemented and the model is 
almost complete because not all unexplained density is due to waters (McRee 1993). 
For example, buffer molecules and/or salt present in the mother liquor may be bound 
by the protein and should be modelled as such in the electron density map. Correctly 
identifying peaks in the F0-Fc map will lead to a reduction in Royst and Rfree. Water 
molecules should be placed in areas of good F0-Fc electron density where they may 
make hydrogen bonds with suitable residues in the model (Kleywegt and Jones 1997). 
Waters close to the protein surface typically form hydrogen bonds with polar groups on 
the protein. The total number of waters that can be added depends upon the maximum 
resolution and the quality of the maps but, for a good model, two waters can be 
modelled for every amino acid residue.
2.7.3 Structure Validation
The crystallographic map is a time-average of all the molecular structures in 
the crystal and, therefore, may not represent a true structure, especially if the protein is 
in motion. So, the final model should be validated before it is analysed.
The error in the atomic coordinates of the molecular model is calculated using 
the Luzzati plot. This analysis is based upon the assumption that the difference
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between |F0bsl and |Fcaic|, as quantified by the R-factor, is due solely to errors in the 
positional coordinates of the atoms (Drenth 1999). For a well-refined model, the Luzzati 
coordinate error can be expected to fall in the range 0.2-0.3A. B-factors are also 
calculated for each non-hydrogen residue in the model (McRee 1993). The average B- 
factors in a well-ordered model should not exceed 30A2, although the values for water 
molecules and surface loops may be slightly higher (Drenth 1999).
Structural analysis of peptides has provided a wealth of information on the 
stereochemistry of protein functional groups and these data can be used to evaluate 
the quality of a crystallographically-determined protein structure (McRee 1993). Ideal 
values for bond distances, bond angles, dihedral angles and van der Waals contact 
distances are compared with the molecular model to calculate its deviation from ideal 
stereochemistry (Kleywegt and Jones 1997). Bond lengths and bond angles should not 
deviate from ideal values by more than 0.03-0.05A or 3°, respectively. The main chain 
dihedral angles (<|) and y) in a protein can only take on a limited range of values and 
the Ramachandran plot (Ramachandran et al, 1963) highlights those values that are 
stereochemically viable. The plot is divided into four regions (allowed, additional 
allowed, generously allowed and disallowed) and a good structural model will have at 
least 90% of amino acid residues in the core regions of the plot (Morris et al. 1992). If a 
residue does not meet these criteria, the structure should be analysed to uncover any 
features that may explain the deviation.
The shape and chemical characteristics of the protein surface determine the 
nature of its interactions with other biological molecules (McRee 1993). So, structural 
analysis is concerned with studying the structure of the protein to glean information on 
its function and to uncover any unique features. Lattice contacts should be checked to 
find protein-protein interactions, such as those occurring at the interfaces of multimeric 
proteins. Lattice contacts also provide information on the packing of molecules in the 
crystal lattice -  if atoms are closer than van der Waals packing distances allow, there is 
some error in the model because two atoms cannot occupy the same position in the 
crystal (McRee 1993). Information on the formation of hydrogen bonds with other 
protein molecules, ligands and the solvent is also useful for understanding the function 
and overall structure of the protein. A hydrogen bond is assumed to be formed if a 
proper acceptor-donor pair exists within the correct bonding distance of 2.7-3.0A 
(McRee 1993). If the protein under investigation is an enzyme, information on the 
protonation state of certain amino acids can also provide clues as to the mechanism of 
action. The surface of the protein is studied to determine the solvent accessibility of 
specific residues and to look for features, such as depressions or clefts that may
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indicate the location of a binding or active site. Interactions between the protein and 
any bound ligands should be carefully investigated in order to glean information on the 
function and/or mechanism of action of the protein.
The final step in protein crystallography is deposition of the coordinates of the 
protein in the PDB to enable other scientists to access the information. There is an 
obligation to deposit atomic coordinates within a certain period after the structure has 
been solved and published.
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CHAPTER THREE 
CRYSTAL STRUCTURE OF ERYTHRINA CRISTAGALLI
LECTIN
3.1 INTRODUCTION
Lectins are carbohydrate-binding proteins of non-immune origin. They do not 
exhibit catalytic activity and thus cannot be described as enzymes. The carbohydrate- 
binding site is therefore not an active site, and is known as a “combining site”. Lectins 
of different families exhibit variation in their three-dimensional structures (reviewed in 
Loris 2002) and exist in a variety of oligomeric states. Lectins are also found in a wide 
range of species, from bacteria and viruses to plants and animals.
Lectins recognise and bind to a number of mono-, di- and oligosaccharides as 
well as to glycoproteins to mediate a number of cell-cell interactions and biological 
processes. Protein-carbohydrate interactions represent an important mechanism of 
cellular targeting and recognition. Oligosaccharides post-translationally added to many 
proteins act as a recognition motif and are, therefore, the most likely natural ligands of 
lectins.
3.1.1 Glycosylation of Proteins
Glycosylation of proteins is the most common form of post-translational 
modification in eukaryotes, particularly among membrane proteins and secretory 
proteins (Ashford and Platt 1999). The addition of saccharide units to proteins not only 
affects their physical properties, such as solubility, but also influences their activities.
3.1.1.1 N-Linked Glycosylation
Sugars are commonly linked to eukaryotic proteins by the formation of an N- 
glycosidic bond between N-acetylglucosamine (GlcNAc) and the side chain of an 
asparagine residue. The target asparagine must be located within the motif Asn-X- 
Thr/Ser (where X can be any amino acid except proline). N-glycosylation of proteins 
begins with the addition of a dolichol-linked “high-mannose” structure, comprising two 
GlcNAc, nine mannose and three glucose residues. This oligomannose saccharide is 
assembled in the endoplasmic reticulum linked to dolichyl pyrophosphate and 
transferred to the target protein by an oligosaccharyltransferase enzyme. The high- 
mannose structure can then be further processed to produce a variety of 
oligosaccharide units (Spiro 2000; Turco and Robbins 1979).
52
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
3.1.1.2 Role of Glycosylation
The post-translational addition of sugars to proteins provides a mechanism by 
which other proteins can specifically recognise them. In addition to the most common 
N-linked form of glycosylation, sugars can be linked to proteins by O-glycosidic 
linkages, C-mannosylation, phosphoglycation and glypiation (reviewed in Spiro 2002). 
O-linked glycosylation attaches sugars to amino acids with side chains that contain 
hydroxyl groups (i.e. serine, threonine, tyrosine, hydroxyproline and hydroxylysine). C- 
mannosyl bonds, first observed in Eosinophil Derived Neurotoxin, can be formed 
between an a-mannosyl residue and C2 atom of a tryptophan residue (Krieg et al. 
1997). The formation of a phosphodiester bond between a sugar and a protein is 
known as phosphoglycation and involves serine residues. Glypiation is the linkage of a 
glycophosphatidylinositol anchor to proteins by the formation of a bond between the 
target protein and phosphoethanolamine linked to mannose.
One common role of the bound carbohydrate is to affect the rate of clearance 
of proteins from serum. Oligosaccharides are also recognition molecules that are 
involved in interactions with a variety of cells and biological molecules. Glycosylation 
can target proteins to specific regions of the cell membrane or intracellular 
compartments and defects in glycosylation pathways can therefore result in disease. 
Lysosomal enzymes are targeted to the lysosome from the Golgi apparatus by the 
addition of mannose-6-phosphate (Griffiths et al. 1988; Kornfeld and Mellman 1989), 
which is recognised by a specific lectin receptor (Dahms et al. 1989). l-cell disease is 
caused by defects in the enzymes that attach mannose-6-phosphate to proteins 
destined for lysosomes.
3.1.1.3 Cross-Linking and Multivalency
Lectins exhibit high specificity for oligosaccharides expressed on cell surfaces, 
binding their target ligands with high affinity. This high level of specificity and affinity 
(known as avidity) can be achieved in several ways: the presence of several 
recognition sites on ligands (i.e. ligand multivalency); the presence of an extended 
combining site capable of accommodating several sugar residues; and/or the clustering 
of several binding sites by oligomerisation of lectin protomers (i.e. lectin multivalency) 
(Lis and Sharon 1998).
The combination of lectin and ligand multivalency provides the basis for 
multiple high-affinity interactions that can lead to cross-linking (Rini and Lobsanov 
1999). For example, crystallographic analysis of soybean agglutinin (SBA) with 
oligosaccharides revealed the existence of cross-linked lattices involving one SBA
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tetramer and four pentasaccharides (Olsen et al. 1997). In addition, galectin-1 has 
been found to form chains of dimers that are cross-linked through oligosaccharides 
(Bourne et al. 1994; Perillo et al. 1995). Cross-linking is thought to be an important 
process and has been implicated in a variety of biological activities, for example 
apoptosis (Perillo et al. 1995).
3.1.2 Classification of Lectins
3.1.2.1 Monosaccharide-Specificity
Lectins can be divided into five classes on the basis of their carbohydrate 
specificity according to the monosaccharide for which they exhibit the greatest affinity. 
All known lectins are specific for one of the following monosaccharides: GlcNAc; 
mannose (Man); fucose (Fuc); galactose/N-acetylgalactosamine (Gal/GalNAc); or N- 
acetylneuraminic acid (sialic acid). These monosaccharides are typically expressed on 
the surfaces of eukaryotic cells (Lis and Sharon 1998). Despite the binding affinity of 
lectins for monosaccharides being relatively low (i.e. in the millimolar range), some 
lectins are highly selective for the monosaccharide they bind (Lis and Sharon 1998). 
Most lectins also bind to di-, tri- and oligosaccharides, often with higher affinity than 
that with which they bind monosaccharides, and some lectins (for example potato 
lectin, selectins and galectins) only bind oligosaccharides (Lis and Sharon 1998). 
Lectins of the same specificity group often exhibit different binding affinities for 
oligosaccharides (Goldstein and Hayes 1976). For example, the siglecs all bind sialic 
acid, recognising a free hydroxyl group at position C9, but differ in their affinities for 
sialic acids modified at other positions (Kelm et al. 1998). Some lectins specific for the 
same oligosaccharide recognise different regions of its structure.
3.1.2.2 Structural Differentiation
Alternatively, lectins may be grouped into three structural classes -  simple 
lectins, mosaic (multi-domain) lectins or macromolecular assemblies. Simple lectins, 
such as the galectins and most plant lectins, are made up of a small number of 
subunits (protomers) and may have an additional domain besides the combining site. 
Mosaic lectins, for example influenza virus haemagglutinin and mannose-6-phosphate 
receptor, are membrane-bound proteins that consist of several kinds of protein domain, 
of which only one has a combining site. Macromolecular assemblies are filamentous 
organelles (fimbriae or pili) expressed on the surface of a bacterium. They consist of 
helically arranged subunits assembled in a well-defined order and only one of the 
subunits possesses a combining site. Within these three structural classes, lectins can
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be further sub-divided into several families with similar sequences and structural 
properties (Lis and Sharon 1998). Examples of lectins from each structural family are 
presented in Table 2.
Table 2 - Classification of Lectins According to Structure
Simple lectins Legume Concanavalin A
Cereal W heat germ agglutinin
A m a ry l l id a c e a e Snowdrop lectin
M o ra c e a e Jacalin
E u p h o rb ia c e a e Ricin
Galectins Human galectin-7
Pentraxins Human serum amyloid P component




Macromolecular assemblies E .c o li type 1 fimbriae
All lectins can be classified into three groups on the basis of their structure -  simple lectins, mosaic lectins 
and macromolecular assemblies. Within these three structural classes, lectins can be further sub-divided 
into families with similar sequences and structural properties. An example of each lectin family is provided.
3.1.3 Lectins Mediate a Variety of Biological Processes
Protein-carbohydrate interactions are involved in a large number of biological 
processes, predominantly involving cell-cell interactions. Glycoproteins are widespread 
in nature and their recognition is key to many cellular activities. Not only do lectins play 
roles in targeting glycoproteins to cellular locations, they are also implicated in immune 
responses and regulation of levels of proteins in circulation (Lee and Lee 1995).
3.1.3.1 Animal Lectins
There are several classes of C-type lectin, the carbohydrate-binding properties 
of which are calcium-dependent. The collectins, such as mannan binding lectin (Ikeda 
et al. 1987) and ficolins are involved in innate immune responses by binding 
oligomannosides on infectious organisms and causing activation of the complement 
system and lysis of the pathogen (Holmskov et al. 2003). The mammalian hepatic 
lectins are receptors that mediate the internalisation and lysosomal degradation of 
galactose/GalNAc-containing glycoproteins (Ashwell and Harford 1982; Weigel 1994). 
Selectins are membrane proteins that mediate the adhesion of circulating leukocytes to
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endothelial cells of blood vessels and the subsequent migration of these leukocytes 
into tissues (Lasky 1991). Endothelial leukocyte adhesion molecule 1, for example, 
mediates the adhesion of blood neutrophils (Bevilacqua et al. 1989). Leukocyte 
trafficking to sites of infection is an important regulatory process but can also cause 
harmful inflammation, for example in rheumatoid arthritis (Lis and Sharon 1998).
The l-type lectins play roles in cell adhesion and signalling. Sialoadhesin, for 
example, is active in the immune system (van den Berg et al. 1992). The P-type lectins 
are mannose-6-phosphate receptors that target lysosomal enzymes to the lysosome 
(reviewed in Hille-Rehfeld 1995). Pentraxins, including C-reactive protein and serum 
amyloid P component, regulate innate immunity against microbes and scavenge 
cellular debris, recognising and clearing apoptotic cells from circulation (reviewed in 
Gewurz et al. 1995).
The galectins (S-type animal lectins) are believed to function in cell adhesion 
and regulation of growth. As their expression is developmental^ regulated, galectins 
have also been postulated to be essential for development and cell differentiation (Lis 
and Sharon 1998). Galectin-1 induces apoptosis in developing T cells in the thymus 
and activated T cells in the periphery (Perillo et al. 1995; Perillo et al. 1997; Vespa et 
al. 1999) and galectin-3 promotes the attachment of neutrophils to fibronectin and 
laminin (Kuwabara and Liu 1996).
3.1.3.2 Plant Lectins
Plant lectins have been known for longer than animal and microbial lectins and 
their carbohydrate-binding specificities and structures have been extensively studied. 
However, their biological functions remain the subject of much debate. The two most 
popular theories are that plant lectins are either involved in the specificity of legume 
root nodulation by bacteria or that they play roles in plant defence.
The lectin recognition hypothesis, proposed in the early 1970s (Bohlool and 
Schmidt 1974; Dazzo and Hubbell 1975; Hamblin and Kent 1973), suggests that lectins 
mediate specificity in the symbiotic relationship between nitrogen-fixing bacteria of the 
genus Rhizobium and leguminous plants. Indeed, the association between bacteria 
and legumes is highly specific, with the rhizobia exhibiting a very narrow host range. 
For example, rhizobia that infect and nodulate soybeans cannot nodulate peas or 
clover (Lis and Sharon 1998; van Rhijn et al. 1998) and it is thought that legume lectins 
facilitate the attachment of rhizobial bacteria to legume root hairs (Hirsch et al. 2001). 
However, whilst there is a great deal of support for this hypothesis, it does not explain 
the presence or role of lectins in non-leguminous plants. The other potential role of
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lectins in plants is in defence against predators and pathogenic fungi (reviewed in 
Peumans and van Damme 1995). Animal lectins have been implicated in innate 
immunity and it is plausible that plant lectins might play a similar role. Plant lectins are 
known to be toxic to animals and inhibit fungal growth, which is the basis for this 
potential role in defence (Lis and Sharon 1998).
3.1.3.3 Bacterial and Viral Lectins
Lectins expressed on the surfaces of viruses and bacteria mediate adhesion 
of the organism to host cells as a first step in the infection process. The first example of 
this was the influenza virus haemagglutinin, which binds to gangliosides on the host 
cell surface to gain entry to the cell and replicate (Bergelson et al. 1982). Influenza 
virus haemagglutinin specifically binds to N-acetylneuraminic acid residues expressed 
on host cells, enabling the viral and cellular membranes to fuse as a prerequisite for 
viral infection. Adherence of the influenza haemagglutinin to neutrophils may allow the 
virus to spread from respiratory epithelial cells to lymph nodes (Ratcliffe et al. 1992). 
Structural knowledge of this lectin has enabled the rational design of an inhibitor that 
targets acts as a substrate analogue and can be used to treat influenza (Smith et al. 
2001; von Itzstein et al. 1996).
Following the attachment of a pathogenic microbe to the host cell, it is thought 
that biological cross-talk via the lectin activates the host cell, leading to disease. For 
example, the attachment of Escherichia coli to intestinal epithelial cells leads to the 
transmigration of polymorphonuclear leukocytes to the infected tissue (Savkovic et al.
1996). In addition, secretion of chloride ions from epithelial cells is induced by the 
action of enterotoxins, produced by E.coli, that activate the cyclic GMP pathway and 
this causes diarrhoea (Uzzau and Fasano 2000).
3.1.3.4 Therapeutic Applications of Lectins
The specificity of lectins for glycoproteins can be exploited in medicine and 
research to distinguish between different cell types. For example, agglutination of B 
and T splenocytes by SBA is employed to purge human bone marrow for 
transplantation into children with severe combined immune deficiency or leukaemia 
(Aversa et al. 1994). The haemagglutinating activities of lectins are also used in blood- 
typing. Furthermore, mitogenic lectins (for example phytohaemagglutinin) that activate 
lymphocytes and cause them to divide are used to assess immunocompetence. 
Several lectins can be used in combination to stain urinary cell types to monitor kidney 
function post-transplantation (Grupp et al. 2002; Grupp et al. 2001). P-fimbriated E.coli
57
Structurai Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
that recognise and bind to uroepithelial cells can be used as a marker to detect risk 
groups among patients with recurrent urinary tract infections (Jacobson et al. 1986).
Animal and plant lectins are also thought to be of potential use in targeted 
drug delivery, particularly for the treatment of cancer and immune diseases (Clark et al. 
2000; Lehr 2000). Selectins are thought to be of potential use in targeting anti­
inflammatory drugs to sites of inflammation (Eniola et al. 2002). Wheat germ agglutinin 
(WGA) has potential as a vehicle for the delivery of modified liposomes in oral vaccines 
(Chen et al. 1996). It binds a variety of cell types (Aubery et al. 1990; Gabor et al. 
1998; Lotan et al. 1975) and has been used to target chemotherapeutic prodrugs to 
colon carcinoma cells (Wirth et al. 1998).
3.1.4 Legume Lectins
The legume lectins are mainly isolated from the seeds of leguminous plants 
(Loris et al. 1998). Members of this protein family are highly homologous with respect 
to their amino acid sequences and share a common tertiary structure but exhibit 
structural variation at the quarternary level.
Legume lectins are typically synthesised as precursor polypeptides, which are 
post-translationally cleaved, beginning with the removal of an N-terminal signal peptide, 
to yield the mature protein (Loris et al. 1998). Legume lectin protomers have molecular 
weights in the range 25-30kDa and comprise a polypeptide chain of -250 amino acids. 
Each protomer contains two metal ions, calcium and manganese, located close to the 
combining site that are required for carbohydrate binding. All known legume lectins are 
active as either dimers or tetramers, although each protomer possesses a functional 
carbohydrate-combining site with the combining site in each protomer having the same 
specificity (Sharon and Lis 2002). Many legume lectins are glycoproteins, in which the 
protomers carry one or two N-linked oligosaccharides (Lis and Sharon 1998). The 
presence of bound oligosaccharides has been postulated to influence the quarternary 
structures of the legume lectins (discussed later).
3.1.4.1 Sequence Homology Among Legume Lectins
There is high sequence homology among the legume lectins, with members of 
this protein family sharing up to 99% sequence identity (Manoj and Suguna 2001). An 
alignment of the sequences often legume lectins is presented in Figure 10. Analysis of 
19 legume lectins of known tertiary structure revealed that 69 amino acids were 
conserved, of which 21 were identical, among their sequences (Manoj and Suguna 
2001). The residues conserved in all legume lectin sequences are involved in 
carbohydrate binding and coordination of the calcium and manganese ions that are
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bound close to the combining site (Lis and Sharon 1998). It is interesting to note that 
there are ten amino acids different between the sequence of recECL determined for 
this investigation by DNA sequencing (Stancombe et al 2003) and that reported for the 
SvenECL (Svensson et al 2002).
Figure 10 - Sequence Alignment of Ten Legume Lectins
PSL ---MASLQTQ MISFYAIFLS ILLTTILFFK VNSTETTS
LenL ---------      TETTSl
SBA -MATSKLKTQ NVWSLSLTL TLVLVLLTSK ANSAETVs)
GSIV ---------  ---------- ---------  ---QN
PHA-L -----------  MASSKFF TVLFLVLLTH ANSSNDI
ECorL ------- MAT YKLCSVLALS LTLFLLILNK VNSVETIS|
ECL        VETISFS
SvenECL ---------      ---VETIS|S
 ..... — ------------------  — m kt isJn fnq§h
ConA MAISKKSSLF LPIFTFITMF LMWNKVSSS THETN.
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q i h l i r H s I
Alignment of the amino acid sequences of ten legume lectins whose three-dimensional structures have 
been determined was performed using clustalw (Thompson et al. 1994) with sequences taken from the 
SwissProt database (Boeckmann et al. 2003). The sequence of ECL quoted above is that of recECL, 
determined for this investigation by DNA sequencing (Stancombe et al 2003), whilst the SvenECL 
sequence is that of the recently reported crystal structure of ECL (Svensson et al 2002). Six sequences 
include the N-terminal signal sequence that is post-translationally cleaved to yield the mature protein. 
Legume lectins are highly homologous in terms of their primary structures, sharing up to 99% sequence 
identity. In this figure, the amino acid residues highlighted in blue are identical among the sequences and 
those highlighted in yellow are conservatively substituted. The conserved residues are involved in 
coordinating the calcium and manganese ions as well as in binding carbohydrates.
(Abbreviations: PSL, pea lectin; LenL, lentil lectin; SBA, soybean agglutinin; GSIV, G r if fo n ia  s im p lic ifo l ia  
lectin 4; PHA-L, phytohaemagglutinin; ECorL, E ry th r in a  c o ra llo d e n d ro n  lectin; ECL, E ry th r in a  c r is ta g a l l i  
lectin; WBA-1 winged bean acidic lectin; ConA, concanavalin A; and PNA, peanut agglutinin).
Carbohydrate binding requires three amino acids -  an aspartic acid, an 
asparagine and an aromatic residue or leucine -  that are invariant among all the 
legume lectins, regardless of their monosaccharide specificity (Lis and Sharon 1998). 
The Asp and Asn residues are also involved in coordinating the bound calcium ion, 
which explains the requirement of this metal ion for carbohydrate binding by legume 
lectins. Differences in carbohydrate specificity are conferred by variation in the amino 
acid residues, other than the conserved triad, that line the shallow cleft that makes up 
the combining site.
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3.1.4.2 The Legume Lectin Fold
Figure 11 - The Jelly-roll Motif (Legume Lectin Fold)
This figure, prepared using the programs Molscript (Kraulis 1991), Povray (www.povray.org/) and GIMP  
(www.gimp.org/), shows the three-dimensional structure of Concanavalin A (Reeke et al. 1975; PDB code 
2CNA). The overall topology is described as a jelly-roll and is also known as the legume lectin fold. The 
structure comprises three 0-sheets: one flat, six-stranded anti-parallel 0-sheet at the back of the lectin in 
this figure; a curved, seven-stranded anti-parallel 0-sheet at the front of the molecule; and a small, five- 
stranded 0-sheet at the bottom. These sheets are joined by a series of loops. A typical legume lectin, Con 
A contains two metal ions (calcium and manganese, shown in green and navy, respectively) that are 
required for its carbohydrate-binding activity. The metal ions are bound close to the combining site, which 
is located in a shallow depression on the surface of the curved, seven-stranded 0-sheet.
The first lectin to be structurally characterised was concanavalin A (ConA), 
which is isolated from the jack bean, Canavalia ensiformis, a leguminous plant 
(Hardman and Ainsworth 1972). The overall fold, characterised by two anti-parallel (3- 
sheets, is described as the “jelly-roll” motif (Figure 11). This toplogy has since been
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observed in many lectins and is also referred to as the legume-lectin fold. The legume 
lectin fold comprises three p-sheets connected by a series of loops. As depicted in 
Figure 11, towards the back of the structure is a flat, six-stranded sheet and towards 
the front is a curved, seven-stranded sheet, both of which are entirely anti-parallel. 
There is also a small five-membered p-sheet, seen at the bottom of the molecule in 
Figure 11. The carbohydrate-combining site is located in a shallow depression on the 
surface of the lectin and involves four loops associated with the curved, seven- 
stranded p-sheet. In each protomer, there are two metal ions, Ca2+ and Mn2+, bound 
close to the legume lectin combining site that are essential for the carbohydrate binding 
activity of these proteins.
The Ca2+ and Mn2+ are thought to maintain the correct spatial arrangement of 
combining site residues (Derewenda et al. 1989). The metal ions are each coordinated 
by the side chains of four amino acids and two water molecules. The manganese ion in 
SBA can be substituted with other transition metals (nickel, cobalt and cadmium) with 
no loss of carbohydrate-binding activity (Jaffe et al. 1977). Furthermore, the crystal 
structures of ConA in which the manganese ion has been replaced by cobalt or 
cadmium reveal that the overall geometry of the metal binding site is independent of 
the nature of the transition metal present (Emmerich et al. 1994).
In legume lectins, the Ca2+ and Mn2+ ions also stabilise a conserved cis- 
peptide bond between the carbohydrate-binding aspartate residue and the preceding 
amino acid, which is typically alanine. The stereochemistry of the c/s-peptide bond 
places the side chain of the aspartate residue in the correct orientation for 
carbohydrate binding (Lis and Sharon 1998). Interestingly, the structures of metal- 
stripped ConA determined at different stages of metal replenishment have revealed a 
trans to c/s isomerisation of the Ala-Asp peptide bond upon metal-induced activation of 
the lectin (Bouckaert et al. 1995; Bouckaert et al. 1996).
Legume lectins are classed as simple lectins and, although they are all 
biologically active as dimers or tetramers, the association of protomers does not affect 
carbohydrate-binding because each protomer is equipped with a fully-functional, pre­
formed combining site. However, it is interesting that the legume lectins exhibit 
variation in their quarternary association considering the high-level of homology among 
their structures at the primary and tertiary levels.
3.1.4.3 Variation in Quarternary Association Among Legume Lectins
Despite a high degree of similarity among their tertiary structures the legume 
lectins exhibit a range of quarternary structures. All legume lectins are biologically
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active as dimers or tetramers (which are considered dimers of dimers). There are five 
types of interface, all of which involve the flat, six-stranded p-sheet. In ll-type 
interfaces, protomers associate side-by-side and in X1, X2, X3 and X4 type interfaces, 
protomers associate back-to-back.
The canonical mode of dimerisation was originally observed for ConA and 
involves the side-by-side (ll-type) association of two protomers such that the two six- 
stranded p-sheets form one contiguous 12-stranded p-sheet (Hardman and Ainsworth 
1972). The X3-type of dimer, first observed in Erythrina corallodendron lectin (ECorL), 
is described as the “handshake motif because protomers associate back-to-back with 
the six-stranded sheet from one protomer tilted with respect to the other (Shaanan et 
al. 1991). Protomers of the lectin isolated from Griffonia simplicifolia (GSIV) also 
dimerise back-to-back, but in a different way to ECorL, forming an X4-type interface 
(Delbaere et al. 1993).
X1 and X2-type interfaces are observed in tetrameric lectin structures. In the 
lectin isolated from Dolichos biflorus, two X1-type dimers associate side-by-side, 
forming a ll-type interface (Hamelryck et al. 1999). ConA can exist as a dimer and as a 
tetramer, with the tetrameric structure formed by two ll-type dimers associating back- 
to-back, forming an X2-type interface (Bouckaert et al. 1995; Reeke et al. 1975). 
Peanut lectin (PNA) has the most unusual quarternary structure, described as an 
“open” arrangement. Unlike in the other tetrameric lectins, the protomers of peanut 
lectin are arranged as two back-to-back dimers with interactions between the dimers 
involving different interfaces (Banerjee et al. 1994). Although, the two dimers associate 
side-by-side, they do not form a contiguous 12-stranded p-sheet but are connected by 
a set of water bridges.
Originally, the observed variation in quarternary association was explained by 
the presence of N-linked glycosylation close to residues that would be involved in the 
formation of a canonical dimer interface and to small differences in primary structure. 
The presence of a branched oligosaccharide N-linked to Asn17 of ECorL was deemed 
responsible for forcing the protomers into a non-canonical dimer structure (Shaanan et 
al. 1991). However, the glycosylation sites in basic winged bean lectin, which shares 
63% sequence identity with ECorL and forms X3-type dimers (Prabu et al. 1998), are 
distant from the region that would constitute the interface in a canonical dimer. In 
addition, peanut lectin is not glycosylated but the dimeric interface of the tetramer is 
non-canonical. Taken together, these data suggest that factors other than the presence 
of glycosylation influence the mode of quarternary association in legume lectins (Prabu 
et al. 1999).
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Assessment of the different interfaces in terms of hydrophobic surface area 
buried upon association, interaction and energy, and shape complementarity revealed 
that the native mode of dimerisation or tetramerisation for each of the lectins studied 
was the most favourable arrangement (Prabu et al. 1999). Analysis of the primary 
structures of several legume lectins has since pinpointed a small number of residues 
that appear to play a role in determining certain modes of dimerisation (Manoj and 
Suguna 2001). However, it is not yet possible to accurately predict the quarternary 
structures of uncharacterised lectins.
3.1.4.4 Carbohydrate Binding in Legume Lectins
The architecture of the combining site is conserved among legume lectins, as 
are many of the amino acids involved in carbohydrate binding (Sharma and Surolia
1997). The combining site comprises a shallow cleft involving four loops (designated A- 
D) that are associated with the curved, seven-stranded p-sheet. Two conserved 
residues, an asparagine and an aspartic acid, are essential for carbohydrate binding 
along with the main chain nitrogen of a glycine or arginine (Sharma and Surolia 1997). 
These residues form hydrogen bonds with the monosaccharide in the combining site. 
Sugar binding is further stabilised by stacking interactions with either a leucine or a 
hydrophobic residue. The conserved aspartic acid and glycine/arginine are present on 
combining site loops A and B, respectively (Sharma and Surolia 1997). The asparagine 
and leucine/hydrophobic residue are located in loop C and loop D provides residues 
that interact with the bound monosaccharide via the peptide backbone. Analysis of the 
sequences of 26 legume lectins revealed a link between the length of combining site 
loop D and monosaccharide specificity, whereby the length of the loop alters the shape 
of the combining site (Sharma and Surolia 1997). For example, legume lectins that are 
specific for galactose/GalNAc have longer D loops than those that recognise mannose, 
glucose or fucose.
Legume lectins are highly selective for the monosaccharides they bind. For 
example, those that are galactose-specific do not bind Man or glucose, even though 
they are epimers of Gal. Monosaccharides can only bind in an orientation that directs 
an equatorial hydroxyl group towards the space between the Asp-Gly/Arg-Asn triad and 
provides an axial hydroxyl or hydroxymethyl group as a hydrogen-bonding partner for 
the aspartic acid (Sharma and Surolia 1997). Lectins bind carbohydrates by forming a 
network of hydrogen bonds and hydrophobic interactions (Lis and Sharon 1998). The 
hydroxyl groups on the sugar form hydrophobic patches that interact with hydrophobic 
regions on the lectin, for example the stacking interactions observed between pyranose
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rings and aromatic side chains. It has also been shown that water molecules bridge 
hydrogen bonds between carbohydrate and lectin. For example, one of the waters that 
co-ordinates Ca2+ also forms a bridge with the carbonyl group of the carbohydrate- 
binding aspartic acid (Adar et al. 1998; Loris et al. 1994).
3.1.5 Erythrina Cristagalli Lectin
The lectin isolated from seeds of the coral tree Erythrina cristagalli is known as 
ECL or ECA. Trees and shrubs of the genus Erythrina are deciduous legumes found in 
tropical and subtropical habitats (Lis and Sharon 1987). Lectins isolated from Erythrina 
species are glycoproteins, comprising 3-10% carbohydrate, with molecular weights in 
the range 56-68kDa. Erythrina lectins are specific for Gal- or GalNAc-containing 
carbohydrates and are biologically active as dimers (Lis and Sharon 1987). They are 
typical legume lectins, with protomers that adopt the legume lectin fold and contain one 
calcium and one manganese ion. All Erythrina lectins agglutinate human erythrocytes 
of all blood groups and most are mitogenic for human peripheral blood lymphocytes 
(Lis and Sharon 1987).
3.1.5.1 Carbohydrate Specificity of ECL
ECL selectively binds to terminal unsubstituted N-acetyllactosamine (LacNAc) 
(Iglesias et al. 1982). In vitro, 0.4mM LacNAc completely inhibits the activity of four 
agglutinating units of ECL (one unit of activity is defined as the lowest concentration of 
lectin giving visible haemagglutination). ECL binds lactose, GalNAc and Gal with lower 
affinity than LacNAc, with the binding affinity for these sugars decreasing in the order 
they are listed (Iglesias et al. 1982). However, it has recently been shown that ECL has 
the highest affinity for fucosyllactose and fucosyllactosamine, binding both sugars with 
similar affinity. In this respect, ECL differs from lectins isolated from other Erythrina 
species, which exhibit a preference for fucosyllactose (Moreno et al. 1997).
The biological function of ECL in the legume is currently unknown. In vitro, 
ECL agglutinates human erythrocytes of all blood types and is mitogenic for human 
peripheral blood T lymphocytes (Iglesias et al. 1982). ECL might be a useful marker to 
follow changes in cell surface carbohydrates during differentiation. For example, ECL 
recognises oligosaccharides expressed on human cervical carcinoma cells that are not 
expressed on healthy cervical cells (Banerjee et al. 1995). More recently, ECL has 
been used to select subpopulations of insect cells by the character of their cell-surface 
oligosaccharides (Donaldson and Shuler 1999).
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3.1.5.2 Molecular Structure of ECL
ECL is expressed as a precursor protein that is post-translationally processed 
(involving the removal of the 26-amino acid signal sequence from the N-terminus and 
addition of oligosaccharide) to yield the mature protein. The sequence of ECL is 96% 
identical to that of ECorL -  there are only nine differences between their 241-amino 
acid sequences. Unlike ECorL, the ECL sequence contains a single potential N-linked 
glycosylation site at residue Asn113 and the molecular weight of the unglycosylated 
protomer is predicted to be 26kDa (Stancombe et al. 2003).
ECL is biologically active as a dimer of ~56.8kDa. Sodium dodecylsulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) of ECL produces two bands that both 
stain positively for protein and carbohydrate (Iglesias et al. 1982). This indicates that 
ECL is a heterodimer, made up of two protomers that are both glycosylated, with a 
single carbohydrate chain bound to each. The oligosaccharides bound to ECL have 
been characterised with the major component identified as a heptasaccharide of 8.8 
glucose units (Figure 12) and minor components of 8.0, 7.2 and 5.8 glucose units 
(Ashford et al. 1991). The glycosylation profile of ECL matches those of four other 
lectins isolated from Erythrina species and five unrelated legume lectins.










The major component of the oligosaccharides isolated from ECL is the heptasaccharide diagrammatically 
represented in this figure. This glycosylation profile has also been observed in four other E ry th r in a  lectins 
and five unrelated legume lectins.
3.1.5.3 Crystal Structure of ECL
The crystal structures of ECL in complex with 2’-a-L-fucosyllactose and 
lactose (PDB codes 1GZ9 and 1GZC, respectively) were recently reported (Svensson 
et al. 2002). Four sequences for ECL have been reported (Svensson et al. 2002). The 
sequence determined by mass spectrometry contained only 229 out of 241 amino 
acids and differed at two positions from the sequence of SvenECL according to the 
observed electron density (Svensson et al. 2002). Peptide mapping was reportedly
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attempted by analysing fragments of SvenECL (created by enzymatic digestion of the 
protein) using tandem mass spectrometry. However, sequence coverage of only 89% 
of the amino acid residues (i.e. 213 of 239) was obtained by this method (Svensson et 
al 2002).
The SvenECL protomer was confirmed to adopt the jelly-roll fold and 
protomers were shown to dimerise back-to-back via the handshake motif. N-linked 
glycosylation was apparently observed at two positions in the structure, Asn17 and 
Asn113, although the sugars were not modelled into the observed electron density. The 
influence of bound carbohydrate on the quarternary structures of legume lectins is still 
the subject of much debate. In ECorL, which also forms dimers via the handshake 
motif, the heptasaccharide bound to Asn17 was proposed to sterically hinder the 
formation of a canonical dimer and the same reasoning has been applied to SvenECL 
(Svensson et al. 2002).
In the SvenECL combining site, the side-chains of Asp89, Gly107 and Asn133
create a strong hydrogen-bonding network for carbohydrate binding, a structural water
molecule mediates interaction between the main chain carbonyl oxygen of Leu86 and 
galactose and the side-chain of Phe131 forms hydrophobic stacking interactions with the 
galactose pyranose ring. Residues Ala218 and Gin219 also form hydrogen bonds with 
the bound carbohydrate. On the basis of the crystallographic data, it was proposed 
that observed differences in the binding affinities of ECL and ECorL for the same 
carbohydrates are due to differences in the amino acid sequences of the two proteins 
at positions 111 and 125 (Svensson et al. 2002). It is thought that substitutions at 
these positions cause the side chain of Val92 to rotate, transmitting structural changes 
to the combining site, although this remains to be proved.
3.2 MATERIALS AND METHODS
3.2.1 Materials
Native and recombinant forms of ECL (nECL and recECL, respectively) were 
provided by Dr J.A. Chaddock (Health Protection Agency, UK). nECL was purchased 
from Sigma (UK) and recECL was expressed and purified by the Toxin Therapeutics 
Division at CAMR as reported (Stancombe et al. 2003) and briefly described in 
Appendix 1. The amino acid sequence of recECL (Figure 13) does not differ from that 
of nECL. Purified protein stocks were stored at -20°C in buffer comprising 50mM 
sodium chloride and 20mM HEPES, pH 7.4. The protein concentrations of the nECL 
and recECL stocks were estimated as ~10.0mg/ml and ~14.5mg/ml, respectively.
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Figure 13 - Amino Acid Sequence of recECL compared with that of SvenECL
nECL VETISFSFSE FEPGNNDLTL QGAAIITQSG VLQLTKINQN
SvenECL VETISFSFSE FEPGNDNLTL QGAALITQSG VLQLTKINQN
nECL GMPAWDSTGR TLYTKPVHIW DMTTGTVASF ETRFSFSIEQ
SvenECL GMPAWDSTGR TLYTKPVHMW DSTTGTVASF ETRFSFSIEQ
nECL PYTRPLPADG LVFFMGPTKS KPAQGYGYLG VFNNSKQDNS
SvenECL pytrplpadg lvffmgptks kpaqgygylg vfnnskqdns
nECL YQTLAVEFDT FSNPWDPPQV PHIGIDVNSI RSIKTQPFQL
SvenECL YQTLAVEFDT FSNPWDPPQV PHIGIDVNSI RSIKTQPFQL
nECL DNGQVANWI KYDASSKILL AVLVYPSSGA IYTIAEIVDV
SvenECL DNGQVANWI KYDAPSKILH WLVYPSSGA IYTIAEIVDV
nECL KQVLPEWVDV GLSGATGAQR DAAETHDVYS WSFHASLPET N
SvenECL KQVLPDWVDV GLSGATGAQR DAAETHDVYS WSFQASLPE- -
The ECL gene devoid of the 26-amino acid N-terminal signal peptide was recombinantly over-expressed in 
E .c o li (Stancombe et al, 2003) and the 241-amino acid sequence of the mature nECL protein is presented 
in black type. The amino acid sequence reported for SvenECL is presented in blue.
The sequence of ECL is highly homologous to the sequences of lectins isolated from other E ry th r in a  
species and is 96% identical to ECorL. Unlike ECorL, the ECL sequence contains only one potential site 
for N-linked glycosylation at residue Asn113 (underlined). Analysis of the structures of ECL in complex with 
lactose and fucosyllactose (Svensson et al, 2002) has shown that residues Leu86, Asp89, Gly107, Phe131, 
Asn133, Ala218 and Gin219 (highlighted in red in the recECL sequence) are involved in carbohydrate binding.
24-well crystallisation plates (Molecular Dimensions Ltd, UK) were used with 
siliconised coverslips (Hampton Research, USA). Commercial crystallisation screens 
Structure Screen I and II (Molecular Dimensions Ltd) and a PEG/lon matrix (Hampton 
Research) were used in initial crystallisation trials. The contents of these screens are 
listed in Appendix 2. Reagents used to prepare the crystallisation solutions were of 
high quality and purity and solutions were made with AnalaR water (VWR International, 
UK). Sodium chloride and ethanol were purchased from Fisher Chemicals (UK) and
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tert-butanol was obtained from Fluka (UK). Tris, isopropanol and glycerol were 
obtained from VWR International. All other reagents were purchased from Sigma.
Co-crystallisation experiments involved GalNAc; a-lactose (Lac); p-lactose; 
Gal; 2’fucosyllactose and 3-fucosyllactose. A 100mM stock solution of each 
carbohydrate was prepared with milliQ water.
3.2.2 Crystallisation
Crystallisation was attempted using the hanging drop vapour diffusion method. 
Drops comprising 2pl of protein and 2jil of mother liquor were equilibrated against 
800pl of mother liquor at 16°C. For co-crystallisation, 0.4pl of a 100mM carbohydrate 
solution was also added to the drop. Initial crystallisation screens were set up using 
recECL. Structure Screen I, Structure Screen II, and a polyethylene glycol (PEG)/lon 
matrix were used to sample a wide range of potential crystallisation conditions. In 
addition, 2-methyl-2,4-pentanediol (MPD) was tested a precipitant, in a trial based on 
JBScreens 7 and 8 (JenaBioScience, Germany; Appendix 2). Promising conditions 
were repeated and optimised for both nECL and recECL to produce crystals for X-ray 
diffraction experiments. Co-crystallisation with GalNAc, Lac and p-lactose was 
attempted using conditions reported for the crystallisation of ECorL (Shaanan et al. 
1991). Further attempts were also made to co-crystallise both forms of ECL with 
carbohydrates.
3.2.3 Data Collection and Processing
X-ray diffraction data were collected at HOOK using the SRS at Daresbury Laboratory 
(UK) on stations PX14.1 (X = 1.488A) and PX14.2 (X = 0.978A). X-rays for both 
stations are produced using a multipole wiggler, focussed with a rhodium-coated mirror 
and filtered using a silicon monochromator. Diffraction images were recorded on ADSC 
Quantum 4R CCD area detectors.
Each crystal was soaked in cryoprotectant solution (comprising mother liquor 
with 20-25% glycerol) for a few minutes before being mounted in a wire loop. The loop 
was then placed on a goniometer head and the crystal positioned in the centre of the 
X-ray beam under a cold stream of nitrogen gas. A few test images were recorded for 
each crystal to determine the symmetry of the crystal lattice, the maximum resolution 
and the data collection strategy to be used.
A total of six ECL crystal forms were analysed and all diffracted to high 
resolution. Diffraction images collected from crystals of recECL (space group P1), rec- 
Lac (C2), rec-Lac (P2i) and recECL (P2i) were processed, scaled and truncated at
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Daresbury Laboratory using the program suite HKL2000 (Otwinowski and Minor 1997). 
Diffraction images for the two remaining crystals were processed and scaled in house 
using the programs DENZO and SCALEPACK (Otwinowski and Minor 1997) with 
intensities truncated to amplitudes by the program MTZ2XPLOR of the CCP4 suite 
(Bailey 1994).
3.2.4 Molecular Replacement
Molecular replacement was the method chosen to determine initial phases for 
the structure of ECL. ECorL was used as a search model. ECorL is homologous to 
ECL -  the two lectins share 96% sequence identity -  and its crystal structure has been 
determined (Elgavish and Shaanan 1998; PDB code 1AX0).
For each dataset Vm was calculated to estimate the solvent content and 
number of protein molecules per asymmetric unit. Molecular replacement was then 
performed using the program AMoRe (Navaza 1994), which performs rotation and 
translation searches, rigid-body refinement and generates structure factors from a 
model in a large P1 cell. Solutions for the cross-rotation and translation functions were 
ranked according to the calculated correlation coefficient (CCF) and R factor (RF) of 
each peak. As a general rule, the top peak (that with the highest CCF and lowest RF) 
from each search was fixed in the subsequent translation search.
3.2.4.1 nECL
Initial phase angles were taken from the crystal structure of ECorL. The model 
was truncated to comprise only the coordinates of amino acids 3-239 from one ECorL 
protomer (i.e. all heteroatoms, ligands and water molecules were removed). The side 
chains of seven of the nine non-conserved residues (Asp16, Asn17, Leu25, lie111, Gin134, 
His180, Gin234) in the ECorL model were mutated to alanine using 6d_moleman from the 
CCP4 suite of programs (Bailey 1994). It was not necessary to alter the side chains of 
residues Ala54 and Gly125 in the ECorL model because they are small and unlikely to 
affect the success of the molecular replacement method.
The resolution range for the rotation search was limited to 10-3.0A. The cell 
model had dimensions 78 x 63 x 58A and the sphere of integration was of 15A radius.
The molecular replacement solutions were viewed in O (Jones et al. 1991) to 
ensure that there were no steric clashes between the molecules or symmetry-related 
molecules and the coordinates of the two molecules were then written out as PDB files. 
The separate chains were relabelled (chain A and chain B) and consolidated into a 
single PDB file that was used as the initial model for refinement.
70
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
3.2.4.2 recECL Structures
The refined coordinates of one nECL protomer (with all heteroatoms, ligands 
and waters removed) were used as a model for molecular replacement for the recECL 
structures. The resolution range used for the rotation search was limited to 10-3.0A, the 
cell model was 85 x 69 x 65A and the sphere of integration had a radius of 15A.
3.2.5 Refinement and Model Building
The PDB file generated for each crystal structure after molecular replacement 
was refined using the Crystallography & NMR Suite of programs (Brunger et al. 1998; 
http://cns.csb.yale.edu/v1.01) to produce an initial structural model and electron density 
maps for analysis. Coordinate and structure factor files were generated for the initial 
model and a “test-set” (comprising ~5% of the reflections) was created to calculate the 
Rfree value for cross-validation (Brunger 1992). Two rounds of rigid body refinement 
were performed (Adams et al. 1997; Pannu and Read 1996): the first with all atoms 
refined as one rigid body and the second with each protomer refined as a separate 
rigid body. This was followed by crystallographic conjugate gradient minimisation 
refinement; restrained, individual B-factor refinement; and crystallographic simulated 
annealing refinement at 1500K (Adams et al. 1997; Brunger et al. 1990; Brunger et al. 
1987; Rice and Brunger 1994). Electron density for each structure was calculated from 
F0-Fc and 2F0-FC using phase information averaged over the three PDB files output 
from simulated annealing refinement (Brunger et al. 1997; Kleywegt and Brunger 1996; 
Read 1986). Electron density maps were then drawn using MAPMAN (Kleywegt and 
Jones 1996). The 2F0-FC map was viewed to ensure that the peptide backbone 
followed the pattern of electron density. The F0-Fc map was then carefully analysed to 
identify electron density corresponding to the positions of the manganese and calcium 
ions and carbohydrate ligands.
Refinement and model building were then repeated cyclically to improve the 
model of the protein. In subsequent rounds of refinement, the rigid body refinement 
was omitted and no changes were made to the test-set of reflections. The temperature 
of simulated annealing was gradually increased to 2500K. In the latter stages of model 
building and refinement, water molecules were inserted using a water-pick program 
(Kleywegt and Brunger 1996; Read 1986).
3.2.5.1 nECL
Careful examination of the initial electron density maps allowed mutation of 
the non-conserved residues back to their native side-chains. The N- and C-terminal
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residues removed from the search model were modelled into the electron density. 
Atomic coordinates for Mn2+ and Ca2+ and lactose were obtained from the Hetero- 
compound Information Centre (HIC-Up) (Kleywegt and Jones 1998; 
http://alpha2.bmc.uu.se/hicup/) and modelled into the combining site of each protomer. 
The geometry of the c/s-peptide bond between Ala88 and Asp89 was manually built into 
the structure of each protomer, based upon electron density in the F0-Fc map. F0-Fc 
electron density revealed the positions of the oligosaccharide attached to Asn113. 
Coordinates for the sugars involved were downloaded from the HIC-Up server and 
modelled into the electron density. As there was still some F0-Fc density remaining 
after energy minimisation and B-factor refinement, the occupancy of the sugars was 
reduced from 1.0 to 0.25-0.5. Water molecules were inserted into the model if there 
were peaks in the F0-Fc electron density map with heights greater than 3a at hydrogen 
bond forming distances from the appropriate atoms, but those with a temperature factor 
higher than 60A2 were excluded from the model.
3.2.5.2 recECL Structures
Model building and refinement for the five recECL structures were undertaken 
as described for nECL. Where appropriate, coordinates for combining-site ligands were 
obtained from the HIC-Up server and modelled into the electron density before the 
addition of water molecules. No oligosaccharide was modelled into the recECL 
structures because the protein was recombinantly over-expressed in E.coli, which does 
not have the cellular machinery to post-translationally modify proteins in that manner.
3.2.6 Structure Validation and Analysis
The final structural model for each ECL crystal analysed was validated using 
PROCHECK (Laskowski et al. 1993), a set of programs that assess the stereochemical 
quality of protein structures. Interactions between the Mn2+ and Ca2+ ions and the 
protein were determined using the intermolecular contacts program of the CCP4 suite 
(Collaborative Computational Project Number 4. 1994). In addition, the number of 
hydrogen bonds formed with lactose and water molecules was assessed using the 
hydrogen bonds program. Cross-validation of the outputs from the two programs 
allowed the amino acid side chains involved in carbohydrate binding to be identified. 
The structures of the dimers formed by /?ECL and recECL were analysed to determine 
which residues are located in the dimer interface and, thus, are involved in forming 
protomer-protomer contacts and also to look at the influence of glycosylation on the 
quarternary structure. The intermolecular contacts and hydrogen bonds programs from
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the CCP4 suite were used to identify hydrogen bonds and van der Waals contacts 
between two protomers in the dimer.
3.3 RESULTS
3.3.1 Crystallisation of ECL
Crystals of ECL were grown at 16°C using the hanging drop vapour diffusion
method. Within 4-6 weeks, crystals were observed in three morphologies in different
conditions (Figure 14): Thin, needle crystals were grown in drops equilibrated against 
70% MPD and 0.1M HEPES, pH 7.5. Trigonal crystals were produced in mother liquor 
comprising 2.0M ammonium phosphate and 0.1M Tris-HCI, pH 8.5. A third crystal form 
was observed in drops equilibrated against 2.0M ammonium sulphate and 5% 
isopropanol.
The initial crystallisation screens produced crystals in three different morphologies. Crystals in slide A  were 
grown from mother liquor comprising 70% MPD and 0.1 M HEPES. The trigonal crystals shown in slide B 
were grown from mother liquor comprising 2.0M ammonium phosphate and 0.1 M Tris-HCI. Crystals in 
slide C were grown from mother liquor containing 2.0M ammonium sulphate and 5% isopropanol. These 
conditions were repeated and optimised to produce crystals of diffraction quality.
nECL only crystallised in hexagonal form but recECL crystallised in several 
crystal forms under a variety of conditions. The same protein can crystallise in different 
space groups under different conditions because changes in pH, solvent or precipitant 
can alter the crystal packing (Blundell and Johnson 1976). In the case of recECL, the 
concentration of PEG 3350 and the presence and absence of imidazole and lactose in 
the crystallisation drop altered the structure of the crystal lattice, producing crystals with 
triclinic or monoclinic lattices. Mother liquor comprising 17% PEG 3350, 0.3M sodium 
chloride and 0.02M imidazole yielded crystals in space group P1. The addition of Lac to 
drops containing and equilibrated against the same mother liquor led to the production 
of crystals in space group C2. Similar crystallisation conditions also produced crystals
A
Figure 14 -Three Crystal Morphologies
B C
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in space group P2i. On the other hand, recECL only crystallised in trigonal form from 
conditions containing ammonium phosphate. recECL crystals were also grown in 
conditions containing ammonium sulphate and MPD, but these crystals were not of 
diffraction quality.
Co-crystallisation of both nECL and recECL with a variety of galactose-based 
carbohydrates was also attempted. nECL only crystallised in the presence of Lac (i.e. 
no crystals of nECL alone were produced despite several attempts). Fortunately, 
recECL crystallised alone and co-crystal I ised with Lac, GalNAc and galactose, 
although crystals of the GalNAc and galactose complexes were too small to be used in 
X-ray diffraction experiments.
Table 3 - Growth of ECL Crystals for Diffraction Experiments
nECL + Lac 70% MPD
0.1M HEPES pH 7.0
P65 2 66.73
recECL 17% PEG 3350 
0.3M sodium chloride 
0.02M imidazole
P1 4 48.57
recECL 20% PEG 3350 
0.3M sodium chloride 
5% glycerol
P2i 4 49.21
recECL + Lac 20% PEG 3350 
0.2M imidazole
P2i 4 48.17
recECL + Lac 17% PEG 3350 





2.0M ammonium phosphate 
0.1M Tris-HCI pH 8.6 
5% glycerol
P3212 3 45.71
The conditions used to produce the six ECL crystals used in diffraction experiments are presented. ECL 
was crystallised in five different space groups under a variety of conditions. Three crystals resulted from 
co-crystallisation of nECL and recECL with lactose (Lac) and one recECL crystal was soaked with N- 
acetylgalactosamine (GalNAc) prior to data collection.
A total of six ECL crystal forms in five different space groups were analysed 
and the conditions used to produce these crystals are detailed in Table 3. The three 
crystal forms of the nECL-Lac and recECL-Lac complexes were produced by co­
crystallisation. The three remaining crystal forms were of recECL alone, one of which
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was soaked in a solution containing mother liquor and 50mM GalNAc for four hours 
prior to data collection. The high solvent content of protein crystals can easily be 
exploited to allow the diffusion of substrates, ligands or inhibitors into the crystal to 
interact with the protein molecules and this was the rationale behind soaking one 
recECL crystal with GalNAc prior to data collection.
3.3.2 X-Ray Diffraction Data
Table 4 - Data Collection Strategies
Space group P65 P1 P2i C2 P3212 P2i
Beamline 14.1 14.1 14.1 14.2 14.2 14.1
Distance (mm) 100 110 75 200 200 70
Maximum resolution (A) 2.00 2.13 1.70 2.45 2.30 1.65
Oscillation range (°) 1.0 1.0 0.4 1.0 1.0 0.75
Exposure time (s) 15 10 10 15 10 10
No of images 74 225 200 150 100 200
Data collection statistics for the six ECL crystals analysed are presented. Diffraction data were collected to 
high resolution using the SRS at Daresbury, UK, on beamlines 14.1 and 14.2. In each case, the data 
collection strategy was determined by the quality of diffraction by the crystal. A greater number of 
diffraction images were recorded for crystals of lower symmetry in order to collect reflections from all parts 
of the crystal. The crystals were stable in the X-ray beam, allowing a complete dataset to be collected from 
a single crystal.
Details of data collection for the crystals analysed are summarised in Table 4. 
A greater number of diffraction images were collected from crystals of lower order 
symmetry to ensure that each unique reflection was recorded at least once. The 
recorded diffraction patterns were well resolved (for example, Figure 15) with the 
intensities of the reflections easily distinguishable from the level of background 
radiation and lunes were clearly visible. The crystals also exhibited low mosaicity and 
were stable in the X-ray beam, enabling a complete dataset to be collected from a 
single crystal in each case. By indexing the first recorded images, the Bravais lattice of 
each crystal was determined.
All diffraction data for each crystal were scaled and merged until l/al was 
greater than 2 and x2 was close to 1 in each resolution shell. After scaling, each 
dataset was at least 80% complete overall (and at least 77% complete in the highest 
resolution shell) with low R factors. Details of diffraction data processing and 
refinement statistics for each of the six crystal structures are presented in Table 5.
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Figure 15 - Diffraction Pattern Recorded from a Crystal of ECL
This diffraction pattern was recorded from the crystal of native ECL in complex with lactose (space group 
P65). These data were recorded at CCLRC Daresbury Laboratory on station PX14.1 {X  = 1.488A) to a 
maximum of 2.0A resolution. The lunes and reflections are well resolved and mosaicity in the crystal is low. 
This diffraction pattern is typical of those recorded for the ECL crystals analysed.
The final models for each of the six structures were well refined, with values 
for Rcryst and Rfree in good agreement. The average B-factors for the crystal structures 
were low (in the range 20.32 to 33.78A2) and the average B-factor for bulk solvent 
ranged from 40.38 to 59.16A2. There was low root-mean-square deviation (rmsd) from 
ideality for main chain bonds and bond angles. Ramachandran plots (Appendix 1) 
revealed that >99% of amino acid residues within each structure adopted allowed 
configurations and the covalent geometry (i.e. main-chain bond lengths and bond 
angles and planarity of aromatic rings) was within the normal range for most of the 
residues in each model. This is consistent with geometrically well-defined crystal 
structures of similar resolution. Electron density for 240 of the amino acids that 
comprise an ECL protomer enabled all residues except Asn241 to be modelled. There 
was also well-resolved electron density for the Ca2+ and Mn2+ ions in all the structures 
and for bound carbohydrate in the ECL-Lac complexes.
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Table 5 - Data Processing and Refinement Statistics
PROCESSING:
Space group P65 P1 P2i P2i C2 P3212
Cell dimensions
(A)
a = 134.02 
b =  134.02 
c = 81.64 
a  = 90°
P = 90° 
y =  120°
a = 55.28 
b = 55.37  
c = 86.93  
a  = 86.23° 
P = 75.37° 
y = 82.13°
a = 55.47  
b = 115.17 
c = 80.93  
a  = 90° 
p = 93.52° 
Y = 90°
a = 54.90 
b =  167.23 
c = 55.13  
a  = 90°
P = 97.09° 
Y = 90°
a = 203.26  
b =  101.13 
c = 55.28  
a  = 90°
P = 102.43° 
Y = 90°
a = 81.05  
b = 81.05  
c =  190.95  
a  = 90° 
p = 90° 
Y =  120°
Vm (AJ/Da) 3.73 2.45 2.48 2.41 3.53 2.32
Resolution (A) 2.00 2.13 1.65 1.70 2.45 2.13
Reflections
measured
414754 399699 306951 1021770 440979 362378





























Rsymm * 0.070 0.077 0.085 0.058 0.122 0.135
REFINEMENT:
Rcryst (%) * * 21.14 19.29 25.52 17.79 25.58 21.85
Rfree (%) * * 24.70 25.36 29.03 17.84 33.29 29.35
Average B factor
(A2)
27.96 24.45 23.50 20.32 33.78 28.60
Wilson B factor
(A2)
23.1 25.5 20.8 19.2 40.5 32.4
RMSD from 
ideality:
Bonds (A) 0.006 0.006 0.006 0.008 0.008 0.008
Bond angles (deg) 1.42 1.40 1.41 1.49 1.49 1.65
Dihedrals (deg) 25.32 25.66 25.67 25.67 25.64 25.89
Impropers (deg) 0.77 0.75 0.84 0.80 0.89 0.83
* Rsymm = S/iwS(|I/{/7/c/)-<I>(A)/c/)| /  !/,*/!,I , w h e r e  <I> is the averaged intensity of the /' observations of 
reflection hkl
**  Rcryst = I||Fo|-|Fc|| / S|Fo|, where F0 and Fc are the observed and calculated structure factor 
amplitudes, respectively
**  Rfree is equal to Rcryst for a randomly selected 5% subset of reflections not used in the refinement
Data processing and refinement statistics for the six crystal structures are presented. Data were collected 
to high resolution and at least 75% completeness. In each case, I/c l was greater than 2.0 and Rsymm W3S 
low. The final models were well refined with low B factors and values for Rcryst and Rfree in good agreement.
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3.3.2.1 Native ECL in Complex with Lactose
nECL co-crystallised with Lac in space group P65, producing small, needle-like 
crystals that diffracted to a maximum of 2.0A resolution. There were two nECL 
molecules per asymmetric unit and 67% of the crystal volume was occupied by solvent. 
Indexing revealed the Bravais lattice of the crystal to be hexagonal and scaling reduced 
the possible space groups to P6! and P65. Molecular replacement gave the correct 
space group as P65 (Table 6) identified by the highest correlation coefficient and lowest 
R factor.
Table 6 - Determination of nECL Space Group
CCF RF CCF RF
Roting 17.4 55.7 17.4 55.7
Traing 22.6 54.1 36.4 49.7
Traing2 31.2 51.0 59.7 40.6
Fiting 42.7 48.2 73.3 34.4
The results of molecular replacement for nECL in the four hexagonal space groups P61, P65, P6i22 and 
P6522 are presented. CCF and RF are the correlation coefficient and R-factor, respectively, of the rotation 
function (Roting), translation functions (Traing and Traing2) and the refinement function (Fiting) of the 
molecular replacement program AMoRe (Navaza 1994). The correct space group was easily identified as 
P65 because it was the space group that gave the highest correlation coefficient and lowest R factor in 
each of the rotation and translation searches.
The initial electron density maps for the nECL-Lac complex were well defined 
with few breaks in the density. The peptide backbone of both protein molecules in the 
asymmetric unit fitted well into the observed 2F0-FC electron density. One lactose 
molecule was bound in the combining site of each nECL molecule, with F0-Fc electron 
density for the disaccharide clearly resolved (Figure 16). Lactose was modelled into the 
combining site and made hydrogen bond contacts with combining site residues through 
structural water molecules (described in section 3.3.3.3). There were also clear peaks 
in the F0-Fc electron density map close to the carbohydrate-combining site 
corresponding to the calcium and manganese ions and their associated water 
molecules.
There was also some F0-Fc electron density surrounding the peptide bond 
between Ala88 and Asp89 and analysis of the Ramachandran plot revealed that the side 
chain of Asp89 adopted a disallowed configuration. This was because the peptide bond 
was originally modelled in the trans conformation when, in fact, this peptide bond
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should be in the cis conformation. There is a cis-peptide bond at this position in all of 
the legume lectin structures solved to date (Lis and Sharon 1998) that is proposed to 
hold the side chain of Asp89 in the correct orientation for carbohydrate binding. The cis- 
configuration of the peptide bond is stabilised by one of the water molecules that 
coordinates the calcium ion.
Figure 16 - Electron Density for Lactose in the Combining Site of nECL
The initial electron density maps clearly defined the location of the lactose molecule within the combining 
site of each nECL molecule in the structural model. The disaccharide was modelled into the electron 
density, as shown above, such that the galactose moiety was in close proximity to combining site residues 
Asp89 and Asn133. Lactose fitted well into the observed electron density and made hydrogen bond contacts 
with a number of combining site residues through structural water molecules (see Figure 25).
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Figure 17 - F0-Fc Electron Density For the Glycosylation Attached to Asn113
The glycosylation profile of ECL has been characterised and the major component is a heptasaccharide 
(Ashford et al. 1991). The same glycosylation profile has been observed in other lectins isolated from 
E ry th r in a  species and also in some unrelated legume lectins. This figure shows the Fo-Fc electron density 
observed near the side chain of Asn113 in one of the nECL molecules in the structural model, indicating the 
positions of the first three sugar residues of the attached oligosaccharide. The Fo-Fc density observed for 
the oligosaccharide in the second protein molecule was much stronger, enabling six of the seven sugar 
residues to be modelled (see Figure 21).
Further analysis of the initial electron density maps revealed a large region of 
F0-Fc electron density near the side chain of Asn113 in both of the protein molecules 
(Figure 17). Since Asn113 is the only potential glycosylation site in the nECL sequence 
(Figure 13), this electron density was assumed to represent the bound oligosaccharide. 
The glycosylation profile of ECL has been characterised (Ashford et al. 1991) and the 
heptasaccharide a-D-Manp-(1^3)-[a-D-Manp-(1^6)]-[(3-D-Xylp-(1->2)]-(3-D-Manp-(3-D- 
GlcpNAc-(1-*4)-[a-L-Fucp(1->3)]-D-GlcNAc -  where Xyl is xylose -  makes up the 
major component. Residues from this profile were modelled into the observed electron 
density.
The final structural model for nECL had an Roy* of 21.14% (Rfree 24.70%) and 
contained 476 amino acids, two lactose molecules, two calcium and manganese ions,
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413 water molecules, four GlcNAc residues and two Fuc, one Xyl and two Man 
residues. The average B factor for protein atoms was 27.96A2 compared to 59.16A2 for 
bulk solvent and the estimated Luzzati coordinate error was 0.24A. Analysis of the 
Ramachandran plot revealed that only two residues, Tyr106 from each molecule, 
adopted generously allowed configurations (all other residues had allowed and 
additional allowed configurations). The side chain of only one of the aromatic residues 
was non-planar and a potential alternative side-chain configuration was observed for 
Arg50, lie59 and Gin202 in one of the protein molecules in the asymmetric unit.
3.3.2.2 Recombinant ECL
recECL was crystallised in the absence of any added carbohydrate ligand in 
two crystal forms. The triclinic form had four molecules per unit cell with 49% of the 
crystal occupied by solvent and the monoclinic form also had four molecules per 
asymmetric unit with 49% of the crystal volume occupied by solvent.
X-ray diffraction data for recECL in triclinic form were recorded to a maximum 
of 2.13A resolution. F0-Fc density observed in the combining sites of two of the protein 
molecules was modelled as glycerol because glycerol was added to the cryoprotectant 
solution used prior to data collection. The final model had an Royst of 19.29% (Rfree 
25.36%) and contained 958 amino acids, four calcium and manganese ions, three 
glycerol molecules and 856 water molecules. The average B factor was 24.45A2 for 
protein atoms and 58.98A2for bulk solvent. The estimated Luzzati coordinate error was 
0.23A. The Ramachandran plot revealed no amino acid side chains were in disallowed 
configurations and that only one residue (Tyr106 in one protein molecule) adopted a 
generously allowed configuration. Possible alternative configurations were observed in 
the F0-Fc electron density map for the side chains of Arg50, Arg84, Met95 and Ser120, but 
not in all four of the protein molecules in the unit cell.
Data for the monoclinic form of recECL (space group P20 were recorded to 
1.65A resolution. Although no carbohydrate had been added to the crystallisation drop, 
F0-Fc electron density corresponding to the structure of two pyranose sugar rings was 
observed in the combining site of three of the four molecules. Lac was modelled into 
this F0-Fc density and the R factors dropped in subsequent refinement steps. The final 
model of recECL in space group P2, had an R ^ t of 25.52% (Rfree 29.03%) and 
contained 953 amino acids, three Lac molecules, four calcium and manganese ions 
and 745 water molecules. The average B factor was 23.50A2 for protein atoms and 
53.93A2 for bulk solvent. The estimated Luzzati coordinate error was 0.28A. No amino 
acid side chains were located in disallowed regions of the Ramachandran plot,
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although six side chains (Tyr106 in all four molecules and Leu109 and Asp221 each in only 
one molecule) adopted generously allowed configurations. Possible alternative 
configurations were noted for the side chains of residues Leu20, Ser29, Leu34, lie59, 
Val67, Arg84, Met95, Lys116, lie197 and Leu237 in at least one of the four protein molecules 
present in the crystal structure.
Investigation into why Lac was present in the combining site of recECL when 
no carbohydrate had been added to the crystallisation drop revealed that Lac was likely 
present as a result of the purification procedure. The final purification step involves an 
immobilised-lactose affinity column from which recECL is eluted with 0.3M lactose. 
Although recECL was dialysed after purification, analysis by mass spectroscopy 
revealed a shoulder on the ECL peak (26.7kDa) of higher molecular weight (27.5kDa), 
that could represent one ECL protomer bound to two lactose molecules (JAChaddock, 
personal communication). As ECL exhibits a high binding affinity for Lac -  4 units of the 
lectin are completely inhibited by 2.0mM Lac (Iglesias et al. 1982) -  it is not surprising 
that dialysis of purified recECL was not sufficient to remove all the bound lactose. 
However, the peak in the mass spectrum postulated to represent an ECL-Lac complex 
was small and not significantly higher than the background signal. This low level of 
contamination might explain why not all of the protein molecules in the affected 
structures were seen to bind lactose. Since an electron density map represents a time- 
averaged structure, if not all the lectin protomers in the crystal bound Lac it would not 
be observed in all the protein molecules in the structural model. This could also explain 
why Lac was not observed in the triclinic structure of recECL, even though it was 
crystallised from the same batch of protein. Unfortunately, the presence of Lac in the 
protein sample was not detected until the electron density maps were analysed.
3.3.2.3 Recombinant ECL Complexes
In addition, three recECL-carbohydrate complexes were studied. Two were 
monoclinic crystals, space groups P2, and C2, produced by co-crystallising recECL 
with Lac. The third complex in trigonal form (space group P3212) was obtained by 
soaking one recECL crystal in a solution containing 50mM GalNAc for four hours prior 
to data collection.
recECL co-crystallised with Lac in space group P2, with four molecules per 
asymmetric unit and 49% of the crystal volume occupied by solvent. Each of the four 
protein molecules had Lac bound at the combining site. The final model at 1.70A 
resolution had an Rcryst of 17.79% (Rfree 17.84%) and contained 958 amino acids, four 
Lac molecules, four calcium and manganese ions and 1089 water molecules. The
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average B factor was 20.32A2 for protein atoms and 52.73A2 for bulk solvent and the 
estimated Luzzati coordinate error was 0.18A. One main chain bond was considered 
too short -  Ca-Cp in Asp89, which takes part in the conserved c/s-peptide bond. The 
Ramachandran plot revealed that five amino acid side chains adopted generously 
allowed configurations (Tyr106 in all four protomers and Asp221 in only one protomer) but 
no side chains had disallowed configurations. The following amino acid side chains 
were found to have possible alternative configurations, but not in all of the protein 
molecules in the crystal structure: Thr3, Asn16, lie25, Met42, Thr54, Lys55, lie59, Ser77, 
Arg84, Met95, Lys99, Gin104, Asn114, Asn119, Ser120, Ser152, Ser175, Leu180, Val182, Arg220, 
His234 and Ser236.
recECL also co-crystallised with Lac in space group C2 with three molecules 
per asymmetric unit and 65% of the crystal volume occupied by solvent. However, Lac 
could only be modelled into F0-Fc density in the combining sites of two of the three 
molecules. The final model had an Rc^t of 25.58% (Rfree 33.29%) and contained 712 
amino acids, two Lac molecules, three calcium and manganese ions and 218 water 
molecules. The estimated Luzzati coordinate error was 0.38A. The average B factor 
was 33.78A2 for protein atoms and 47.53A2 for bulk solvent. Analysis of the 
Ramachandran plot revealed that no residues adopted disallowed configurations, but 
four side chains had generously allowed configurations of the plot -  Tyr106 in each 
molecule and lie4 from one molecule. Only residue Arg84 in one of the three protein 
molecules was observed to have a potential alternative configuration.
One crystal of recECL in trigonal space group P3212 was soaked with GalNAc 
because co-crystallisation had been unsuccessful. There were three molecules per 
asymmetric unit with 46% of the crystal volume occupied by solvent. Although the 
Bravais lattice was identified as trigonal by indexing, the space group had to be 
uniquely identified by molecular replacement, as described for nECL. Scaling reduced 
the number of possible space groups to P3f21, P3i12 and P3212 and was confirmed as 
P3212 by molecular replacement (Table 7). Initially, GalNAc was modelled into the Fo- 
Fc electron density observed in the combining site of each molecule but during later 
stages of refinement it became clear that there was extra density consistent with the 
presence of another pyranose sugar ring. Lac was then modelled into the density and 
found to fit neatly. This trigonal crystal was grown from the same batch of protein as 
that used to grow the monoclinic recECL crystal that unexpectedly had lactose present 
in the combining site (section 3.3.2.2). As this batch of protein was contaminated with 
lactose, soaking with GalNAc would not provide any data on a new complex structure 
because lactose is a stronger inhibitor of the activity of this lectin (Iglesias et al. 1982).
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Only N-acetyllactosamine, fucosyllactose and fucosyllactosamine bind ECL with higher 
affinity than lactose (Iglesias et al. 1982; Teneberg et al. 1994).
Table 7 - Determining the Space Group of recECL in Trigonal Crystal Form
CCF RF CCF RF CCF RF
Roting 13.0 57.4 13.1 57.3 13.1 57.3
Traing 16.7 57.2 16.9 57.2 22.3 55.2
Traing2 19.0 57.3 18.5 56.6 33.8 51.5
Fiting 33.7 54.4 30.3 54.8 48.6 47.6
The space group could not be uniquely identified without performing the rotation and translation searches 
during molecular replacement, as previously described for nECL in complex with lactose. The calculated 
values for the correlation coefficient (CCF) and R-factor (RF) for the top peak in each search revealed the 
space group to be P3212.
The final model of recECL in trigonal form at 2.13A resolution had an R ^ t  of 
21.85% (Rfree 29.35%) and contained 713 amino acids, three Lac molecules, three 
calcium and manganese ions and 412 water molecules. The average B factor for 
protein atoms was 28.60A2 and 40.38A2 for bulk solvent. The estimated Luzzati 
coordinate error was 0.29A. Analysis of the Ramachandran plot revealed that four 
residues were located in generously allowed regions (Tyr106 in two molecules and 
Asp221 and Asp118 each in one molecule). No residues were found in disallowed regions 
of the plot. Seven aromatic side chains were found to deviate from planarity. The side 
chains of residues Arg50, Val67, Ala68, Ser77, Ala88, Gin117, Gin159, Leu180 and Lys201 were 
observed to have possible alternative configurations, but not in all three of the protein 
molecules in the asymmetric unit.
3.3.3 Crystal Structure of ECL
3.3.3.1 Tertiary Structure
Protomers of nECL and recECL adopt the jelly-roll fold that is characteristic of 
the legume lectins (Figure 18). As described previously, the legume lectin fold is made 
up of a flat, six-stranded (3-sheet; a curved, seven-stranded (3-sheet; a short five- 
membered p-sheet and several loops that connect the three sheets. The seven- and 
six-stranded sheets are both entirely anti-parallel.
Between the six ECL structures solved, 240 of the 241 amino acids that make 
up one protomer could be modelled into the observed electron density. Only residue 
Asn241 could not be located in any of the structural models. When determining protein
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structures by X-ray crystallography it is not always possible to model residues at the isl­
and C-termini because these regions can be relatively mobile. In the case of ECL, the 
N- and C-termini associate together, forming the first two strands of the six-stranded p- 
sheet and, consequently, the electron density for these residues was well resolved in 
the six structural models. However, not all 240 residues were modelled in all of the 
protein molecules in all six structural models.
Figure 18 - Jelly-Roll Structure of the ECL Protomer
The tertiary structure of nECL and recECL adopts the same jelly-roll fold in common with all other legume 
lectins that have been structurally characterised. This motif comprises a flat, six-stranded “back” p-sheet, a 
curved, seven-stranded “front” p-sheet and a short five-stranded p-sheet with loops connecting the three 
sheets. The calcium and manganese ions (shown as green and navy spheres, respectively) are bound 
close to the combining site. This figure was prepared using Molscript, Povray and GIMP.
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The combining site is located in a shallow cleft on the surface of the lectin and 
accommodates only the galactose moiety of bound carbohydrates. Analysis of the 
crystal structures of other galactose-specific legume lectins - ECorL (Shaanan et al. 
1991); SBA (Dessen et al. 1995); GSIV (Delbaere et al. 1993); and PNA (Banerjee et 
al. 1994), revealed that the conserved aspartic acid donated by combining site loop A 
recognises the equatorial hydroxyl of C3 and axial hydroxyl of C4 in the galactose ring 
(Sharma and Surolia 1997). The C3 hydroxyi group aiso forms hydrogen bonds with 
the backbone amine of the conserved glycine residue in loop B and the asparagine in 
loop C. The C4 hydroxyl group hydrogen bonds with residues in loop D. The 
corresponding residues in ECL that can be expected to be involved in carbohydrate 
binding are: Asp89, Gly107, Phe131 and Asn133. The differing affinities of these lectins for 
galactose and GalNAc have been attributed to the length of combining site loop C (i.e. 
those lectins with a shorter loop exhibit a preference for GalNAc and those with a 
longer loop bind galactose with higher affinity) (Sharma and Surolia 1997). The mode 
of carbohydrate binding by ECL is discussed later in section 3.3.3.3.
Figure 19 - Electron Density for Ca2+ and Mn2+ Ions In the Combining Site of ECL 
A B
In the figures above, the metal ions are depicted as yellow spheres and water molecules as red spheres. 
Panel A (left) shows electron density for the four amino acid side chains and two water molecules that 
coordinate the Mn2+ ion bound near the combining site of ECL. Panel B (right) shows electron density for 
the waters and side chains that coordinate the Ca2+ ion. Both metal ions are required for the carbohydrate 
binding activity of ECL and are thought to stabilise the spatial arrangement of key combining site residues.
In common with all legume lectins, each ECL protomer contains one calcium 
and one manganese ion, both of which are located close to the combining site (Figure 
18). Their presence in the structure is associated with maintaining the correct spatial
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orientation of the combining site residues for carbohydrate binding. Treatment of ECL 
with chelating agents did not remove the metal ions from the lectin or ablate its 
carbohydrate-binding activity (Iglesias et al. 1982). Ca2+ and Mn2+ are situated 
approximately 4.3A apart in the ECL protomer. As shown in Figure 19 and detailed in 
Table 8, each metal coordinates two water molecules and makes contacts with four 
amino acid side chains. Mn2+ makes contacts with Glu127, Asp129, Asp136 and His142 and 
Ca2+ makes contacts with Asp129, Phe131, Asn133 and Asp136. One of the water 
molecules that co-ordinates Ca2+ also stabilises the conserved cis-peptide bond (Ala88- 
Asp89) that correctly orients the side chain of Asp89 for carbohydrate binding. In addition 
to binding Ca2+, the side chains of residues Phe131 and Asn133 are also implicated in 
lactose binding.















This table details the contact distances between amino acid residues within and near the combining site of 
ECL and the bound calcium and manganese ions.
Analysis of the six ECL structures revealed a number of residues with possible 
alternative side chain configurations. Although these amino acids were not observed to 
have alternative configurations in all of the protomers in all of the structures, several of 
the residues (Arg50, Val67, Ser77, Arg84, Met95, Ser120 and Leu180) were noted to have 
possible alternative configurations in more than one form of ECL. Of these seven 
amino acids, only Arg84 is involved in its biological activity as one of the residues that 
stabilise the dimer interface (see section 3.3.3.4). It is possible that the long side chains 
of arginine and methionine may be flexible in the crystal structure and therefore adopt
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more than one configuration. F0-Fc density associated with the side chains of serine 
residues at positions 77 and 120 may represent alternative configurations or indicate 
the presence of a water molecule interacting with the hydroxyl group. Since valine and 
leucine are aliphatic in nature, water molecules will not be associated with their side 
chains. Instead, it is more likely that the observed F0-Fc electron density represents a 
small amount of movement in the positions of side chain atoms.
The crystal structures of nECL and recECL at 2.0A and 2.13A, respectively, 
superimpose with an overall rmsd of 0.31A. Comparison of the structures indicated that 
there are no significant differences between the crystal structures of native and 
recombinant forms of ECL and, thus, confirmed that recECL adopts a native structure. 
The only difference between native and recombinant forms of ECL is the absence of N- 
linked carbohydrate from recECL. This is a consequence of using E.coli as an 
expression host. Therefore, it can be concluded that the presence of bound 
oligosaccharide does not influence the tertiary structure of ECL.
3.3.3.2 N-Linked Glycosylation






GlcNAc 1—>4 GlcNAc 1->ND2 (Asn113)
Fucose
This cartoon represents the sugar residues and glycosidic linkages in the hexasaccharide modelled into 
the structure of nECL. The major component of the glycosylation on ECL is a heptasaccharide. Six of the 
seven sugar residues were observed in one of the protein molecules, but weaker electron density in the 
other protein molecule allowed only the first three residues to be modelled.
The oligosaccharide bound to nECL is covalently linked to ND2 of amino acid 
residue Asn113. This residue is the only possible location for the attachment of N-linked 
glycosylation in the 241-amino acid sequence of ECL (Figure 13). The initial F0-Fc 
electron density map for nECL revealed the positions of several sugar residues (Figure 
17). In one of the two protein molecules in the structural model, there was enough
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electron density to model six of the seven sugar residues in the heptasaccharide that 
makes up the major component of carbohydrates bound to ECL. This hexasaccharide 
has the profile displayed in Figure 20. The trisaccharide modelled into the other protein 
molecule comprised only the first three residues of this hexasaccharide.
The modelled sugars fitted well into the observed electron density (Figure 21). 
However, after energy minimisation and B-factor refinement there was still some F0-Fc 
density surrounding the oligosaccharide in each protein molecule of the structural 
model. This residual F0-Fc density likely reflects the flexible structure of the bound 
carbohydrate, which can be expected to be mobile in the crystal because it is present 
on the surface of the lectin and is oriented away from the body of the protein. The 
structural flexibility and inherent mobility of the oligosaccharide produces a diffuse 
electron density profile because the electron density map represents a time-averaged 
picture of all structures in the crystal. Therefore, if the carbohydrate occupies a slightly 
different position in each protein molecule, its exact orientation and location cannot be 
pinpointed because the electron density map will reveal the positions of all the sugars 
in the crystal. To reduce the residual F0-Fc density, the occupancy of the modelled 
sugars was reduced from 1.0 to 0.25 for the trisaccharide in one molecule and 0.5 for 
the hexasaccharide in the other. In a good structural model, all atoms will have 
occupancy of 1.0, indicating that their positions are accurately modelled and represent 
their true positions. Reducing the occupancy of atoms indicates that they are not 
accurately positioned for all of the molecules in the crystal structure.
The structural flexibility and mobility of oligosaccharides also explains why 
weaker F0-Fc density was observed for the carbohydrate in one of the molecules in the 
structural model compared to the other. However, several oligosaccharides have been 
characterised from ECL (Ashford et al. 1991). Whilst the major component is known to 
be the heptasaccharide represented in Figure 12, three smaller carbohydrates, 
including a hexasaccharide, have also been identified. The structure of the 
hexasaccharide differs from the major component by the absence of the fucose 
residue, therefore it was obvious from the observed electron density that the bound 
oligosaccharide was in fact the major component but that there was no density 
recorded for the seventh residue. The fact that the major heptasaccharide component 
makes up 79% of the carbohydrate bound to ECL (Ashford et al. 1991), coupled with 
the observation that ECL runs as two bands on SDS-PAGE (Iglesias et al. 1982) 
indicates that ECL exists as a heterodimer in which the two protomers are differently 
glycosylated.
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Figure 21 - Electron Density for the Hexasaccharide Modelled into the Structure
of nECL
Jsnl 13
This figure shows how the six sugar residues were modelled into the electron density for one of the nECL 
protomers in the crystal structure. Unfortunately, no electron density was observed for the seventh sugar 
residue (another mannose) so it could not be modelled into the structure. There was some Fo-Fc density 
associated with the mannose and xylose residues and this was probably because of the structural flexibility 
of the bound oligosaccharide.
As shown in Figure 22, Asn113 is located in a loop associated with the curved, 
seven-stranded |3-sheet of the legume lectin fold. The carbohydrate-combining site is 
also associated with loops on this face of the lectin, but the combining and 
glycosylation sites are not adjacent in the ECL protomer. The bound oligosaccharide 
does not influence the carbohydrate-binding properties of ECL. This is demonstrated 
by the equivalent specificities and affinities of nECL and recECL for carbohydrates and 
DRG (Stancombe et al. 2003). The oligosaccharide is also not located close to the 
dimer interface and plays no part in the quarternary association of ECL protomers 
(discussed later in section 3.3.3.4). Analysis of the modelled hexasaccharide revealed
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that whilst the sugars in the bound oligosaccharide make contacts with each other, with 
Asn113 and with water molecules, they do not make contacts with any other parts of the 
lectin protomer. The role of glycosylation on legume lectins is currently unknown, but 
the sugar might act as a recognition motif for other proteins. ECL is synthesised with a 
signal sequence and is post-translationally modified. It is possible that glycosylation of 
ECL targets the lectin to a specific cellular location. However, until the biological 
function of ECL in the legume is determined, the role of bound carbohydrate remains 
the subject of speculation.
Figure 22 - Location of the Glycosylation Site Relative to the Combining Site
This figure, prepared using Molscript, Povray and GIMP, displays the location of the bound oligosaccharide 
in ECL with respect to the combining site. The hexasaccharide (depicted in blue) is attached to Asn113, 
which is located in a loop associated with the concave face of the seven-stranded p-sheet. The combining 
site is a shallow cleft formed by four loops also associated with the seven-stranded p-sheet. It can be seen 
that the glycosylation site and combining site are not adjacent in the tertiary structure of ECL and that there 
are no contacts between the oligosaccharide and the bound ligand. The oligosaccharide is also not 
associated with the dimer interface and, with the exception of Asn113, does not make contacts with any part 
of the lectin.
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Figure 23 - The Crystal Structures of Native and Recombinant ECL
I.actosc
Trisaccharide
This figure shows the superposition of recECL-Lac (at 1.7A resolution), in blue, on nECL-Lac (at 2.0A  
resolution), in pink. Three of the attached sugar units in the native structure are also shown in pink and the 
bound lactose molecules are shown in gold. The absence of the bound oligosaccharide from recECL does 
not seem to alter the overall tertiary structure of the lectin, as seen above. There are a few small 
differences in the positions of some loops but this probably results from the difference in resolution of the 
two crystal structures.
Comparison of the crystal structures of nECL-Lac and recECL-Lac at 2.0A and 
1.7A, respectively (Figure 23), revealed that there are no significant structural 
differences between native and recombinant forms of the lectin. This confirms that the 
presence of glycosylation does not influence the structure of the ECL protomer and has 
no effect on the structure of the combining site or carbohydrate binding. The first few 
sugar residues appear to be replaced by water molecules in the recombinant structure. 
Although small differences can be observed in the positions of some of the loop 
structures, these probably result from the difference in resolution between the two 
structures. There are no large structural rearrangements and the positions of the 
lactose and metal ions in the combining sites of the two ECL forms are equivalent.
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Phel31
Lactose
Figure 24 - interaction Between the Lactose and Oligosaccharide
6.70
-  -  _  14
GlcNAc
Asn 113
This figure shows the long-range interactions (distances are in Angstroms) between the N-linked 
oligosaccharide on molecule B in the asymmetric unit and the lactose molecule bound to a symmetry- 
related copy of molecule A. This is likely a result of the crystal packing, as it is not observed with molecule 
A and symmetry-related molecules.
However, possible communication was observed between the first sugar 
residue of the bound oligisaccharide in one protein molecule in the asymmetric unit 
(molecule B) with the glucose moiety of the lactose bound in the combining site of a 
symmetry-related molecule (of molecule A). The sugars are positioned approximately 
5A apart and oriented almost perpendicular to each other (Figure 24). As displayed in 
Figure 24, there are only two long-range interactions between the two sugar residues, 
between 0 1 ’ of the lactose molecule and 06  of both GlcNAc molecules in the bound 
oligosaccharide. However, no communication was observed between the glycosylation 
on molecule A in the asymmetric unit and symmetry-related molecules. Instead, the 
symmetry-related molecules close to molecule A packed were oriented such that the
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bound lactose molecules were positioned distant from the glycosylation on molecule A. 
This suggests that the “interaction” observed between molecule B and a symmetry- 
related copy of molecule A is merely a consequence of the crystal packing. Whilst it is 
crystallographically interesting, it does not represent an interaction that affects the 
biological activity of nECL.
ECorL (Shaanan et al. 1991) and SvenECL (Svensson et al. 2002) are 
reported to have two N-linked glycosylation sites at Asn17 and Asn113. In contrast, nECL 
has only one glycosylation site -  Asn113. In the sequence of nECL (Figure 13), the 
amino acid at position 17 is aspartic acid, not asparagine, and differs in this respect 
from ECorL and SvenECL. The presence of a heptasaccharide bound to ECorL at 
Asn17 was postulated to force the lectin into a non-canonical dimer structure and a 
similar rationale was applied to SvenECL. However, the absence of bound 
carbohydrate at this position in nECL indicates that there must be factors other than 
glycosylation influencing the quarternary association of legume lectin protomers. The 
dimeric structure of nECL will be discussed in greater detail in section 3.3.3.4.
3.3.3.3 Lactose Binding
Analysis of contacts between lectin and lactose revealed that lactose binding 
by ECL is mediated by a set hydrogen bonds between the lectin and the disaccharide. 
Water molecules mediate indirect hydrogen bonds between Leu86, Gly107, Asn133, Ala218 
and Gin219 and the 02, 03  and 06  of galactose and 02  of glucose. In addition, Lac 
also makes contacts with further water molecules in the combining site. Some of the 
recECL-Lac contacts are displayed in Figure 25. This is similar to the mode of 
carbohydrate binding observed in ECorL, in which the galactose ring of lactose forms 
hydrophobic interactions with the side chains of Ala88, Tyr106, Phe131 and Ala218 and 
hydrogen bonds with the side chains of Asp89 and Asn133 (Shaanan et al. 1991). It has 
been suggested that the side chain of Ala218 that prevents ECorL binding glucose or 
mannose by sterically hindering the optimal orientation of monosaccharides with an 
equatorial 4-OH in the combining site. Based upon similarities in the architecture of 
their combining sites and conservation of combining site residues, this would also hold 
true for ECL.
ECL has similar carbohydrate-binding properties to ECorL, although ECorL 
has a higher affinity for fucosyl-N-acetyllactosamine compared to LacNAc (Moreno et 
al. 1997; Teneberg et al. 1994). The altered carbohydrate specificities of SvenECL and 
ECorL are postulated to be due to differences in their amino acid sequences at 
positions 111 and 125 (Svensson et al. 2002). The substitution of residues at these
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positions causes rotation of the side chain of Val92 and this is thought to induce 
structural changes in the combining site. Although there are no contacts between these 
three residues in the crystal structure of nECL, Val92 was found to make contacts with 
Val126, which is located close to the combining site. Thus, it is possible that 
substitutions causing movement of Val92 might affect carbohydrate binding, however, 
this remains to be proved.
Lactose
Figure 25 - Interaction of Lactose with Combining Site Residues in recECL
Lactose binding by ECL is mediated by a number of hydrogen bonds and van der W aals contacts with a 
number of amino acid side chains and water molecules in the combining site. Only the galactose moiety of 
the disaccharide is accommodated in the combining site in a manner analogous to that observed for 
ECorL. Lactose makes contacts with the side chains of Asp89, Gly107, Asn133, Ala218 and Gin219 and 
carbonyl oxygen of Leu86 and the galactose ring forms hydrophobic interactions with Phe131. This figure 
displays several of the contacts formed between lactose and recECL -  solid lines represent hydrogen 
bonds or van der W aals contacts, with all distances quoted in Angstroms.
95
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
Hydrophobic stacking interactions were noted between the aromatic ring of 
Phe131, the galactose ring of the bound lactose and the side chain of Tyr106 (Figure 26). 
The side chain of Tyr106 was found to adopt a generously allowed configuration in all of 
the ECL-Lac structures solved, as determined by the Ramachandran plot (Appendix 1). 
This is also true for SvenECL (PDB code 1GZC) and the crystal structure of ECorL 
(PDB code 1AX0). However, in the unliganded recECL structure, only Tyr106 in one of 
the four molecuies (one of the three molecules with glycerol bound in the combining 
site) was located in an additional allowed region of the Ramachandran plot. Thus, it 
can be postulated that the configuration of this residue is affected by carbohydrate 
binding.
Figure 26 - Hydrophobic Stacking Interactions Between Lactose and Combining
Site Residues Tyr106 and Phe131
The electron density map clearly outlines the hydrophobic stacking interaction between the galactose ring 
of the bound lactose and the side chains of combining site residues Tyr106 and Phe131. Interestingly, the 
side chain of Tyr106 adopts a generously allowed configuration in the structures of the nECL-Lac and 
recECL-Lac complexes, as was previously observed in the crystal structures of ECorL and ECL in complex 
with lactose (Shaanan et al. 1991; Svensson et al. 2002). However, the side chain of Tyr106 in the recECL
structure solved in the absence of carbohydrate did adopted allowed configurations. This suggests that the
106side chain of Tyr is affected by carbohydrate binding.
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The crystal structures of nECL-Lac and recECL-Lac complexes at 2.0A and 
1.7A, respectively, superimposed with an overall rmsd of 0.29A. Comparison of the 
spatial arrangement of residues in the combining sites of both forms of the lectin 
revealed that recECL binds lactose in the same way as nECL. Further to the observed 
equivalence of carbohydrate binding by nECL and recECL (Stancombe et al. 2003), 
this confirms that recECL is native-like terms of its carbohydrate-binding activity as well 
as its tertiary structure. This analysis also confirms that glycosylation of ECL does not 
influence its carbohydrate binding properties or the structure of the combining site.
Figure 27 - Comparison of the Combining Sites of recECL in Lactose-Bound and
Unliganded Forms
This figure (prepared using Molscript, Povray and GIMP) displays a superposition of combining site 
residues in the crystal structures of recECL in lactose-bound and unliganded forms. The structure of 
recECL in the lactose-bound conformation is shown in blue with Mn2+ and Ca2+ depicted as green and 
navy spheres, respectively and the bound lactose molecule in gold. The structure of recECL with no ligand 
bound is shown in pink. The comparison clearly shows that there are no significant structural changes, with 
respect to the residues in the combining site, upon lactose binding. Instead, the amino acid side chains 
that are involved in carbohydrate recognition appear to be optimally spatially oriented in the ECL protomer, 
even in the absence of bound ligand.
The structures of recECL unliganded and in complex with Lac (at 2.13A and 
1.70A resolution, respectively) superimposed with an overall rmsd of 0.21 A. A direct 
comparison of side chain positions in the combining sites of the two structures (Figure
97
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
27) revealed no structural rearrangements within the combining site upon lactose 
binding. This indicates that the amino acids involved in carbohydrate recognition are 
optimally oriented in the ECL protomer. The calcium and manganese ions maintain the 
orientation of key carbohydrate-binding residues within the combining site and the 
conserved c/s-peptide bond correctly positions the side chain of Asp89. Analysis of the 
crystal structure of ECorL indicates that residues in the combining site are optimally 
oriented for carbohydrate binding in this lectin, even in the absence of ligand (Shaanan 
et al. 1991). So, it appears that lectins recognise their ligands via a “lock-and-key” 
mechanism unlike enzymes, which exhibit an “induced-fit” mode of substrate binding. 
This helps to explain the specificity of lectins for monosaccharides, since rigidity in the 
combining site would prevent galactose-specific lectins, for example, altering their 
shape to accommodate glucose or fucose even though these sugars are epimers of 
galactose.
3.3.3.4 Mode of Dimerisation
ECL is biologically active as a dimer and it is not possible to isolate the lectin 
in monomeric form (J.A. Chaddock, personal communication). Protomers of nECL and 
recECL associate back-to-back, forming dimers via the “handshake motif in which the 
two protomers are tilted with respect to each other (Figure 28). As previously 
mentioned, this non-canonical mode of dimerisation was originally observed for ECorL 
(Shaanan et al. 1991) and was also recently reported for SvenECL (Svensson et al. 
2002). It was proposed that ECorL and SvenECL dimerise in this manner because the 
presence of a heptasaccharide N-linked to Asn17 prevents the formation of a canonical 
dimer. However, this glycosylation site is absent from the nECL studied in this 
investigation and recECL is not glycosylated because it is recombinantly expressed in 
E.coli, yet protomers of both nECL and recECL associate in the same way (i.e. back-to- 
back). This observation throws doubt on the proposed influence of glycosylation on the 
quarternary association of legume lectins and points to the potential importance of 
small sequence changes in determining protein structure (as discussed in (Manoj and 
Suguna 2001).
Examination of legume lectin sequences, focusing on the regions forming 
interfaces between protomers and dimers, identified amino acid residues that might 
influence the mode of oligomerisation (Manoj and Suguna 2001). Extrapolation of these 
results to ECL reveals that the primary structure of this lectin (Figure 13) contains 
features that indicate it could be expected to form ECorL-type (i.e. X3-type) dimers. 
Legume lectins that do not form canonical dimers have charged residues at two critical
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positions, equivalent to Phe11 and Lys55 in ECL. Furthermore, the presence of Arg73 
and Lys171 in ECL indicates the formation of a non-canonical dimer, as arginine and 
lysine residues at equivalent positions are unique to those legume lectins that dimerise 
via the handshake motif. Although this sequence analysis would predict the mode of 
dimerisation observed for ECL, it should not be considered definitive and cannot be 
used to accurately predict the quarternary structures of legume lectins that have not 
been structurally characterised (Manoj and Suguna 2001).
Figure 28 - Quarternary Structure of ECL
Native and recombinant forms of ECL adopt the same quarternary structure, forming ECorL-like dimers in 
which two protomers associate back-to-back via the “handshake m otif. The dimer interface is stabilised by 
residues located in the flat, six-stranded p-sheet and loops connecting this sheet to the curved, seven- 
stranded p-sheet (Figure 29). This figure displays the dimeric structure of nECL in complex with lactose (in 
pink) and shows that the combining site is located on the opposite face of the lectin to the dimer interface. 
The calcium and manganese ions are shown as red and blue spheres, respectively. The bound 
oligosaccharide (not shown) is positioned on the curved seven-stranded 0-sheet, distant from the dimer 
interface, and does not influence the quarternary structure of ECL. This figure was prepared using 
Molscript, Povray and GIMP.
The dimer interface is stabilised by two hydrogen bonds, between Lys171 in 
one protomer and Thr193 in the other, and several van der Waals contacts involving
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residues Arg73, Glu79, Gin80, Pro81, Tyr82, Thr83, Arg84, Lys116, Gin117, Asp118, Asn119, 
Asn148, Asp161, Asn162, Gin164, Lys171, lie191, Thr193, Gin202, Val203 and Asp221. The amino 
acids mediating protomer-protomer contacts are located in four strands of the six- 
stranded, anti-parallel p-sheet and in loops connecting this sheet to the curved, seven- 
stranded p-sheet (Figure 29). The N- and C-termini associate together, forming the first 
two strands of the six-membered sheet, but play no role in dimerisation of the lectin 
because the protomers are tilted with respect to each other such that there are no 
contacts between the N- and C-termini of different protomers. Thus, only the remaining 
four strands of the six-membered sheet associate together in the dimer structure.
Figure 29 - Amino Acid Residues That Stabilise the Dimer Interface in ECL
The structure of the ECL monomer is oriented such that the flat, six-stranded p-sheet is at the forefront. 
The N- and C- termini are labelled and form the first two strands of the anti-parallel sheet. The amino acid 
residues that are involved in forming hydrogen bonds that stabilise the dimer interface (Lys171 and Thr193) 
are coloured in red. Residues that stabilise the dimer interface by forming hydrophobic or van der W aals 
contacts are coloured in blue. Most of these residues are located in the third to sixth strands of the sheet 
and in loops connecting the six-stranded sheet to the curved seven-stranded p-sheet. This figure was 
prepared using the programs Molscript, Povray and GIMP.
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3.3.4 Comparison with the Previously Reported Structure
As previously mentioned, the crystal structures of natively-sourced ECL in 
complex with 2-fucosyllactose and lactose were recently reported (Svensson et al. 
2002). SvenECL protomers adopt the legume lectin fold and associate via the 
handshake motif. However, several differences have been noted between SvenECL 
and the crystal structures of nECL and recECL determined in this investigation.
Figure 30 - Analysis of the Primary Structure of recECL
recECL VETISFSFSE FEPGNNDLTL QGAAIITQSG VLQLTKINQN
SvenECL VETISFSFSE FEPGNDNLTL QGAALITQSG VLQLTKINQN
recECL GMPAWDSTGR TLYTKPVHIW DMTTGTVASF ETRFSFSIEQ
SvenECL GMPAWDSTGR TLYTKPVHMW DSTTGTVASF ETRFSFSIEQ
recECL PYTRPLPADG LVFFMGPTKS KPAQGYGYLG VFNNSKQDNS
SvenECL PYTRPLPADG LVFFMGPTKS KPAQGYGYLG VFNNSKQDNS
recECL YQTLAVEFDT FSNPWDPPQV PHIGIDVNSI RSIKTQPFQL
SvenECL YQTLAVEFDT FSNPWDPPQV PHIGIDVNSI RSIKTQPFQL
recECL DNGQVANWI KYDASSKILL AVLVYPSSGA IYTIAEIVDV
SvenECL DNGQVANWI KYDAPSKILH WLVYPSSGA IYTIAEIVDV
recECL KQVLPEWVDV GLSGATGAQR DAAETHDVYS WSFHASLPET N
SvenECL KQVLPDWVDV GLSGATGAQR DAAETHDVYS WSFQASLPE- -
The primary structure of nE C L  differs at ten positions from the sequence of E C L reported by Svensson et 
al, 2002  (S venE C L). The ten differences are highlighted in green and the N-linked glycosylation sites are 
underlined. None of the differences affect residues involved in carbohydrate binding (highlighted in red) or 
the dimer interface (in blue).
In total, there are ten differences between the amino acid sequence of nECL 
and SvenECL (Figure 30). These are: Ni6D, D17N, l25L, l59M, M62S, S175P, L180H, A 181V, 
E ^ D  and H234Q (where the first residue is that in nECL and the second is that in 
SvenECL). The differences at positions 25, 181 and 206 represent conservative 
substitutions, where the chemical nature of the residue is not changed. The residues at 
positions 16 and 17 appear to be swapped in nECL compared with SvenECL and 
although this alters the chemical nature of the residue each position, the side chains
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are of the same size and shape and cannot be distinguished from one another on the 
basis of the electron density pattern. The remaining variations are not conservative 
substitutions.
Given that the sequence of SvenECL determined by peptide mapping (briefly 
described in section 3.1.5.3) differs from the sequence indicated by the electron density 
map of the protein (Svensson et al 2002), it does not appear to be a reliable method for 
determining protein primary structure. The amino acid sequence of recECL, on the 
other hand, was determined by DNA sequencing using material from two independent 
sources of E.cristagalli (Stancombe et al. 2003) and careful analysis of the calculated 
electron density maps confirmed this sequence at all ten of the locations where it 
differs from SvenECL.
Differences between the sequences of recECL and SvenECL might represent 
subtle variations across the species.None of the sequence differences between 
SvenECL and nECL affect amino acids involved in carbohydrate binding or stabilising 
the dimer interface. However, a potential N-linked glycosylation site at residue 17 is 
absent from nECL. SvenECL is glycosylated at two positions (Asn17 and Asn113), the 
same as ECorL, but although weak electron density for the sugars was observed, the 
bound oligosaccharides were not modelled in the crystal structures (Svensson et al. 
2002). SvenECL crystallised under different conditions and in a different space group 
to both nECL and recECL. As described in section 3.3.1, nECL co-crystallised with Lac 
in space group P65 and recECL crystallised in three forms (P1, P21t and P3212) and 
co-crystallised with Lac in space groups P2i and C2. SvenECL was co-crystallised with 
lactose and 2-fucosyllactose in space group P432i2 (Svensson et al. 2002). The 
structure of the SvenECL-lactose complex at 1.6A resolution (PDB code 1GZC) 
superimposed onto the structure of the nECL-Lac complex (at 2.0A resolution) with an 
overall rmsd of 0.32A.
The equivalence of nECL and SvenECL in terms of their tertiary structures is 
not surprising, considering the conservation of structure among legume lectins. These 
two forms of ECL are 96% identical in terms their primary structures. Sequence identity 
among pairs of legume lectins that have been structurally characterised varies from 28 
to 99% (Manoj and Suguna 2001) yet they all adopt the same tertiary structure 
characterised by two anti-parallel p-sheets (Figure 11). nECL shares 96% sequence 
identity with ECorL, which was used as a model for phase determination by molecular 
replacement. This high level of sequence identity indicates that the proteins are likely to 
fold in a similar manner. Therefore, the tertiary structures of SvenECL and nECL would 
be expected to be almost identical.
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The combining site of nECL was compared with that of SvenECL in complex 
with lactose (Figure 31). There are no significant differences between the positions of 
the amino acid residues involved in carbohydrate binding in the two structures. In both 
crystal structures, the side chain of Tyr106 was found to adopt a generously allowed 
configuration (according to the Ramachandran plot). In conjunction with Phe131, Tyr106 
makes a hydrophobic stacking interaction with the galactose ring of the bound lactose. 
None of the sequence differences between nECL and SvenECL alter the amino acid 
composition of the combining site, so both forms of the lectin would be predicted to 
bind carbohydrates in the same way.
Figure 31 - Comparison of Combining Sites of nECL and the Previously 
Reported Structure of ECL in Complex with Lactose
The combining site of nECL is shown in blue, with the manganese and calcium ions in green and navy, 
respectively, and lactose in purple. The previously reported structure of ECL (Svensson et al. 2002; PDB 
code 1GZC) is shown in gold, with manganese and calcium in orange and red, respectively, and lactose in 
pink. This diagram (produced using Molscript, Povray and GIMP) shows that there are no significant 
differences in the positions of the combining site residues between the two structures.
SvenECL forms ECorL-like (i.e. back-to-back) dimers as do both nECL and 
recECL. The presence of bound carbohydrate at Asn17 in SvenECL was proposed to 
prevent the formation of a canonical dimer (as was originally postulated for ECorL). 
However, this residue is not glycosylated in the structure of nECL, suggesting that
Leu 86
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there are other factors intrinsic to the protomers that influence the quarternary structure 
of the lectin. This hypothesis is further supported by the observation that recECL 
protomers, which are devoid of glycosylation, also associate via the handshake motif.
3.4 SUMMARY OF RESULTS
Native and recombinant forms of ECL were crystallised in five space groups 
(P65t P1, P21t C2 and P3212) under a variety of conditions. Whilst nECL could only be 
crystallised in complex with Lac, recECL was crystallised in the presence and absence 
of carbohydrate. A total of six crystal forms of ECL were analysed and the structures 
were solved using molecular replacement with ECorL as a search model. All residues 
except the C-terminal Asn241 could be modelled in the observed electron density.
Protomers of nECL and recECL adopt the conserved legume lectin fold that is 
characterised by two anti-parallel p-sheets and the presence of Ca2+ and Mn2+ close to 
the carbohydrate-combining site. The overall fold comprises one flat, six-stranded 13- 
sheet; one curved, seven-stranded p-sheet and; one short five-membered p-sheet and 
these structural elements are linked by a series of loops. The combining site is located 
on the surface of the seven-stranded p-sheet, formed by four loops associated with this 
face of the lectin. The N- and C-termini associate together forming the first two strands 
of the six-stranded p-sheet. Protomers of both forms of ECL associate back-to-back, 
forming dimers via the “handshake” motif, as was observed for ECorL. The dimer 
structure is stabilised by two hydrogen bonds and several van der Waals contacts 
between residues in four strands of the flat, six-stranded p-sheet and in loops 
associated with these structural elements.
Equivalence of carbohydrate specificity in nECL and recECL has already been 
documented (Stancombe et al. 2003). Direct comparison of the structure of the 
combining site in the nECL-Lac complex with that in the recECL-Lac complex revealed 
no differences in either the spatial arrangement of combining site residues or in the 
orientation of the bound disaccharide. Furthermore, there are no significant differences 
in the overall fold of the recECL protomer compared to nECL or in the structures of the 
dimers they form. These results clearly demonstrate that recECL is native-like in terms 
of both its structure and mode of carbohydrate binding. The only difference between 
native and recombinant forms of ECL is the absence of bound carbohydrate from 
recECL. The amino acid sequence of nECL contains one potential N-linked 
glycosylation site, Asn113, to which a heptasaccharide is N-linked in the mature protein. 
The structure of the oligosaccharide bound to nECL was modelled into the observed 
electron density and was not found to make contacts with any part of the lectin except
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the asparagine to which it is linked. The role of carbohydrate on lectins is unknown 
and, in the case of ECL, the bound heptasaccharide does not appear to affect 
carbohydrate recognition or influence quarternary structure.
The structure of the combining site in ECL in the absence of carbohydrate is 
not significantly different to that in lactose-bound forms of the lectin. This indicates that 
key carbohydrate-binding residues are optimally positioned in combining site of the 
ECL protomer and suggests that lectins recognise their ligands via a “lock and key” 
mechanism. ECL binds lactose by forming a network of indirect hydrogen bonds with 
the galactose moiety through a number of structural water molecules. The side chains 
of Phe131 and Tyr106 form hydrophobic stacking interactions with the pyranose ring of 
galactose and there are several van der Waals contacts between lectin and 
carbohydrate. Key residues implicated in lactose binding were identified as Leu86, 
Asp89, Tyr106, Gly107, Phe131, Asn133, Ala218 and Gin219.
A different crystal form of native ECL (space group P432i2) was reported in 
2002 that differs in primary structure from nECL and recECL in ten positions. Only one 
of the amino acid substitutions alters the structure of the lectin by removing a potential 
N-linked glycosylation site at position 17. In the reported structure (Svensson et al. 
2002), Asn17 is glycosylated and electron density for the sugar was observed at this 
position, although no sugars were modelled. Despite the presence of carbohydrate at 
Asn17, the tertiary and quarternary structures reported for native ECL do not differ 
significantly from those determined for nECL and recECL in this investigation.
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CHAPTER FOUR 
STRUCTURAL STUDIES ON NON-TOXIC FRAGMENTS 
OF BOTULINUM NEUROTOXIN A
4.1 INTRODUCTION
The botulinum neurotoxins (BoNTs) are among the most poisonous proteins 
known to Man and are the causative agents of the disease botulism. The seven BoNT 
serotypes (A, B, C1, D, E, F and G) are produced and secreted by strains of the 
anaerobic bacteria Clostridium botulinum, Clostridium barati and Clostridium butyricum. 
These toxins cause descending flaccid paralysis by disrupting neurotransmission at the 
neuromuscular junction. Together with tetanus neurotoxin (TeNT), the BoNTs make up 
the Clostridial Neurotoxin (CNT) family. TeNT is produced and secreted by Clostridium 
tetani and causes the disease tetanus, characterised by spastic paralysis. The mouse 
LD50 for the clostridial neurotoxins is 0.1-1.0 ng/kg (Schiavo et al. 2000) and, if medical 
attention is not sought rapidly, both tetanus and botulism can be fatal. However, 
despite their potent toxicity, clostridial neurotoxins have become useful tools in medical 
research and are used as pharmaceutical therapeutic agents for a variety of conditions.
Nota bene: A review of recent research into the structures, functions and 
therapeutic applications of clostridial neurotoxins (Turton et al. 2002) is presented in 
Appendix 3.
4.1.1 Botulism and Tetanus
4.1.1.1 Botulism
Although botulism was first described in the eighteenth century, the bacteria 
and proteins responsible were not identified until the 1890s. The BoNT serotypes 
associated with botulism in humans are A, B and E, with few cases reportedly caused 
by BoNT/F (Montecucco et al. 1996). There are three recognised types of botulism in 
humans: food-borne, wound and infant botulism. The most common form is food-borne 
botulism, an intoxication resulting from the ingestion of foods contaminated with 
C.botulinum spores that have germinated and produced BoNT. Wound botulism is 
comparatively rare and is caused by the germination of C.botulinum spores in open 
wounds. Symptoms of both types normally appear within 12-36 hours of intoxication or 
infection. The disease proceeds with symptoms of food poisoning (in the case of food- 
borne botulism), dry mouth and visual impairment, followed by general muscle 
weakness and a rapidly progressing, descending flaccid paralysis. If left untreated,
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botulism is fatal because respiratory failure or cardiac arrest will occur (Niemann 1991). 
Infant botulism is a toxic infection that results from germination and proliferation of 
C.botulinum spores in the neonate intestine in the absence of competing bacterial flora 
(Montecucco et al. 1996). Symptoms differ slightly from those reported for food-borne 
and wound botulism and include lethargy, listlessness, hypotonia, feeble cry, poor 
feeding, weakness, drooping eyelids and apnoea.
At present there is no cure for botulism, but few cases of the disease are fatal 
due to advances in medical care. Early diagnosis is important and treatment involves 
the administration of antitoxin, comprising antibodies raised against BoNTs A, B and E 
(Robinson and Nahata 2003). Respiratory monitoring is essential because even early 
administration of antitoxin cannot prevent paralysis and respiratory arrest may occur. 
Recovery is slow and depends upon the BoNT serotype involved. Different serotypes 
are active for differing periods of time, with BoNT/A exhibiting the longest duration of 
action (paralysis lasts for up to 4-6 months). The differences in duration of action are 
due to replenishment of substrate proteins (observed for BoNTs E and F) or longevity 
of protease action, as for BoNTs A, B and C1 (Foran et al. 2002). The fact that full 
recovery is possible indicates that BoNTs do not cause lasting structural damage to 
neurons, although complete restoration of exocytosis and relief from paralysis cannot 
occur until the toxin has been fully degraded (Ahnert-Hilger and Bigalke 1995). Nerve 
sprouting from neurons poisoned by BoNT/A creates new synapses that mediate 
neurotransmission, allowing the onset of recovery (Meunier et al. 2003). These neurite 
sprouts are retracted upon restoration of activity to poisoned synapses (dePaiva et al. 
1999). Thus, full restoration of synaptic function is possible without the need for 
permanent synaptic remodelling.
There is no widely available anti-botulism vaccine, but a pentavalent toxoid 
vaccine that protects against serotypes A-E is administered to people deemed “at risk” 
of infection, for example health workers and members of the armed forces. The vaccine 
is manufactured by detoxifying BoNTs A-E with formalin, but it is expensive to produce 
because it requires dedicated facilities and can produce some unpleasant side effects 
due to the presence of residual formaldehyde. Efforts are underway to produce 
recombinant vaccines, as this would remove the need for a dedicated manufacturing 
facility, reduce production costs and eliminate the side effects caused by formaldehyde. 
Fragments of BoNTs A, C and F have been recombinantly expressed and used to 
induce immune responses in mice (Byrne et al. 1998; Byrne et al. 2000; Clayton et al. 
1995; Kiyatkin et al. 1997; LaPenotiere et al. 1995). The potential of DNA vaccination
107
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
has also been investigated and it is thought to be a viable method of protection 
(Clayton and Middlebrook 2000).
4.1.1.2 Tetanus
Cases and symptoms of tetanus have long been known, but the bacterium 
responsible for the disease was not isolated until 1891 (Schiavo et al. 2000). Spores of 
C.tetani germinate under anaerobic conditions, such as those in a deep wound, 
producing TeNT. Initial symptoms include headache, neck and back pains, fever and 
muscle stiffness, which proceeds to an overall spastic paralysis with generalised reflex 
spasms (Niemann 1991). Respiratory failure occurs if medical attention is not sought 
quickly. The opposite symptoms of tetanus and botulism result from the different sites 
of action of TeNT and BoNTs, although at high concentrations TeNT may induce 
symptoms of botulism (Singh et al. 1995). Treatment of tetanus involves the use of 
muscle relaxants and artificial respiration and full recovery is possible with no lasting 
nervous damage. An effective toxoid vaccine, composed of formaldehyde-treated 
TeNT, is widely available and its use has almost eliminated tetanus from the developed 
world (Niemann 1991).
4.1.2 Molecular Biology of Clostridial Neurotoxins
CNTs are synthesised in the bacterial cytosol as single-chain polypeptides. 
These precursor polypeptides are post-translationally nicked within a surface-exposed 
loop to form di-chain molecules of ~150kDa in which the light and heavy chains are 
linked by a single disulphide bond. This proteolytic nicking activates the toxin, as has 
been observed for several other bacterial toxins, including E.coli labile toxin, cholera 
toxin and diphtheria toxin (Lencer et al. 1997; Tsuneoka et al. 1993). The proteases 
responsible for CNT activation remain to be identified and might be serotype-specific 
because BoNTs B and E are not substrates for the protease that nicks BoNT/A 
(Dekleva and DasGupta 1989).
CNTs comprise three functional domains (Figure 32) each of which is involved 
in the mechanism of action. The ~50kDa light chain (LC) is the catalytic domain with 
zinc-dependent protease activity. The toxin heavy chain contains two domains, each of 
~50kDa. The N-terminal half (HN) is the translocation domain, which is known to form 
ion-conducting channels, and the C-terminal half (Hc) is the binding domain, which 
targets the toxins to cholinergic and CNS neurons.
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Figure 32 - Cartoon Depicting the Di-Chain Structure of Botulinum Neurotoxin A
448





437 Light chain (LC)
Botulinum neurotoxin A, a typical clostridial neurotoxin, is synthesised as a single-chain polypeptide and is 
post-translationally nicked to form an active di-chain molecule in which the light and heavy chains are 
linked by a disulphide bond (Cys430-Cys454). Within their di-chain structures, the clostridial neurotoxins are 
divided into three functional domains, each of approximately 50kDa. The light chain (depicted in red) is the 
catalytic domain, which acts as a zinc-dependent endopeptidase. The translocation domain (in blue) and 
the binding domain (in green) make up the heavy chain. The translocation domain forms ion channels in 
lipid bilayers and the binding domain facilitates internalisation of the toxins into their target neurons.
The eight CNTs are thought to have developed from a single ancestral gene 
because they exhibit 30-40% amino acid sequence similarity among their light and 
heavy chains (Ahnert-Hilger and Bigalke 1995). TeNT shares -65%  sequence 
homology (and -35%  identity) with the BoNTs (Lacy and Stevens 1999) and sequence 
alignment of the toxins (Appendix 4) reveals areas of high similarity. Further evidence 
for the existence of a common ancestor comes from the observation that neurotoxin 
gene elements are mobile and that gene transfer may take place between toxigenic 
and non-toxigenic strains of C.botulinum via phages, plasmids or conjugation 
transposons (Schiavo et al. 2000). Indeed, strains of the bacterium have been isolated 
that produce a “mosaic” BoNT, containing a mixture of elements from serotypes C and 
D (Moriishi et al. 1996a; Moriishi et al. 1996b).
CNTs are substrates for protein tyrosine kinases (Ferrer-Montiel et al. 1996) 
and phosphorylation increases their catalytic activity and thermal stability. The catalytic 
activity of BoNTs A and E increases with increased tyrosine phosphorylation and it has 
been postulated that CNTs are biologically active only in the phosphorylated form. 
Phosphorylation is accompanied by conformational changes that make the protein 
structure more compact, which may explain the enhanced catalytic activity (Encinar et 
al. 1998). The light and heavy chains of TeNT and BoNTs A, B, E are phosphorylated 
by Src, but serine/threonine kinases do not appear to act upon CNTs (Ferrer-Montiel et
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al. 1996). This observation suggests that cell-signalling pathways in the neuron might 
be involved in the mechanism of action of the clostridial neurotoxins.
4.1.2.1 Neurotoxin-Associated Proteins
BoNT/A has been purified as a 900kDa complex, comprising the 150kDa 
neurotoxin and a non-toxic haemagglutinin component, and it is this complex that is the 
causative agent of botuiism (Chen et al. 1998). The complex has 360-fold higher oral 
toxicity in rats (Ohishi et al. 1977) and higher enzymatic activity (Cai et al. 1999) than 
the neurotoxin component alone. The non-toxic component of the complex consists of 
several proteins (known as neurotoxin-associated proteins or NAPs), some of which 
have haemagglutinating activity. The NAPs appear to be translated from a polycistronic 
mRNA, indicating that the neurotoxin and NAP genes are expressed simultaneously 
(Singh et al. 1995). In addition to the 900kDa complex, two smaller BoNT/A complexes 
of 500 and 300kDa have been purified, although the 300kDa complex does not exhibit 
haemagglutinin activity (Sagane et al. 2000).
Following ingestion, BoNTs are taken up by epithelial cells. The mouth is the 
least effective site of absorption, with the stomach intermediate and the intestine the 
most effective (Maksymowych and Simpson 1998). The 900kDa complex withstands 
the acidic, protease-rich conditions of the digestive tract but dissociates in the alkaline 
environment of the intestine. The haemagglutinins aid absorption of the complex to 
intestinal epithelial cells (Fujinaga et al. 1997). The neurotoxin is transcytosed to the 
mucosal side of the epithelium and enters the lymph and circulatory systems.
TeNT, on the other hand, is not released in complex with NAPs. It has never 
been isolated as a complex and there is no open reading frame upstream of the TeNT 
gene (Singh et al. 1995). Considering the protective role of NAPs in oral BoNT 
intoxication, the absence of NAP genes from the C.tetani genome may explain why 
TeNT is not a food poison.
4.1.2.2 Do CNTs Form a Novel Class of Zinc Protease?
CNTs have been described as a new class of zinc protease because they 
exhibit several properties that have not been observed for other zinc-dependent 
endopeptidases (Montecucco and Schiavo 1993): Firstly, CNTs are synthesised as 
inactive protein precursors that require specific proteolytic cleavage for activation 
(Pellizzari et al. 1999). Whilst this has been observed for other bacterial toxins, it is not 
known for other zinc-dependent proteases (Montecucco and Schiavo 1993). CNTs are 
also inactive outside their target cells (whereas many zinc proteases remain active in 
extracellular environments). In addition, CNTs demonstrate extremely high substrate
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specificity and show little sequence similarity with other zinc proteases in the region of 
the zinc-binding motif (Montecucco and Schiavo 1993). There are two types of zinc- 
dependent endopeptidase, based upon the mode of zinc coordination, astacin-like and 
thermolysin-like. However, whilst the CNT LCs share greater sequence and structural 
similarity with thermolysin, coordination of Zn2+ in CNTs involves five ligands, as in 
astacin. Removal of Zn2+ from BoNT abolishes its catalytic activity, but the substitution 
of other divalent metal ions for Zn2+ in TeNT supports proteolysis, a feature not 
observed for other zinc proteases (Tonello et al. 1997).
It has been postulated that, unlike in other zinc proteases, the Zn2+ plays both 
a structural and a functional role in CNTs, although this issue remains unresolved. 
Structural studies following the removal and replenishment of Zn2+ showed that the 
activity of BoNT/A cannot be recovered, suggesting that loss of the zinc ion results in 
irreversible structural changes (Fu et al. 1998). However, this was contradicted by the 
observation that Zn2+-depleted BoNT/A can block neurotransmission by binding zinc in 
the neuron cytosol, indicating that loss of Zn2+ does not lead to irreversible structural 
changes (Simpson et al. 2001). Further studies into the proposed structural role of zinc 
in BoNTs (Li and Singh 2000a) demonstrated partial recovery of catalytic activity 
following removal and addition of Zn2+, accompanied by some irreversible structural 
changes that do not block zinc binding.
4.1.3 CNT Structure
The crystal structures of BoNT/A (Lacy et al. 1998) (Figure 33), BoNT/B 
(Hanson and Stevens 2000; Swaminathan and Eswaramoorthy 2000b) and TeNT-Hc 
(Umland et al. 1997) have been determined. The BoNT/A and BoNT/B holotoxins are 
structurally similar at the tertiary level and there are similarities between the structures 
of the Hc domains of the three toxins. The three functional domains (LC, HN and Hc) in 
BoNTs A and B are structurally distinct and arranged in a linear fashion, such that there 
are no contacts between the catalytic and binding domains.
4.1.3.1 Catalytic Domain (LC)
The catalytic domains of the seven BoNTs share up to 36% sequence identity 
and the light chains of TeNT and BoNT/B are over 50% identical. The LC comprises a 
mixture of a-helix and p-strand elements and acts as a zinc-dependent endopeptidase. 
The active site, located in a deep cleft on the LC surface, is accessible via a channel 
and contains a zinc ion (or two, in the case of BoNT/C1) and a conserved zinc-binding 
motif (HExxH) that is characteristic of all zinc-dependent endopeptidases.
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Figure 33 - Crystal Structure of Botulinum Neurotoxin A
The crystal structure of BoNT/A (PDB code 3BTA; Lacy et al. 1998) revealed that the three functional 
domains are structurally distinct and arranged in a linear fashion such that there are no contacts between 
the catalytic and binding domains. The catalytic domain (depicted in red) contains the catalytic zinc ion (in 
cyan). The translocation domain (in blue) has two unique structural features: The first is a long loop, 
known as the translocation belt, that wraps around the catalytic domain and the second is the pair of long 
a-helices that run anti-parallel to, and wrap around, each other. The binding domain (in green) is divided 
into two sub-domains, one of which adopts a p-trefoil fold and the other with jelly-roll topology, and is 
oriented such that the C-terminal sub-domain makes no contacts with the central translocation domain. 
This figure was prepared using Molscript, Povray and GIMP.
The Zn2+ is coordinated by the imidazole rings of the two histidines of the 
HExxH motif and a water molecule bound to the glutamic acid (Pellizzari et al. 1999). In 
addition, the crystal structure of BoNT/A (Lacy et al. 1998) revealed the presence of a 
second glutamic acid and a tyrosine close to the zinc. These residues are conserved 
among the CNTs and mutation of this tyrosine in TeNT to alanine abolishes catalytic 
activity (Rigoni et al. 2001). Based on structural similarity between their active sites, the 
catalytic mechanism of BoNT/A is believed to be similar to that of thermolysin (in which 
Zn2+ is coordinated by four ligands, the histidines of the HExxH motif, a glutamic acid 
and one water molecule). Substrate binding by thermolysin displaces the water
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molecule and proteolysis proceeds via a general-base-type mechanism in which the 
unprotonated imidazole ring of one histidine functions as a base, hydrating the metal- 
activated substrate (Mock and Stanford 1996).
Site-directed mutagenesis studies identified active site residues involved in the 
catalytic mechanism of BoNT/A. Substitution of Glu224 (the glutamic acid of the HExxH 
motif) with glutamine abolished catalytic activity, whilst substitution with aspartic acid 
retained -1%  of the activity of the native toxin (Li et al. 2000). This indicates that the 
carboxyl group of Glu224 is essential for proteolysis (in the proposed mechanism, it 
coordinates the structural water molecule) and that its location is precisely positioned in 
the active site. Glu271 and Tyr375 in TeNT (equivalent to Glu261 and Tyr365 in BoNT/A) 
are also essential for proteolysis (Rossetto et al. 2001) and are involved in transition 
state stabilisation (Binz et al. 2002). Evidence for this was first provided by analysis of 
the crystal structure of BoNT/B in complex with synaptobrevin II (Hanson and Stevens
2000) where loop rearrangements upon substrate binding were observed to bring 
Arg369 and Tyr372 into closer proximity with the scissile bond of the substrate.
4.1.3.2 Translocation Domain (HN)
The central translocation domain has two unique structural features, the most 
prominent of which is a pair of long, amphipathic a-helices that run anti-parallel to, and 
wrap around, each other. The other is a long loop, known as the translocation belt, that 
wraps around the catalytic domain. In BoNT/A, the active site cleft is shielded by the 
translocation belt but in BoNT/B, this loop is shorter and occupies a different position, 
exposing the active site (Hanson and Stevens 2000).
The heavy chains of BoNTs A and B form ion-conducting channels that span 
artificial membranes (Blaustein et al. 1987; Donovan and Middlebrook 1986; Schmid et 
al. 1993). The channels gate cations and are maximally active at acidic pH (Sheridan 
1998). Channel-forming activity has been assigned to the CNT-Hn, although reduction 
of the interchain disulphide bond removes the ability of the BoNT/B to form channels in 
phospholipid bilayers (Flicker et al. 1999), indicating that structural elements from the 
other domains may also be required. The pore-forming domains of other bacterial 
toxins share a common structural motif that is not observed in BoNT/A (Lacy et al. 
1998). Instead, the tertiary structure of BoNT/A-Hn more closely resembles coiled-coil 
viral proteins, which have an acid-induced ability to undergo conformational changes 
and penetrate membranes but do not translocate through pores. However, the long 
helices in BoNT/A-Hn lack the heptad repeat that is associated with true coiled coils.
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The candidate transmembrane region in BoNT/A (residues 659-681) increases 
the permeability of lipid bilayers (Oblatt-Montal et al. 1995). The transmembrane 
sections of pore-forming proteins tend to be a-helical but in the crystal structures of 
BoNT/A (Lacy et al. 1998) and BoNT/B (Swaminathan and Eswaramoorthy 2000b), the 
putative membrane-spanning regions do not adopt a helical conformation. 
Furthermore, channel formation by CNTs is pH-dependent and the residues in BoNT/A 
most likely to titrate at low pH, His551 and His560, are located in a loop connecting the 
translocation belt to the main body of the HN domain (Lacy et al. 1998). Taken together, 
these observations suggest that some conformational changes must take place in HN 
leading to channel formation.
4.1.3.3 Binding Domain (Hc)
CNTs are structurally homologous with respect to their binding domains but 
sequence identity among them is low. The Hc has two sub-domains of roughly equal 
size, both composed of mainly p-sheet secondary structure, oriented such that there 
are no contacts between the C-terminal sub-domain and HN (Lacy et al. 1998). The Hc 
facilitates the first step in the CNT mechanism of action by recognising and binding to 
ganglioside and protein receptors on presynaptic nerve termini. The jelly-roll topology 
of the N-terminal sub-domain is similar to the structure of many lectins but mutations in 
the C-terminal half of TeNT-Hc, which adopts a p-trefoil fold, have been shown to affect 
ganglioside binding. A stretch of 34 amino acids at the carboxyl terminus of TeNT 
(residues 1282-1315) have been identified as sufficient for ganglioside binding (Shapiro 
et al. 1997) and co-crystallisation of TeNT with carbohydrates identified areas on the 
toxin surface that bind sugars (Emsley et al. 2000).
Sequence-to-structure alignment of the CNTs (Ginalski et al. 2000) revealed a 
set of five conserved residues within the C-terminal sub-domain of Hc. Located in a 
shallow cleft on the TeNT-Hc surface, Asp1222, Ser1287, Trp1289, Tyr1290 and Gly1300 are 
postulated to form the ganglioside-binding motif. Site-directed mutagenesis has since 
proved that Tyr1290 is required for ganglioside binding and TeNT activity (Sutton et al.
2001). Furthermore, the motif S1287XWY1290...G1300 has been shown to form a sugar- 
binding pocket in conjunction with residues Asn1219, Asp1222 and His1271 (Rummel et al. 
2003). The crystal structure of BoNT/B in complex with sialyllactose revealed that the 
sugar binds in a cleft between Trp1261 and His1240, forming hydrogen bonds with Glu1188, 
Glu1189, His1240 and Tyr1262 and hydrophobic interactions with Trp1261 (Swaminathan and 
Eswaramoorthy 2000b). However, the sugar did not interact with residues Lys1267, 
Arg1268, Lys1269 or Glu1265, as was proposed for TeNT (Shapiro et al. 1997).
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Cartoon outlining the steps involved in the mechanism of action of Botulinum Neurotoxins (this diagram is 
reproduced from Turton et al (2002) Trends Biochem Sci, 27, 552-558; see Appendix 3).
The toxin recognises and binds to protein and ganglioside receptors on the surface of the neuron via the 
He domain (in blue). Once a ternary complex has been formed, the toxin is taken up by receptor-mediated 
endocytosis into an endosome-like compartment. The low pH of the endosome interior induces structural 
rearrangement of the HN domain (in green), culminating in the formation of an ion-conducting channel that 
spans the endosomal membrane. The catalytic light chain (in yellow) translocates through the pore of this 
channel and is released from the toxin heavy chain by reduction of the interchain disulphide bond. Inside 
the cytosol, the light chain interacts with and cleaves its target SNARE protein (syntaxin, synaptobrevin or 
SNAP-25), thereby inhibiting the release of neurotransmitter into the synapse.
The mechanism of action of BoNT can be divided into four stages (Figure 34). 
The toxin binds to specific receptors on the neuron surface and is internalised into an 
endosomal compartment. The low pH of the endosome interior induces structural 
rearrangement enabling the toxin to form an ion channel spanning the endosomal 
membrane. The catalytic domain translocates through the ion channel and, following 
reduction of the interchain disulphide bond, moves through the neuron cytoplasm to act
115
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
upon its target protein. The targets for all CNTs are the soluble NSF-attachment protein 
receptors (SNAREs) (see section 4.1.4.3). The roles of receptor-mediated endocytosis, 
pH-dependent translocation and the zinc ion in the mechanism of action of BoNT/A 
have been experimentally confirmed (Kalandakanond and Coffield 2001).
4.1.4.1 Recognition and Internalisation of BoNT by Neurons
BoNTs bind to gangiiosides on presynaptic nerve termini via their Hc domains. 
Gangliosides are glycosphingolipids that are abundant in neuronal cell membranes. 
They contain a common core to which at least one sialic acid residue is bound. GM1 
and GD1b gangliosides have one and two sialic acids, respectively, attached to the 
internal galactose of the core, whilst GT1b and GQ1b gangliosides have one and two 
sialic acids bound to the terminal galactose. GD1b and GT1b gangliosides, which have 
the highest affinity for CNTs, are thought to be present only at synapses, accounting for 
the high specificity of BoNTs for nerve cells (Ahnert-Hilger and Bigalke 1995).
However, the affinity of BoNTs for GD1b and GT1b gangliosides is too weak 
to account for their potent toxicity. The binding affinity also varies with toxin serotype, 
type of ganglioside, temperature, pH and ionic conditions (Ahnert-Hilger and Bigalke 
1995). In addition, some birds with a high content of polysialogangliosides in their 
neuronal cell membranes are resistant to TeNT (Montecucco 1986). Taken together, 
these data suggest that the mechanism of CNT recognition by neurons is not solely 
dependent upon gangliosides. A “double-receptor model” has been proposed 
(Montecucco 1986) whereby CNTs must also bind to a specific protein receptor on the 
neuron surface. The activity of BoNT/A has since been shown to require the presence 
of gangliosides and synaptotagmin I in neuronal cell membranes (Yowler et al. 2002) 
and BoNT/B recognises a complex of GT1b/GD1a gangliosides and synaptotagmin II 
on reconstituted lipid vesicles (Kozaki et al. 1998).
Peripheral cholinergic neurons are the major target for BoNTs, although CNS 
neurons are also susceptible to intoxication (Verderio et al. 1999). Once a ternary 
complex comprising the toxin and its receptors has been formed, BoNT is internalised 
by the neuron into an acidic membrane-bound compartment. Internalisation is thought 
to occur via receptor-mediated endocytosis involving clathrin-coated vesicles because 
the uptake of BoNT/A can be inhibited by the application of drugs that inhibit 
endocytosis (Simpson 1988). After internalisation, BoNT can no longer be neutralised 
by anti-toxin antibodies (Montecucco et al. 1994).
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4.1.4.2 Channel Formation and LC Translocation
In common with other bacterial toxins, BoNT is thought to undergo structural 
rearrangement inside an acidic compartment within the neuron. Diphtheria toxin (DT) 
enters cells via receptor-mediated endocytosis and its catalytic domain is transported 
to the cytosol across the endosomal membrane following a channel-formation step 
induced by the low pH of the endosome interior (Donovan et al. 1981; Kagan et al. 
1981). Following internalisation by the neuron, BoNT is also contained within an 
endosome and the low pH environment is thought to induce structural changes leading 
to channel formation (Montecucco and Schiavo 1995; Pellizzari et al. 1999). Treatment 
of neuronal cells with methylamine hydrochloride (a compound that blocks endosome 
acidification) antagonises the action of BoNT/A, indicating that the toxin must be 
located within an acidic compartment within the neuron at some point during its 
mechanism of action (Kalandakanond and Coffield 2001). Electron microscopy has 
confirmed the formation of pores by BoNT/A in vesicle membranes (Schmid et al.
1993).
The pores of channels formed by DT (~18A in diameter) are large enough for 
the toxin’s catalytic domain to pass through (Kagan et al. 1981). Similarities noted 
among the channel-forming properties of BoNTs, TeNT and DT (Blaustein et al. 1987) 
have led to the proposal that the CNT LC passes through the channel formed by the 
toxin heavy chain (Hoch et al. 1985). Channel formation by all these toxins requires low 
pH on the “endosomal” side of the membrane, compared with neutral pH on the other, 
and both channel activity and conductance increase when the pH on the “cytosolic” 
side of the membrane is elevated. In addition, channel formation by BoNT/B requires 
the interchain disulphide bond to be intact (Flicker et al. 1999), indicating that the light 
and heavy chains of BoNT do not dissociate until transcytosis has taken place. 
However, there is some evidence to suggest that the LC occludes the heavy-chain 
channel and that reduction of the interchain disulphide bond unblocks the HN channel 
(Koriazova and Montal 2003).
Circular dichroism spectroscopy revealed that the BoNT/A-LC could only 
move through the channel formed by the heavy chain in an unfolded conformation 
(Koriazova and Montal 2003). This is in agreement with the finding that the diameter of 
channels formed by BoNTs in artificial membranes is only ~8A (i.e. too small to 
accommodate a fully-folded 50kDa globular protein) (Hoch et al. 1985). The structural 
changes induced in BoNT/A-LC by low pH are completely reversible and do not affect 
zinc binding (Li and Singh 2000b). Therefore, the mechanism of translocation is 
postulated to involve partial unfolding of the LC within the endosome followed by
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translocation into the cytosol where the LC dissociates from the toxin heavy chain and 
refolds to an active conformation (Koriazova and Montal 2003).
4.1.4.3 Inhibition of Neurotransmitter Release
Structural changes in BoNT/A-LC upon reduction of the interchain disulphide 
bond increase enzymatic activity (Cai et al. 1999), suggesting that the structure of the 
LC is different when it is released from the endosome to its structure in the holotoxin. It 
is thought that these structural changes increase the accessibility of the catalytic site by 
orienting key active site residues for optimal activity (Hanson and Stevens 2000). The 
crystal structure of BoNT/B in complex with synaptobrevin-2 (Hanson and Stevens 
2000) revealed rearrangement of three active site loops upon separation of the two 
chains that bring Arg369 and Tyr372 into close proximity with the scissile bond of 
synaptobrevin. Separation of the LC from the toxin heavy chain also relieves the 
hindrance imposed by the translocation belt, which in the crystal structure of BoNT/A 
(Lacy et al. 1998) can be seen to occlude the active site cleft.
Table 9 - Substrate Specificity of the Botulinum Neurotoxins
A SNAP-25 Gln197-Arg198






D Synaptobrevin II Lys49-lle50
E SNAP-25 Arg 180-I le 181
F Synaptobrevin II Gln48-Lys49
G Synaptobrevin II Ala81-Ala82
The targets of BoNTs within the neuron cytosol are the SNARE proteins SNAP-25, VAMP-2 and syntaxin. 
The toxins show remarkable substrate specificity, despite a high level of homology among their amino acid 
sequences, in that no two BoNTs cleave the same substrate at the same peptide bond. In addition, the 
BoNTs show a requirement for substrates of a certain size. This is because the BoNT-LC contains two 
SNARE recognition sites, one for the nine-residue SNARE motif and one for the scissile peptide bond, and 
the substrate must bind to both sites for cleavage to occur.
The targets of all CNTs are the SNAREs, proteins that mediate membrane 
fusion at the nerve terminal and, thus, play an essential role in the release of 
neurotransmitters into the synapse. BoNTs A and E cleave SNAP-25 (synaptosomal 
associated protein of 25kDa); BoNT serotypes B, D, F, and G act upon vesicle- 
associated membrane protein (VAMP-2, also known as synaptobrevin II); and
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BoNT/C1 targets both syntaxin and SNAP-25. BoNTs exhibit remarkable substrate 
specificity in that no two serotypes cleave the same protein at the same peptide bond 
(Table 9). Not only are the BoNTs highly specific for their substrates in terms of 
sequence, but they also show a requirement for substrates of a minimum length. 
BoNT/B, for example, will only cleave substrates comprising at least 30 amino acid 
residues whilst TeNT and BoNT/A require substrates of at least 50 amino acids (Shone 
et al. 1993). This is because the BoNT-LC contains two substrate recognition sites and 
the target SNARE must bind to both for proteolysis to occur (Pellizzari et al. 1996).
The SNARE proteins share a common nine-residue structural motif, known as 
the SNARE motif, which is thought to adopt a helical conformation (Rossetto et al. 
1994). There are at least two copies of this motif in each SNARE -  VAMP-2 and 
syntaxin each contain two copies and SNAP-25 has four copies. It is thought that 
BoNTs bind the SNARE motif and the scissile peptide bond, which is located further 
towards the C-terminus in the amino acid sequence than the SNARE motif (Rossetto et 
al. 1994). This explains the requirement of BoNTs for substrates of a certain length. 
Furthermore, residues located N-terminal to the cleavage site in VAMP-2 are known to 
be important for substrate recognition by BoNT/B (Wictome et al. 1996).
4.1.4.4 Role of SNARE Complex Assembly in Neurotransmission
The release of neurotransmitters into synapses requires the formation of a 
trimeric complex by the SNARE proteins syntaxin, synaptobrevin and SNAP-25. Both 
syntaxin and SNAP-25 reside in the plasma membrane at the nerve terminal, whilst 
synaptobrevin is present in synaptic vesicle membranes. Syntaxin and SNAP-25 are 
localised in overlapping regions of the plasma membrane, generating a high local 
concentration of SNAREs for efficient membrane fusion (Lang et al. 2001). These 
“clusters” are distinct from the protein-containing lipid rafts that are involved in toxin 
internalisation. Formation of the trimeric “SNARE complex” brings synaptic vesicles 
close to the plasma membrane at the nerve terminal, facilitating membrane fusion and 
the release of neurotransmitters in response to Ca2+ influx. Disruption of the Ca2+- 
dependent triggering of exocytosis by CNTs indicates that SNARE complex assembly 
occurs immediately prior to membrane fusion (Gerona et al. 2000).
The SNARE complex is stabilised by the coiled-coil interactions of four a- 
helices from the three SNAREs (Poirier et al. 1998). Although sequence similarity is 
low between the SNAREs, a pattern of conserved hydrophobic amino acids arranged in 
heptad repeats has been observed (Weimbs et al. 1997). The first and fourth residues 
of each heptad are hydrophobic, forming an a-helix with a hydrophobic face (Weis and
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Scheller 1998). The SNARE complex assembly brings together the hydrophobic faces 
of four helices, one each from syntaxin and synaptobrevin and two from SNAP-25 
(Jahn and Sudhof 1999). Pairs of SNAREs bind each other weakly, but their 
association is greatly enhanced when all three proteins are present (Hayashi et al. 
1994). The stability of the four-helix bundle is extremely high (Fasshauer et al. 1998) 
and the SNARE complex must be actively disassembled by the ATPase N- 
ethylmaleimide-sensitive factor (NSF) and the soluble NSF-attachment protein a-SNAP 
following neurotransmitter release. The cleavage of SNAREs by CNTs does not 
prevent SNARE complex assembly, but results in the formation of a non-functional 
complex that cannot couple Ca2+ influx with neurotransmission (Humeau et al. 2000).
Synaptobrevin is protected from proteolysis by CNTs when it forms a complex 
with the other two SNAREs or with NSF and a-SNAP (Pellegrini et al. 1994). VAMP-2 
was found to bind to BoNT/B in a random coil conformation (Hanson and Stevens 
2000), but must be helical for the formation of a functional SNARE complex. SNARE 
complex assembly must therefore protect the scissile bond and/or SNARE motif in 
each SNARE from recognition by CNTs. It has also been suggested that the high 
entropic cost associated with helix formation might lead to the preferential binding of 
uncomplexed VAMP to BoNT/B, which binds it in a random coil conformation (Hanson 
and Stevens 2000). If this is true, SNAREs will bind to CNTs in preference to forming 
functional SNARE complexes in intoxicated neurons.
4.1.4.5 Mechanism of Action of TeNT
Unlike BoNTs, TeNT enters the neuron via synaptic vesicle recycling (Matteoli 
et al. 1996). Inhibition of ganglioside synthesis has been shown to protect neurons 
against TeNT activity (Williamson et al. 1999). The high sensitivity of neurons to TeNT 
requires lipid rafts and at least one protein receptor (Munro et al. 2001), but the identity 
of this 15kDa glycoprotein receptor remains elusive (Herreras et al. 2000). After 
internalisation, TeNT moves through the neuron by retrograde axonal transport and is 
transcytosed to the spinal cord inhibitory interneurons where it cleaves its target 
SNARE VAMP-2 (Verderio et al. 1999). The resultant spastic paralysis is due to the 
loss of spinal inhibitory control over motorneuron activity.
TeNT cleaves VAMP-2 at the same peptide bond as BoNT/B (Pellegrini et al.
1994). It has been shown that VAMP-2 is not the major substrate for TeNT in adrenal 
chromaffin cells because the inhibition of neurotransmission by TeNT in these cells is 
not attenuated by the application of captopril (a metallopeptidase inhibitor) (Hohne-Zell 
et al. 1993). TeNT can activate a calcium-dependent transglutaminase (Facchiano and
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Luini 1992) and it has since been postulated that TeNT inhibits neurotransmission by 
the proteolysis of both synaptobrevin and the transglutaminase (Ashton et al. 1995).
4.1.5 Medical Applications for Botulinum Neurotoxins
Preparations of BoNT/A have been licensed for use as pharmaceuticals since 
1989, when it was shown to be an effective treatment for strabismus, hemifacial spasm 
and blepharospasm (Johnson 1999). The preparation Botox is perhaps most famous 
for its use as a non-surgical cosmetic treatment for removing facial wrinkles. The high 
specificity of BoNT/A for motorneurons combined with its longevity of action (up to 4-6 
months) make it a useful biopharmaceutical and its use has now been extended to a 
variety of neuromuscular disorders and an increasing number of other syndromes.
4.1.5.1 Therapeutic Utility of BoNT/A
Local injections of the toxin weaken overactive muscles, providing relief from 
spasticity. BoNT/A is now well established as a treatment for several ophthalmologic 
disorders, such as strabismus, and movement disorders, including writer’s cramp and 
torticollis (Munchau and Bhatia 2000). BoNT/A has also been tested as a potential 
therapeutic agent for many more muscular disorders, such as tic disorders, tremor and 
spasticity after stroke. In addition to its effects at the neuromuscular junction, BoNT/A 
also acts upon cholinergic autonomic neurons (Hambleton 1992) and may, therefore, 
be used for the treatment of a variety of autonomic disorders, such as anal fissure 
(Naumann et al. 1999). BoNT/A is a useful therapy for hyperhidrosis, which is caused 
by sympathetic neurotransmission in sweat glands (Heckmann et al. 2001). However, 
many of the potential applications of BoNT/A to the autonomic nervous system remain 
to be thoroughly tested.
BoNT/A is currently being investigated as a treatment for chronic pain. In fact, 
BoNT/A in combination with physiotherapy has been demonstrated to provide better 
relief from myofascial pain syndrome than conventional steroid treatment (Porta 2000). 
BoNT/A can also be an effective treatment for migraine with the added advantage of 
reducing migraine severity, frequency and associated side effects (Silberstein et al.
2000).
4.1.5.2 Side-effects Associated with BoNT/A Therapy
As with all pharmaceuticals, there are several side effects and complications 
associated with the therapeutic use of BoNT/A. There is a need for repeated injections 
because the paralysis induced only lasts for 4-6 months, but the main problem with the 
therapy is the development of resistance by the production of anti-BoNT/A antibodies.
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Reducing the dose and frequency of injections can limit antibody production, although 
resistance to BoNT/A can be overcome by the use of alternative BoNT serotypes. 
BoNT/C1 has been demonstrated to have a similar effect and longevity of action to 
BoNT/A (Eleopra et al. 1997) and may become a valid alternative therapy. Another side 
effect is that the toxin can diffuse from the site of injection into neighbouring muscles, 
causing transient ptosis (Johnson 1999). This can be debilitating (e.g. dysphagia) and 
as long lasting as the duration of action of the toxin. Whilst no allergic reactions to 
BoNT/A have been reported, other side effects include symptoms of influenza and 
brachial plexopathy (Munchau and Bhatia 2000). The therapeutic use of BoNT/A in 
children is carefully monitored and it is contra-indicated during pregnancy and while 
breast-feeding.
4.1.5.3 Retargeting the Endopeptidase Activity of BoNT/A
Non-toxic fragments of TeNT-Hc have been proposed as delivery vehicles for 
specifically targeting ligands to peripheral or CNS neurons because the CNT binding 
domain is highly specific for cholinergic nerve terminals. The heavy chains of TeNT, 
BoNT/A and BoNT/B have recently been used to target model compounds to human 
neuroblastoma cells (Goodnough et al. 2002; Zdanovskaia et al. 2000). However, the 
potent endopeptidase activity of these toxins can potentially be retargeted to a variety 
of neuronal tissues if the Hc domain is replaced by a non-native cell-binding moiety 
with an alternative specificity.
A fragment of BoNT/A comprising only the LC and HN domains (LHN/A) has 
been recombinantly expressed and purified (Chaddock et al. 2002). LHN/A retains the 
full catalytic activity of the BoNT/A holotoxin but is considered non-toxic because it 
lacks a cell-binding domain. LHN/A has been chemically coupled to nerve growth factor 
(Chaddock et al. 2000a), wheat germ agglutinin (Chaddock et al. 2000b) and Erythrina 
cristagalli lectin (Duggan et al. 2002) and specifically retargeted in vitro to cells of 
neuronal and non-neuronal origin. The conjugate comprising LHN/A and ECL (known 
as LHn/A-ECL) exhibits an in vitro selectivity for nociceptive afferents and is of potential 
therapeutic use in the treatment of chronic pain (Duggan et al. 2002). As described in 
Chapter One, LHN/A-ECL has equivalent potency and longevity of action within DRG to 
the BoNT/A holotoxin in its target neurons and a catalytically inactive mutant of this 
fragment (LHN/A(H227Y)) has been used as a negative activity control.
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4.2 MATERIALS AND METHODS
4.2.1 Materials
LHn/A and LHN/A(H227Y) were provided by Dr J.A. Chaddock (Health 
Protection Agency, UK). The toxin fragments (873 amino acids in length, including a 
two amino acid N-terminal extension arising from expression) were expressed and 
purified by the Toxin Therapeutics Division at CAMR as previously reported (Chaddock 
et al. 2002) and briefly described in Appendix 4. The purified protein stocks were stored 
at -20°C in a buffer comprising 100mM sodium chloride and 20mM HEPES pH 7.0. For 
crystallisation trials, the protein stocks were diluted to 7-13mg/ml with milliQ water.
The electrophoresis system was purchased from BioRad (UK) and High and 
Low Molecular Weight Markers were obtained from Pharmacia (UK). Slide-A-Lyzer 
dialysis kits were purchased from Pierce (USA). Glycerol and Tris were obtained from 
VWR International. Sodium dodecyl sulphate, HEPES, bromophenol blue, citric acid 
and glycine were purchased from Sigma. Methanol, sodium chloride and acetic acid 
were purchased from Fisher Chemicals. All buffers were prepared with milliQ water.
Reagents used to prepare crystallisation solutions were of high quality and 
purity. All crystallisation solutions were made with AnalaR water (VWR International). 
Crystallisation plates and Structure Screen I and II were purchased from Molecular 
Dimensions Ltd. Glass coverslips, Crystal Screen and a PEG/lon matrix were 
purchased from Hampton Research and JBScreen 7 from JenaBioScience. PEG 
4000, PEG 5000 MME, PEG 20000, tert-butanol, dioxane, potassium thiocyanate, 
sodium sulphate and malate were purchased from Fluka. PEG 6000, isopropanol, 
ammonium chloride and glycerol were obtained from VWR International. Potassium 
phosphate, sodium phosphate, acetone and ethanol were purchased from Fisher 
Chemicals. Potassium chloride was obtained from Fissons (UK). All other reagents 
were purchased from Sigma.
4.2.2 SDS-PAGE
Samples from the LHn/A and LHN/A(H227Y) protein stocks were diluted with 
milliQ water to a concentration of ~0.2mg/ml and mixed in a 1:1 ratio with sample buffer 
(20% glycerol, 100mM Tris, pH 6.8, 4% SDS and 0.01% bromophenol blue). High and 
Low Molecular Weight protein markers were heated for 5 minutes in a heating block. 
Markers and samples were loaded onto a 5% stacking gel and separated on a 10% gel 
in running buffer (25mM Tris, 250mM glycine, pH 8.3, and 0.1% SDS) at 12mA until the
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dye front ran off the bottom of the gel. The gel was stained overnight in Coomassie 
Brilliant Blue, then destained with methanol/acetic acid before being photographed.
4.2.3 Crystallisation Trials
The hanging drop vapour diffusion method was employed. Crystallisation 
plates were incubated at 4°C, 16°C or 22°C in temperature-controlled incubators or at 
room temperature. Drops comprising 1.5pl protein and 1 .5jliI mother liquor were 
equilibrated against wells containing 700^1 of mother liquor.
4.2.3.1 LHn/A
Randomised sparse matrix crystallisation screens (Crystal Screen and 
Structure Screens I and n) were set up to sample a wide range of potential 
crystallisation conditions. The conditions included in the commercial crystallisation 
screens are listed in Appendix 2. A PEG/lon matrix was used in conjunction with grid 
screens, in which the concentrations of PEG 4000, PEG 6000 or ammonium sulphate 
were varied with pH, because PEG and ammonium sulphate are the precipitants most 
commonly reported for protein crystallisation. In addition, conditions reported for the 
crystallisation of BoNT/A were tested (Kadkhodayan et al. 2000; Lacy et al. 1998; 
Stevens etal. 1991).
A literature search was performed to uncover conditions previously reported for 
successful crystallisation of toxins. These conditions mainly involved PEG and MPD, so 
JBScreen 7 (Appendix 2) was also tested. An alcohol/pH screen tested the effect of 
MPD, tert-butanol, 1,6-hexanediol and isopropanol as precipitants with four buffers in 
the pH range 4.6-7.0. In addition, isopropanol and alcohol screens based on 
JBScreens 8 and 9 were set up.
Conditions reported for the crystallisation of CNTs and CNT fragments, that 
had not previously been used, and a variety of conditions reported for the crystallisation 
of zinc-dependent proteases (Appendix 4) were set up to cover a range of conditions 
that may yield crystals of LHN/A. Those conditions producing interesting results were 
repeated and optimised. The technique of streak-seeding was reported as essential for 
the growth of diffraction-quality crystals of BoNT/B (Swaminathan and Eswaramoorthy 
2000a; Swaminathan and Eswaramoorthy 2000b), so it was applied to LHN/A.
4.2.3.2 LHn/A(H“ 7Y)
Initial crystallisation screens involved Structure Screens I and II, a PEG/lon matrix and 
a PEG 6000 grid screen as well as conditions reported for the crystallisation of
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BoNT/A. Based upon their reported success as crystallisation agents (McPherson
2001) and the observation that a salt-based condition had produced shiny crystalloids, 
sodium malonate, sodium tartrate and ammonium formate were tested as precipitation 
agents. An alcohol/pH comparison, a divalent cation screen and the conditions 
reported for the crystallisation of CNTs and zinc-dependent proteases were set up, as 
for LHn/A. Two alcohol-based screens were set up in which the concentrations of MPD 
and 1,6-hexanediol were varied with increasing pH. Crystallisation trials based on 
JBScreens 8 and 9 were also set up.
4.2.4 Circular Dichroism Spectroscopy
4.2.4.1 Dialysis and Protein Estimation
Samples of the LHN/A and LHN/A(H227Y) protein stocks were diluted 1/50 with 
milliQ water for CD spectroscopy. . A diluted sample of the buffer (100mM sodium 
chloride and 20mM HEPES, pH 7.0) was also prepared, so that a blank (i.e. protein- 
free) CD spectrum could be recorded.
200jnl samples of LHN/A(H227Y) were injected into Slide-A-Lyzer cassettes and 
dialysed overnight at 4°C against 100mM sodium chloride and 20mM sodium HEPES 
(pH 7.0 buffer) or 100mM sodium chloride and 20mM sodium citrate (pH 5.0 buffer). 
After dialysis, the protein solutions were diluted 1/50 with milliQ water and the protein 
concentration of each was determined. A sample of each buffer was also diluted 1/50
and analysed for protein content. The diluted protein and buffer samples were then
used in CD experiments.
The concentration of protein in each of the four diluted protein samples was 
determined using the spectrophotometric method and related to the theoretical molar 
extinction coefficient using the Beer Lambert law:
A28O = ECl
where: A28o is the absorbance of UV radiation at 280nm
s is the extinction coefficient of the sample at 280nm 
c is the concentration of the protein sample 
I is the path length
The amount of light (of wavelength 280nm) absorbed by each sample was measured 
with an Ultrospec 2000 spectrophotometer (Pharmacia Biotech, UK) in a 1cm path- 
length quartz cuvette.
125
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
4.2.4.2 Circular Dichroism Spectroscopy
CD spectra were recorded with a JASCO J-600 spectropolarimeter across the 
wavelength range 250-185nm. Six scans were recorded, using a quartz cell with a path 
length of 0.02cm, and averaged for each sample to increase the signal-to-noise ratio. 
The scan speed was 10nm/min and the response time was fixed at 4s. CD spectra for 
the buffer blanks were recorded separately (using the same parameters as for the 
corresponding protein sample) from samples of dialysis buffer diluted 1/50 (so that the 
final concentration of sodium chloride was the same as in the protein samples).
CD spectra recorded for the protein samples were normalised, by subtracting 
the appropriate buffer blank, and corrected for protein concentration. CD was then 
converted to mean residue ellipticity and the spectra were analysed by three different 
algorithms.
4.2.4.3 Analysis of CD Spectra
CD spectra were deconvoluted and secondary structures assigned using the 
CONTINLL, SELCON3 and CDSSTR programs available through the DICHROWEB 
server (http://public-1.cryst.bbk.ac.uk/cdweb/html; Lobley and Wallace 2001; Lobley et 
al. 2002). Two protein reference sets were used in conjunction with each analysis 
method: Reference set 3 comprises 37 proteins and reference set 6 comprises 42 
proteins, five of which are denatured (Sreerama et al. 2000; Sreerama and Woody
2000). Both reference sets cover the wavelength range 185-240nm, which closely 
matches the wavelength range across which the experimental data were collected.
4.3 RESULTS
4.3.1 Crystallisation of LH„/A and LHn/A^227^
Crystallisation trials with LHN/A and LHN/A(H227Y) produced similar results. As 
the two toxin fragments differ in primary structure by only one amino acid, it was 
expected that they would crystallise under the same, or very similar, conditions. 
However, despite setting up a large number of crystallisation trials, involving several 
hundred conditions, no crystals of LHN/A or LHn^ H 22^ )  were grown. The hanging 
drops were studied regularly under a polarising light microscope and optimisation of the 
crystallisation conditions was based upon the appearance of the drops. A number of 
clear drops were observed, but several of the crystallisation conditions tested produced 
precipitation or phase separation. After several months, large crystals were observed in 
three drops, but upon investigation by X-ray diffraction, they were discovered to be 
composed of salt.
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An unusual phase separation effect was observed with five different mother 
liquors for LHn/A:
• 35% PEG 4000, 0.2M ammonium sulphate and 0.1M sodium acetate, pH 5.6
• 2.5M 1,6-hexanediol, 0.01 M manganese chloride and 0.1 M sodium citrate, pH 5.6
• 2.0M sodium chloride and 10% PEG 6000
• 35% dioxane
• 1.5M sodium chloride and 10% ethanol
The shiny crystalloids were birefringent under polarised light and it was suggested that 
they might be some kind of liquid-crystal (therefore, they were described as “shiny 
crystalloids”). Conditions leading to the formation of shiny crystalloids were repeated 
and expanded in an attempt to grow crystals suitable for diffraction. It was observed 
that the removal of manganese chloride from mother liquor comprising 1,6-hexanediol, 
manganese chloride and HEPES, pH 7.0 produced smaller crystalloids, so a screen 
was set up to determine the effect of five divalent cations on crystalloid quality. 
Increasing concentrations of zinc chloride, calcium chloride, manganese chloride, 
magnesium chloride and cadmium chloride were assayed in conjunction with 2.0M 1,6- 
hexanediol at pH 7.0. Phase separation and shiny crystalloids were observed in 
several drops containing MPD or hexanediol in the pH range 5.6-8.5. It was noted that 
alcohols as precipitants seemed to produce more promising results than mother liquors 
containing PEG or inorganic salts. Although no crystals had been grown, in addition to 
shiny crystalloids, small, round, crystal-like structures (referred to as “microcrystals”) 
were observed with several crystallisation conditions. As these were thought to be 
promising results, all conditions giving rise to microcrystals were repeated and 
expanded. Mother liquors used for seeding were those that had produced microcrystals 
and/or crystalloids. Further optimisation of conditions based upon alcohols and PEG 
were tested, as these precipitants produced promising results.
Initial crystallisation trials involving LHn/A ^ 22^ )  did not produce any crystals, 
but shiny crystalloids were grown from four different mother liquors:
• 25% PEG 4000, 0.2M ammonium sulphate and 0.1 M sodium acetate, pH 5.6
• 20% isopropanol, 0.2M tri-sodium citrate and 0.1 M HEPES, pH 7.5
• 2.0M sodium chloride, 0.1 M sodium phosphate monobasic, 0.1M potassium 
phosphate monobasic and 0.1 M MES, pH 6.5
• 2.5M 1,6-hexanediol, 0.01 M manganese chloride and 0.1M sodium citrate, pH 5.6
As observed for LHN/A, three of these conditions involved PEG or an alcohol 
as a precipitant, but one salt-based condition also produced shiny crystalloids. These 
four conditions were repeated and expanded. No crystals were obtained, but more
127
Structural Studies on Eryihrina cristagalli Lectin and Botulinum Neurotoxin A
shiny crystalloids were grown in several conditions comprising 2.5-3.2M 1,6-hexanediol 
and 0.01-0.02M manganese chloride in the pH range 5.6-7.5. As with LHN/A, mother 
liquors containing alcohols appeared to produce more promising results than salt- 
based conditions. Although no crystals of LHn/ACH22^ )  were yielded from these 
experiments, MPD and isopropanol seemed to produce the best results, so further 
optimisation was based on these two precipitants.
4.3.1.1 Analysis of Hanging Drops
Clear drops indicate that the protein and/or precipitant concentration is too low 
for nucleation and crystallisation (Zeelen 1999). The protein stock was used at a 
concentration of 7-13mg/ml in a 1:1 ratio with crystallisation buffer in the hanging 
drops, giving a final protein concentration in each drop of ~5mg/ml. As many different 
crystallisation conditions were initially tested, those leading to clear drops were not 
repeated or optimised and the focus of subsequent crystallisation experiments was 
shifted to those drops in which precipitates or phase separation were observed.
The cause of protein precipitate in a drop might be that the mother liquor does 
not favour crystallisation (Zeelen 1999). Alternatively, as is the case for clear drops, the 
concentration of protein and/or precipitant may be too low. The production of a 
gelatinous precipitate that is dark in colour, however, may be a good starting point for 
the optimisation of crystallisation conditions. Several of the conditions producing such 
precipitates were repeated and optimised, by changing the pH, buffer, precipitant and 
by adding some additive compounds. Different types of phase separation were also 
observed in many of the hanging drops. Whilst this can be another good starting point 
for optimisation, it is also possible for crystals to grow in the highly concentrated protein 
phase of the drop. The conditions leading to phase separation were optimised, by 
changing the concentration and nature of the precipitant, changing the buffer and pH 
and by the addition of some additives.
The incubation temperature may also have influenced the success of the 
crystallisation trials. Many conditions reported for the crystallisation of toxins were 
incubated at 20-24°C. A number of experiments on LHN/A and LHm/A ^ 22^ )  were set 
up at room temperature, with the crystallisation plates stored inside polystyrene boxes 
in the laboratory. After several months, when no crystals were observed, it was feared 
that the temperature inside the boxes might have fluctuated with temperature changes 
in the laboratory. Changes in temperature alter the degree of supersaturation in the 
drop and, thus, can hinder nucleation and crystal growth (Drenth 1999). To try to 
overcome any adverse effects that might be caused by temperature fluctuations, a
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refrigeration incubator was set to 22°C and several of the promising conditions were 
repeated, but no crystals were yielded. Crystallisation plates were also incubated at 4, 
8 or 16°C, but these experiments too were unsuccessful.
4.3.1.2 Shiny Crystalloids and Microcrystals
Figure 35 - Shiny Crystalloids
This unusual form of phase separation (dubbed “shiny crystalloids”) was observed in several of the drops 
equilibrated against mother liquors containing high concentrations of alcohol as a precipitant. The shiny 
crystalloids are birefringent when viewed under polarised light and might be some kind of liquid-crystal. 
However, attempts to optimise the conditions producing these crystalloid structures to yield true crystals of 
LHn/A  and LHn/A(H227Y) were unsuccessful.
An unusual form of phase separation, dubbed “shiny crystalloids” due to their 
birefringence under polarised light (Figure 35), was observed for both LHN/A and 
LHn/A(H227Y) under a variety of crystallisation conditions. Shiny crystalloids were not 
considered to be true crystals, but rather some kind of liquid-crystal. The conditions 
that generated them were repeated and expanded in order to try to grow true crystals. 
Most of the crystallisation media producing shiny crystalloids involved alcohols, such as 
MPD, 1,6-hexanediol and isopropanol, at quite high concentrations as precipitants. It 
was, therefore, thought that alcohol-based solutions would be more likely to lead to 
crystals of LHN/A and LHn/ A ^ 22^ )  than salt or PEG-based conditions. The nature and 
concentration of the alcohol was varied, as was the pH and nature of the buffer 
involved, but no crystals were yielded. Substitution of PEG 500 for MPD as a 
precipitant and the use of PEG 500 as an additive were also ineffective.
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In addition, several further crystallisation conditions produced another form of 
phase separation, termed “microcrystals”. These structures were thought to be very 
small protein crystals, but as they were not observed to grow, it is possible they may 
represent another form of crystalline precipitate. The conditions producing 
microcrystals also mostly involved alcohols as precipitation agents. Optimisation was, 
therefore, based upon the strategy used for optimising the conditions producing shiny 
crystalloids. However, despite setting up a large number of further experiments, no 
crystals of LHN/A or LHn/A ^ 22^ )  were grown.
Streak seeding was reported to be necessary for growing crystals of BoNT/B 
(Swaminathan and Eswaramoorthy 2000a). Initial crystallisation screens produced thin, 
plate-like crystals of BoNT/B, but it was only by seeding with cat whiskers that 
diffraction-quality crystals could be obtained. In the absence of plate or needle crystals 
in the LHN/A and LHN/A(H277Y) crystallisation trials, shiny crystalloids and microcrystals 
were used as seeds for macroseeding and streak-seeding experiments. Macroseeding 
involved the removal of one or two microcrystals from a drop and transfer (via a 
washing step) to a fresh, pre-equilibrated drop containing precipitant at a slightly lower 
concentration to that used for microcrystal growth. Streak-seeding, on the other hand, 
was performed by touching a cat whisker onto some shiny crystalloids (to pick up some 
crystal seeds) and streaking the seeded whisker across a fresh, pre-equilibrated drop, 
again with a lower concentration of precipitant than that used to grow the crystalloids. 
However, neither macroseeding nor streak-seeding yielded crystals of LHN/A.
As LHn/A and LHn/A ^ 22^ )  comprise only two of the three functional domains 
of BoNT/A, it was thought that there might be a large hydrophobic face on one side of 
Hn that would be protected by the Hc domain in the holotoxin. The different types of 
phase separation and precipitate observed in many of the hanging drops might, 
therefore, have resulted from the unordered aggregation of protein molecules to 
exclude water from this hydrophobic surface. However, analysis of the crystal structure 
of BoNT/A revealed that the interface between the Hc and HN domains is relatively 
small -  the binding domain buries only ~400A2 of the translocation domain (Lacy and 
Stevens 1999). Close inspection of the surface of LHN/A (Figure 36) reveals that the 
region of HN that is normally in contact with the Hc domain contains both polar and 
hydrophobic residues (in blue and red, respectively). It does not appear to have a high 
density of hydrophobic groups, which suggests that aggregation to exclude solvent 
molecules from this region would probably not occur.
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Figure 36 - Surface Diagram of the LC and HN Domains of BoNT/A
This region of Hn 
makes contacts 
with the He domain
This figure was generated from the crystal structure of the BoNT/A holotoxin (PDB code 3BTA) using the 
program GRASP (Nicholls et al. 1991). Only residues of the LC and HN domains are displayed. The 
surface of the molecule is coloured according to the nature of the amino acids -  hydrophobic residues red 
and polar residues blue. The region of H n that makes contacts with the He domain (highlighted) contains 
both hydrophobic and polar residues. Therefore, the likelihood that LHN/A molecules aggregate in order to 
exclude solvent molecules from the region that normally binds He (thus hindering crystallisation) is low.
4.3.1.3 SDS-PAGE
The possibility that crystallisation trials were unsuccessful because the protein 
stocks had been stored at -20°C for a prolonged period of time was investigated. The 
purity of the protein samples had been tested by SDS-PAGE before despatch from 
CAMR (results not shown). Upon receipt from CAMR, the protein stocks had been 
divided into 10Opil aliquots to minimise the need for repeated freeze-thaw, but it was 
suggested that the protein might not be stable at -20°C for more than a few months. 
After 12 months, the proteins were analysed again by “native” SDS-PAGE (i.e. with no 
dithiothreitol in the sample buffer) to ensure that the fragments had not degraded 
during storage at -20°C. The two ~50kDa domains comprising the LHN/A fragment are 
tethered solely by a single disulphide bond, which would be reduced by dithiothreitol. 
Native SDS-PAGE would therefore determine whether or not the disulphide bond 
linking the domains of LHN/A and LHN/A(H227Y) had been reduced during storage.
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The results (Figure 37) clearly show that the LHN/A and LHN/A(H227Y) 
fragments had not degraded during storage at -20°C over 12 months. Based on 
analysis of their primary structures, the molecular weights of LHN/A and LHN/A(H227Y) 
were calculated as 100052.6Da and 100078.6Da, respectively. Both of these 
fragments ran slightly higher on the gel than the 94kDa marker, in accordance with 
their molecular weights. This was another indication that the fragments had not been 
degraded during storage.
Figure 37 - SDS-PAGE of LHN/A and LHN/A(H227Y)
Lane: 1 2 3 4 5 6
Photograph of the gel analysing the stocks of LHn/A  and LHn/A(H227Y) after 12 months stored at -20°C. 
High and Low Molecular Weight Markers were loaded into lanes 1 and 6, respectively. Both LHn/A(H227Y), 
lanes 2 and 3, and LHN/A, lanes 4 and 5, ran as single bands on the gel, indicating that the toxin fragments 
were not degraded during long-term storage at -20°C. The calculated molecular weight of each fragment 
is ~100kDa and both proteins ran on the gel slightly higher than the 94kDa marker.
4.3.2 Circular Dichroism Spectroscopy
Circular dichroism (CD) spectroscopy measures differences in the absorption 
of left-handed versus right-handed circularly-polarised light that arise due to structural 
asymmetry within the molecule under investigation (Kelly and Price 1997). Both right- 
and left-handed circularly-polarised light obey Beer’s law and CD is defined as the 
difference in extinction coefficients:
132
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
AA(X) — A|_A, - ArX,
= [ElW - Sr(X)]
= sic
where: A Is the optical absorbance of the molecule 
s is the exctinction coefficient of the molecule 
X is the wavelength of the incident light 
c is the concentration of the molecule 
(NB: the subscripts indicate the “handedness” of the light).
A CD spectrum is recorded by measuring dichroism as a function of wavelength (Kelly 
and Price 1997), with CD commonly presented in terms of ellipticity.
The asymmetry of the peptide bond makes proteins suitable for analysis by 
CD spectroscopy. However, the technique can only be used to determine the gross 
secondary and tertiary structural features of a protein (i.e. it can reveal the amount of 
protein involved in a-helix and p-sheet conformations, but cannot assign specific 
residues to these structural elements). The composition of secondary structural 
elements is determined by recording CD spectra in the “far-UV” spectral region (250- 
180nm) where the peptide bond acts as a chromophore. A CD signal is recorded when 
the peptide bond is located in a regular, folded environment, a-helix, p-sheet and 
random coil structures give rise to a characteristic shape and magnitude of CD 
spectrum. CD spectra recorded in the “near-UV” spectral region (250-350nm) provide 
information on the tertiary structure of a protein. At these wavelengths, aromatic 
residues and disulphide bonds act as chromophores and CD signals indicate that the 
protein is folded into a well-defined structure.
The structure of BoNT/A in aqueous solution is reported to differ from the 
crystal structure in terms of both secondary and quarternary structure (Cai and Singh
2001). Most notably, the crystal structure of BoNT/A (Lacy et al. 1998) reveals that 
-17% of the structure is in a p-sheet conformation, whereas data obtained by infrared 
spectroscopy suggest that -47% of the residues are in a p-sheet structure. The 
proportion of residues estimated to occupy p-sheet structures by CD spectroscopy is 
44% (Singh and DasGupta 1989b) and 36% by primary structure analysis (Lebeda and 
Olson 1994). Clearly, there is some discrepancy regarding the structure of the toxin in 
aqueous solution and whether or not the crystal structure accurately reflects the native 
conformation of the protein.
In the absence of crystals of LHN/A and LHN/A(H227Y), CD spectroscopy was 
employed to glean information on their structures. Far-UV CD spectra were recorded 
(across the range 185-250nm) to provide information on the secondary structure of
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each fragment. Based upon the crystal structure of BoNT/A (Lacy et al. 1998) it was 
expected that the fragment would contain a large proportion of a-helical structure. It 
was also hoped that crystals would eventually be forthcoming to allow comparison of 
the solution and crystal structures of LHN/A and LHn/ACH22^ ) .
4.3.2.1 Comparison of CD Spectrum Analysis Methods
It has been proposed that the best analysis is obtained by comparing the 
results of these three methods (Sreerama and Woody 2000). However, if the analyses 
provided by the different methods vary widely, the estimates of secondary structure 
should not be considered reliable. The three methods used for CD spectrum analysis 
(CDSSTR, CONTIN and SELCON) were based upon different deconvolution 
algorithms. Previous comparison of these programs (Sreerama and Woody 2000) 
showed that they perform comparably in the deconvolution of many CD spectra. 
Indeed, they provided similar estimates of the secondary structural composition of 
LHn/A and LHn/A(H227Y). It can be seen, from the fit of the experimental data to the 
reconstructed data (Appendix 4), that CDSSTR provided the closest match in all the 
analyses performed. However, the method that provides the closest correlation 
between experimental and reconstructed data does not always give the most accurate 
estimate of secondary structure. A better measure of accuracy is to use several 
deconvolution methods and look at how closely matched the results from all the 
analyses are. Ultimately, due to the high level of agreement between the analyses 
provided by the three methods, the estimated secondary structure for each fragment 
can be considered reliable.
CD spectrum analysis is improved by using a protein reference that includes 
the largest possible representation of spectral features and secondary structural 
combinations (Sreerama and Woody 2000). Two protein reference sets spanning the 
wavelength range 185-240nm were tested, one containing data on five denatured 
proteins (Reference Set 6) and one with no denatured proteins (Reference Set 3). The 
raw data from the spectral analysis (Appendix 4) show that both reference sets provide 
similar estimates of secondary structural composition using either reference set.
CDSSTR (Compton and Johnson 1986; Manavalan and Johnson 1987; 
Sreerama and Woody 2000) uses a fixed number of proteins from the reference set 
(termed the “basis set”). Characteristics not reflected by the test protein are removed 
from the basis set and secondary structure is assigned. This method is believed to 
produce the most accurate analysis results. With CONTIN (Provencher and Glockner 
1981; Van Stokkum et al. 1990), the CD spectrum of the unknown protein is fitted to a
134
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
set of “standard” spectra. SELCON3 (Sreerama et al. 1999; Sreerama and Woody 
1993) arranges reference proteins in the database in order of increasing rmsd from the 
CD spectrum of the protein of interest (those that are most dissimilar are deleted). The 
structure of the unknown protein is estimated and included in the database. Spectra in 
the database are then related to a known mixture of secondary structures and used to 
analyse the conformation of the protein under investigation. The solution replaces the 
initial estimate and the process is repeated until self-consistency is attained.
4.3.2.2 Structures of LHN/A and LHN/A(H227Y)










The CD spectra recorded for LHn/A  (in red) and LHn/A(H227Y) (in blue) at pH 7.0 show that the two toxin 
fragments have almost identical structures at the secondary level. The shapes of the spectra reveal that 
the proteins comprise some a-helical and some p-strand elements and deconvolution of the recorded data 
estimated the composition of LHn/A  to be approximately 33% a-helix, 18% p-strand and 31% random coil.
The samples of LHN/A and LHN/A(H227Y) used to record CD spectra at pH 7.0 
had protein concentrations of 0.106mg/ml and 0.186mg/ml, respectively. Molar 
extinction coefficients at 280nm were calculated as 94549 M'1cm'1 for LHN/A and 95820 
M'1cm'1 for LHN/A(H227Y) using amino acid sequence data for the toxin fragments 
(http://ca.expasy.Org/tools/#protparam.html; Gill and von Hippel 1989) and the mean 
residue weights for LHN/A and LH n/A ^22^ ) ,  were calculated as 114.608 and 114.638, 
respectively. The far-UV CD spectra recorded for LHN/A and LHN/A(H22 7 Y) at pH 7.0 
(Figure 38) confirm that the toxin fragments are almost identical in terms of their 
structures at the secondary level. Analysis of these spectra (Appendix 4) revealed that 
LHn/A is composed of approximately 33% a-helix, 18% p-strand, 19% p-turn and 31%
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random coil, and that LHn/ACH22^ )  comprises -34% a-helix, -19% p-strand, -18% p- 
tum and -30% random coil.
It was expected that the two fragments would have nearly identical secondary 
structures because there is only one amino acid different between them. Whilst the 
mutation renders the LHm/A ^ 22^ )  fragment catalytically inactive, the side chains of 
histidine and tyrosine are of comparable size, so it is unlikely that the mutation will alter 
the tertiary structure. The imidazole ring of histidine acts as a nucleophile and is a 
strong base at neutral pH, whereas tyrosine is an aromatic residue that is nonpolar and 
takes part in electrophilic substitutions. Thus, the H22^  mutation leads to inactivity of 
LHn/A and BoNT/A by altering the chemical composition of the active site and not by 
causing a conformational change that prevents the reaction from taking place.
To my knowledge, no previous structural analyses have been performed on 
the LHn/A fragment. However, CD experiments performed on the BoNT/A-LC alone 
revealed that it is 22% a-helical and it was concluded that the secondary structures of 
the light and heavy chains of BoNT/A are not altered upon their separation (Singh and 
DasGupta 1989a). Crystallography revealed the CNT HN domain to be mainly a-helical, 
with the main feature being two long (105A), amphipathic helices running anti-parallel 
to, and twisting around, each other. The LC domain, on the other hand, comprises a 
mixture of a-helical and p-strand structural elements. Using secondary structural 
information from the PDB file for the BoNT/A holotoxin (PDB code 3BTA), the 
proportion of residues in the LC and HN domains of the crystal structure was calculated 
as 39.% helix and 7% strand. This simple analysis reveals that the proportion of 
residues adopting helical conformation is comparable between the crystal structure and 
the solution structure. However, the CD spectroscopy studies indicate that there is a 
greater proportion of p-strand in the solution structure of LHN/A than in the crystal 
structure.
4.3.2.3 Structure of LHN/A(H227Y) at Neutral and Endosomal pH
It has long been known that BoNT/A forms ion-conducting channels, a function 
assigned to the toxin heavy chain. The formation of channels in planar lipid membranes 
was observed to be pH-dependent, with the maximum rate of channel formation 
achieved at pH 6.1 (Donovan and Middlebrook 1986). Further experiments performed 
in lipid bilayers showed that channel formation requires low pH (4.5-5.5) on one side of 
the membrane and neutral pH on the other, as had previously been seen for diphtheria 
toxin and TeNT (Blaustein et al. 1987). BoNT/A channels formed in phospholipids 
vesicles have been observed to extend across the vesicle wall and appear to arise
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from the interaction of protein molecules on both sides of the channel (Schmid et al. 
1993). However, the predicted channel-forming regions of BoNT/B-Hn do not adopt a 
helical conformation in the crystal structure (Swaminathan and Eswaramoorthy 2000b), 
which suggests that the BoNT heavy chain is subject to conformational changes at low 
pH that are conducive with channel formation. The tertiary structure of BoNT/A-LC was 
recently observed to undergo conformational changes at acidic pH (Li and Singh 
2000b). Therefore, far-UV CD spectra were recorded to determine whether or not there 
is a change in the secondary structural composition of LHN/A(H227Y) at endosomal pH.










The CD spectra reveal that there is no significant change in the secondary structure of LHn/A(H227Y) at low 
pH (in red) compared with its structure at neutral pH (in blue). This was an unexpected result because 
both the LC and HN domains are known to undergo conformational changes in acidic environments.
The protein concentrations of the LHN/A(H227Y) samples at pH 7.0 and 5.0 
used in later experiments were 0.289mg/ml and 0.133mg/ml, respectively. Analysis of 
the spectra (Figure 39; Appendix 4) revealed that the secondary structure of 
LHN/A(H227Y) at pH 5.0 is no different to its structure at pH 7.0.
There are two possible explanations for the results obtained. Firstly, it has 
been shown that the heavy chain alone of BoNT/A or BoNT/A can form functional ion 
channels (Blaustein et al. 1987). Thus, it might be postulated that pore-formation 
requires the presence of the Hc domain, perhaps to contribute some structural stability 
for channel formation or additional functional groups for ion conductance. As 
LHN/A(H227Y) is devoid of the binding domain, this influence over channel-formation is
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absent and might explain why no structural changes were observed at low pH. 
Secondly, previous studies on pore formation by BoNTs were performed in systems 
that comprised lipid bilayers or artificial membranes and it was shown a requirement for 
channel formation is low pH on the “endosomal” side of the membrane and neutral pH 
on the “cytosolic” side. The experimental system used to study the secondary structure 
of LHn/A ^ 22^ ) ,  however, contained no lipids or bilayers. It is likely that the lack of a 
pH gradient and the absence of an artificial membrane system prevented the expected 
structural changes occurring.
4.4 SUMMARY OF RESULTS
Despite setting up several hundred hanging drops, crystallisation experiments 
were unsuccessful and no crystals of either LHN/A or LHN/A(H227Y) were grown during 
the course of this investigation. Several commonly used precipitants were tested at a 
variety of concentrations in conjunction with several buffers over the pH range 4.6 to 
9.0. Although two unusual forms of phase separation, microcrystals and shiny 
crystalloid structures, were observed, attempts to optimise the conditions producing 
these phenomena to yield real crystals of diffraction quality failed. The possibility of 
crystallisation under oil was ruled out because the most promising results were 
obtained with mother liquors comprising alcohols, such as MPD. These compounds are 
soluble in paraffin oil, rendering these conditions unsuitable for crystallisation by this 
method. The technique of streak seeding was reported to be essential for the growth of 
BoNT/A crystals (Swaminathan and Eswaramoorthy 2000a) but did not aid 
crystallisation of LHN/A or LHN/A(H227Y). Analysis of the fragments by non-reducing 
SDS-PAGE confirmed that the proteins had not degraded during storage at -20°C.
Far-UV CD spectroscopy revealed that there were no significant structural 
differences between LHN/A and LHn/ACH22^ )  in terms of their secondary structures. 
The secondary structural composition of both fragments is -33% a-helix, -18% p- 
strand and -31% random coil. The high degree of similarity between the structures of 
LHn/A and LHN/A(H227Y) was expected because there is only one amino acid different 
between the two toxin fragments. In light of reported evidence for conformational 
changes within the HN and LC domains of BoNT/A at low pH, it was expected that 
differences in the structure of LHn/A ^ 22^ )  at endosomal pH would be observed 
compared to its structure at neutral pH, but no such differences were observed via CD 
spectroscopy.
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CHAPTER FIVE 
CONCLUSION
As described in Chapter One, the LHN/A-ECL conjugate is of potential use as 
a novel biopharmaceutical product in the treatment of chronic pain syndromes. The 
biology underlying this therapeutic application is founded upon the ability of botulinum 
neurotoxin A to ablate neurotransmission in intoxicated cells for up to 6 months and the 
specificity of Erythrina cristagalli lectin for galactose-containing glycoconjugates that 
are selectively expressed on nociceptive afferents. The ultimate aim of the project was 
to increase our understanding of the biology of the protein components of the LHn/A- 
ECL conjugate by studying their three dimensional structures.
5.1 CRYSTAL STRUCTURE OF ERYTHRINA CRISTAGALLI LECTIN
Native and recombinant forms of ECL were crystallised by the hanging drop 
vapour diffusion method in five crystal forms under a variety of conditions. Both forms 
of ECL were successfully co-crystallised with lactose and recECL was also crystallised 
in complex with galactose and N-acetylgalactosamine, although the resulting crystals 
were not suitable for diffraction experiments. A total of six crystal forms were analysed 
and the three-dimensional structures of nECL and recECL determined to atomic 
resolution.
The tertiary structure of Erythrina cristagalli lectin is homologous to the known 
structures of other legume lectins. ECL protomers adopt the jelly-roll (legume lectin) 
fold and associate together back-to-back to form dimers via the handshake motif. Each 
protomer contains one manganese ion and one calcium ion, both of which are located 
close to the carbohydrate-combining site. Furthermore, the structure of the 
oligosaccharide bound to Asn113 on native ECL was modelled. There are no significant 
differences between the crystal structures of native and recombinant ECL, confirming 
that the recombinantly over-expressed form has a native-like structure. As the 
conjugate is only manufactured using recombinant ECL, it is important to demonstrate 
that this represents the native form of the lectin in terms of both its structure and 
function. Equivalence of biological activity has already been proved (Stancombe et al. 
2003) and this study confirms structural homology. The only difference between nECL 
and recECL is the absence of glycosylation from the recombinant form -  a 
consequence of using Escherichia coli as an expression host. Direct comparison of the
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structures of nECL and recECL revealed that the presence of bound carbohydrate at 
Asn113 affects neither the structure nor carbohydrate-binding activity of the lectin.
Analysis of the structure of ECL in complex with lactose revealed the mode of 
carbohydrate binding to be similar to that observed in ECorL. Lactose makes a number 
of interactions with the lectin through the galactose moiety, including indirect hydrogen 
bonds mediated by structural water molecules and hydrophobic contacts. The key 
residues involved in lactose binding at the combining site are Leu86, Asp89, Tyr106, 
Gly107, Phe131, Asn133, Ala218 and Gin219. Superposition of the combining sites of native 
and recombinant forms of ECL revealed that both forms of the lectin bind 
carbohydrates in the same way, confirming that the recombinant form of ECL is native­
like with respect to its mode of carbohydrate recognition as well as in terms of its three- 
dimensional structure. Furthermore, comparison of the combining sites of bound and 
unbound forms of ECL showed that there are no structural changes in the vicinity of the 
combining site upon lactose binding. This indicates that the lectin combining site is pre­
formed within each protomer and suggests that lectins interact with their ligands via a 
“lock-and-key” mechanism.
Comparison of the structure of nECL with that recently reported for native ECL 
(Svensson et al. 2002) revealed several differences in the amino acid sequences of the 
two proteins, although there were no significant differences in their structures at the 
tertiary or quarternary levels. One of the amino acid substitutions removes a potential 
N-linked glycosylation site from nECL at position 17 (which is aspartic acid in nECL, but 
asparagine in SvenECL). It was postulated that the presence of a heptasaccharide at 
Asn17 in both ECorL and ECL forced these lectins to dimerise via the non-canonical 
handshake motif (Shaanan et al. 1991; Svensson et al. 2002). However, neither nECL 
nor recECL is glycosylated at this position, yet both form ECorL-type dimers, 
suggesting that glycosylation does not influence the quarternary association of these 
lectins. Taken together, these observations suggest that factors intrinsic to the primary 
structures of the legume lectins determine their mode of oligomerisation.
5.2 STRUCTURAL STUDIES ON BOTULINUM NEUROTOXIN A
No crystals of LHN/A or LHN/A(H227Y) were grown, which meant that an 
alternative technique to X-ray crystallography had to be sought in order to glean 
information on the structures of these proteins. The method used to analyse LHN/A and 
LHn/A(H227Y) in terms of their secondary structures was far-UV circular dichroism 
spectroscopy. At 250-180nm the peptide bond acts as a chromophore when it is 
arranged in a regular repeating structure, such as an a-helix or p-sheet. Each type of
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secondary structural element produces a characteristic spectrum in the far-UV 
wavelength range. Using a deconvolution algorithm, the spectrum recorded for a 
protein of unknown structure can be analysed and the percentage of amino acid 
residues involved in each type of structural element estimated. One disadvantage of 
this technique is that the identities of the residues involved in, for example, an a-helix 
remain elusive.
Using CD spectroscopy, the structures of LHN/A and LHn/ACH22^ )  in aqueous 
solution were directly compared and found to be highly similar. Overall, approximately 
33% of amino acid residues were arranged in helical structures, 18% in p-strand 
elements and 31% in random coil conformations. Furthermore, despite evidence to 
suggest a structural rearrangement in the light and heavy chains of BoNT/A under the 
influence of low pH, the structure of LHn/ACH22^ )  at pH 5.0 was not significantly 
different to its structure at neutral pH.
5.3 SCOPE OF THE PROJECT
To my knowledge, the data generated during the course of this investigation 
represent the first studies into the structures of LHn/A and LHn/A ^ 22^ )  and the first 
description of the crystal structure of recombinantly expressed ECL. Furthermore, the 
structure of recECL has been shown to be identical to the structure of nECL, despite 
the absence of glycosylation, and for the first time the structure of the oligosaccharide 
N-linked to Asn113 of native ECL has been described.
5.3.1 Crystal Structures of ECL
By comparing the crystal structures of nECL (glycosylated at Asn113) and
recECL (not glycosylated) with the reported structure of ECL (glycosylated at Asn17 and
Asn113) we have shown that the presence of heptasaccharide bound to Asn17 does not 
influence the quarternary structure of the lectin. This contradicts previous suggestions 
that ECL and ECorL adopt non-canonical dimer structures because the carbohydrate 
bound at this position prevents canonical dimerisation and supports data suggesting 
that information controlling the mode of quarternary association in legume lectins is 
encoded within the amino acid sequence of each protomer.
It was important to demonstrate the equivalence of native and recombinant 
ECL since the LHN/A-ECL conjugate is prepared using recombinantly expressed ECL. 
The biological activities of both forms of the lectin in vitro have been shown to be 
identical (Stancombe et al, 2003) and the results of this investigation have confirmed 
that there is no difference between nECL and recECL either in terms of their three­
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dimensional structure or their mode of carbohydrate binding. Thus, it can be concluded 
that recECL represents a native-like form of Erythrina cristagalli lectin.
5.3.2 Structures of BoNT/A Fragments
Far-UV CD studies allowed the solution structures of LHN/A and LHn/A ^ 22^ )  
to be directly compared. The structures of these two fragments are nearly identical but 
have not previously been described. The failure of crystallisation trials raised several 
questions about the structures of these toxin fragments, in particular whether or not 
they are stable in solution. SDS-PAGE and CD spectroscopy have revealed that they 
are stable at -20°C for at least 12 months because a secondary structural profile could 
be determined and they ran as single bands on a gel. This is encouraging, since the 
use of these fragments in a biopharmaceutical might require that they should be stable 
during several months’ storage. However, little information could be deduced regarding 
their biological activities from the CD data and future work on LHN/A and LHn/A ^ 22^ )  
should focus on the determination of their three-dimensional structures.
5.4 FUTURE DIRECTIONS
5.4.1 BoNT/A Fragments
Further crystallisation experiments should be undertaken, including the use of 
substrate analogues and active-site inhibitors to try to yield crystals of LHn/A and 
LHn/ACH22^ )  suitable for diffraction experiments. The addition of an inhibitor or 
substrate analogue can provide extra stability to the protein and aid crystallisation. In 
addition, a wider range of alcohols, additives and environmental variables (for example, 
temperature) could be tested to try to crystallise these fragments. Synthetic peptides 
that act as inhibitors and substrate analogues have already been identified (Hallis et al. 
1996; Schmidt et al. 1998), but none of these compounds were tested during the 
course of this project. The possibility of using detergents as additives was considered 
as they have been shown to be useful in the crystallisation of membrane proteins 
(Abramson and Iwata 1999). However, this idea was based upon the assumption that 
LHn/A has a large hydrophobic region where the Hc domain would normally exist and 
crystallographic data reveal suggest this is not the case (Lacy et al. 1998).
In the absence of a crystal structure, further far-UV CD studies involving the 
presence of SDS micelles or lipids could also be performed to try to observe 
conformational changes induced in LHN/A and LHn/A ^ 22^ )  at low pH. In parallel, 
near-UV CD spectra could be recorded to characterise and look for changes in the
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tertiary structures of these toxin fragments in similar experiments to those performed in 
this investigation.
5.4.2 Erythrina cristagalli Lectin
In this investigation, nECL was not successfully crystallised in the absence of 
lactose and only one crystal form of nECL was analysed compared to five different 
forms of recECL. Determination of the structures of both forms of ECL in complex with 
a variety of carbohydrates is desired to gain a more comprehensive understanding of 
carbohydrate recognition by ECL. In particular, it would be of interest to analyse the 
interactions of ECL with larger oligosaccharides and glycoconjugates that more closely 
represent the natural ligands of the lectin to assess the involvement of dimerisation and 
cross-linking in its biological function.Since the lectin combining site is preformed and 
each protomer contains the structural components required to be fully functional in 
carbohydrate recognition, it is not known why ECL exists as a dimer. Although ECL has 
never been isolated in monomeric form, it might be possible to retarget LHN/A to target 
cells using only one protomer. If the lectin can be isolated in monomeric form, it will be 
interesting to compare the activities of a monomeric ECL-LHN/A conjugate with the 
existing conjugate to further assess the effect of dimerisation on ECL activity.
5.4.3 LHN/A-ECL Conjugate
Combining data on the crystal structures of LHN/A and ECL might enable the 
three-dimensional structure of the LHN/A-ECL conjugate to be modelled. However, any 
such model could not be relied upon to be accurate because the exact structure of the 
conjugate is unknown. Crystallisation and structural analysis of LHN/A-ECL itself (both 
unliganded and in complex with its natural ligands) would provide the most useful 
information as the action of this conjugate on dorsal root ganglia compared to the 
anatomically adjacent spinal cord neurons is the basis of its potential use as a 
pharmaceutical. However, at the moment, this is not feasible for several reasons:
Firstly, the conjugation method produces a mixture of products because the 
proteins are non-specifically linked through a primary amine on the surface of the 
LHn/A moiety. It is not known exactly where the lectin and toxin fragment are joined or 
how many different products are formed. Therefore, the exact point of chemical linkage 
cannot be predicted and several different linkages might be formed during each 
conjugation reaction. Furthermore, the stoichiometry of the conjugate is believed to be 
two ECL dimers per unit of LHN/A. However, this represents the average mass of all 
reaction products. Some species may comprise different combinations of dimeric ECL 
and LHn/A. At present, it is not known which of the products are active in vitro and in
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vivo, although it is hoped that further purification of the conjugated material will shed 
light on the nature of the true potential biopharmaceutical. Improving homogeneity will 
hopefully increase the biological activity of the conjugate as less active and inactive 
species will be removed from the purified material.
The heterogeneity of the final product is expected to seriously hinder 
crystallisation attempts. Furthermore, if the conjugate comprises two ECL dimers and 
one LHn/A moiety, the molecular mass would be close to 205kDa, which might also 
make crystallisation difficult. Larger molecules do not tend to pack together very tightly, 
which can reduce the likelihood of forming stable nuclei that would induce crystal 
growth.
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APPENDIX ONE 
ERYTHRINA CRISTAGALLI LECTIN
EXPRESSION AND PURIFICATION OF RECOMBINANT ECL 
RAMACHANDRAN PLOTS FOR CRYSTAL STRUCTURES OF ECL
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Flowchart Outlining the Steps Involved in the Recombinant Expression and
Purification of ECL
(as described in Stancombe et al, 2003)
E.cristagalli seeds were germinated to produce saplings
I
Genomic DNA was prepared from leaf material and amplified by PCR
4,
The PCR products were cloned into pCR2.1 vector and transformed into E.coli TOP10
cells to create clone pCR-ECL
I
DNA encoding mature ECL was amplified from pCR-ECL using oligonucleotides 
containing Ndel and HindUl cleavage sites
4
The PCR product was cloned into housing vector pMTL1015 and clone integrity was
verified by sequencing
I
For expression of the MBP-ECL fusion protein, the ECL sequence was amplified from 
pCR-ECL and cloned into pMal-c2E vector and transformed into E.coli lysogenic strain
BL21(DE3) cells
4,
Cells were grown in Soytone media (8-litre fermentation scale) for 10-14 hours at 37°C
until static growth (OD600 = 30)
4,
E.coli cell paste was processed in 2-litre equivalent quantities
4,
Protein was refolded from inclusion bodies and purified on an immobilised lactose
matrix
4,
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Ramachandran Plot for the Structure of Recombinant ECL at 2.13A Resolution
Phi (degrees)
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Ramachandran Plot for the Structure of Recombinant ECL in Complex with 
Lactose (Space Group P2J at 1.7A Resolution
Phi (degrees)
Plot statistics
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Ramachandran Plot for the Structure of Recombinant ECL in Complex with 
Lactose (Space Group P2i) at 1.68A Resolution
4-5 6 45 90
Phi (degrees)
Plot statistics
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Ramachandran Plot for the Structure of Recombinant ECL in Complex with 
Lactose (Space Group P3212) at 2.3A Resolution
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Ramachandran Plot for the Structure of Recombinant ECL in Complex with 
Lactose (Space Group C2) at 2.45A Resolution
Phi (degrees)
Plot statistics
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Structure Screen 1 - Catalogue Number MD1-01





0.2M Calcium chloride dihydrate
0.2M tri-sodium citrate dihydrate 
0.2M Ammonium sulphate 
0.2M Magnesium acetate 
tetrahydrate
0.2M Magnesium acetate 
tetrahydrate
0.2M Sodium acetate trihydrate 
0.2M Zinc acetate dihydrate 
0.2M Calcium acetate hydrate 
0.2M tri-sodium citrate dihydrate 
0.2M Magnesium chloride 
hexahydrate
0.2M Calcium chloride dihydrate 
0.2M Magnesium chloride 
hexahydrate
0.2M tri-sodium citrate dihydrate
0.1M Na Acetate trihydrate 
pH 4.6
0.1 M Na Acetate trihydrate 
pH 4.6
0.1M Na acetate trihydrate 
pH 4.6
0.1 M Na acetate trihydrate 
pH 4.6
0.1M Na acetate trihydrate 
pH 4.6
0.1M Na acetate trihydrate 
pH 4.6
0.1 M tri-sodium citrate 
dihydrate pH 5.6 
0.1 M tri-sodium citrate 
dihydrate pH 5.6 
0.1 M tri-Sodium citrate 
dihydrate pH 5.6 
0.1M Na Citrate pH 5.6 
0.1 M Na acetate trihydrate 
pH 4.6
0.1M Na Cacodylate pH 6.5 
0.1M Na Cacodylate pH 6.5 
0.1M Na Cacodylate pH 6.5 
0.1M Na Cacodylate pH 6.5
30% v/v
2-methyl-2,4 pentanediol 
30% w/v PEG 4000
25% w/v PEG 4000
2.0M Sodium formate
2.0M Ammonium sulphate
8% w/v PEG 4000
30% w/v PEG 4000
30% v/v 2-methyl-2,4-pentanediol
20% w/v 2-propanol 
20% w/v PEG 4000
1.0M Ammonium dihydrogen phosphate 
20% v/v 2-propanol
1.4M Na acetate trihydrate 
30% v/v 2-propanol 
30% w/v PEG 8000 
20% PEG 8000
0.1 M Na Cacodylate pH 6.5 30% v/v 2-methyl-2,4-pentanediol
0.1M Imidazole pH 6.5 
0.1 M Na Cacodylate pH 6.5 
0.1M Na Cacodylate pH 6.5 
0.1 M Na Cacodylate pH 6.5 
0.1 M Na Hepes pH 7.5 
0.1 M Na Hepes pH 7.5
0.1 M Na Hepes pH 7.5 
0.1M Na Hepes pH 7.5
0.1 M Na Hepes pH 7.5 
0.1M Na Hepes pH 7.5 
0.1M Na Hepes pH 7.5 
0.1 M Na Hepes pH 7.5
0.1M Na Hepes pH 7.5 
0.1M Na Hepes pH 7.5
0.1 M Na Hepes pH 7.5
1.0M Sodium acetate trihydrate
30% w/v PEG 8000
18% w/v PEG 8000
18% w/v PEG 8000
30% v/v 2-methyl-2,4-pentanediol
30% v/v 2-propanol
28% v/v PEG 400 
30% v/v PEG 400
20% v/v 2-propanol
0.8M K, Na tartrate tetrahydrate
1.5M Lithium sulphate monohydrate
0.8M Na dihydrogen phosphate
0.8M K dihydrogen phosphate monohydrate
1.4M tri-Sodium citrate dihydrate
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0.2M Magnesium chloride 
hexahydrate
0.2M tri-sodum citrate dihydrate 
0.2M Lithium sulphate 
monohydrate 
0.2M Ammonium acetate 
0.2M Sodium acetate trihydrate
0.2M Ammonium sulphate 
0.2M Ammonium sulphate
0.05M Potassium dihydrogen 
phosphate
1.0M Lithium sulphate 
monohydrate 
0.5M Lithium sulphate 
monohydrate
0.1M Tris HCI pH 8.5
0.1 M Tris HCI pH 8.5
0.1M Tris HCI pH 8.5
0.1M Tris HCI pH 8.5
0.1M Tris HCI pH 8.5
0.1M Tris HCI pH 8.5
0.1M Tris HCI PH 8.5
0.1M Tris HCI PH 8.5
20% w/v PEG 4000 
2.0M Ammoniium sulphate 
30% w/v PEG 4000
30% v/v PEG 400 
30% w/v PEG 4000
30% v/v 2-propanol 
30% w/v PEG 4000 
8% w/v PEG 8000
2.0M Ammonium dihydrogen phosphate
0.4M K, Na Tartrate tetrahydrate
0.4M Ammonium dihydrogen phosphate
30% w/v PEG 8000
30% w/v PEG 4000
2.0M Ammonium sulphate
4.0M Sodium formate
20% w/v PEG 8000
30% w/v PEG 1500 
0.2M Magnesium formate 
2% w/v PEG 8000
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Structure Screen 2 - Catalogue Number MD1-02




0.01 M Nickel chloride 
hexahydrate
1.5M Ammonium sulphate 
0.2M Ammonium 
phosphate monobasic
0.01 M Nickel chloride 
hexahydrate
0.5M Ammonium sulphate
0.1 M Sodium chloride
0.05M Cadmium sulphate 
octahydrate
0.1 M Na phosphate 
monobasic
1.6M Ammonium sulphate 
0.05M Cesium chloride 
0.01 M Cobalt chloride 
hexahydrate
0.2M Ammonium sulphate 
0.01 M Zinc sulphate 
heptahydrate
0.2M K/Na Tartrate 
0.5M Ammonium sulphate 
0.5M Sodium chloride
0.01 M Feme chloride 
hexahydrate
0.01 M Manganese chloride 
tetrahydrate
0.1 M Bicine pH 9.0 
0.1M Bicine pH 9.0 
0.1 M Bicine pH 9.0 
0.1 M Tris pH 8.5
0.1 M Tris pH 8.5 
0.1 M Tris pH 8.5
O.IMTris pH 8.5 
0.1M Tris pH 8.5
O.IMTris pH 8.5 
O.IMTris pH 8.5
0.1 M Hepes pH 7.5 
0.1 M Hepes pH 7.5
0.1M Hepes pH 7.5 
0.1M Hepes pH 7.5 
0.1M Hepes pH 7.5 
0.1M Hepes pH 7.5
0.1 M Hepes pH 7.5 
0.1M Hepes pH 7.5 
0.1M Hepes pH 7.5
0.1M Mes pH 6.5
0.1M Mes pH 6.5
0.1M Mes pH 6.5
0.1M Mes pH 6.5
0.1M Mes pH 6.5
0.1M Mes pH 6.5
0.1 M Mes pH 6.5
0.1 M Mes pH 6.5
0.1 M Hepes pH 7.5 
0.1 M Sodium citrate pH 5.6 
0.1 M Sodium citrate pH 5.6 
0.1M Sodium citrate pH 5.6 
0.1M Sodium citrate pH 5.6 
0.1 M Sodium citrate pH 5.6
0.1M Sodium citrate pH 5.6
0.1 M Sodium acetate pH 4.6
30% w/v PEG monomethylether 550 
2.0M Magnesium chloride hexahydrate 
10% w/v PEG 20,000 
3.4M 1,6 Hexanediol
25% v/v tert-Butanol 
1.0M Lithium sulphate
12% v/v Glycerol 
50% v/v MPD
20% v/v Ethanol
20% w/v PEG monomethylether 2000
30% v/v MPD 
10% w/v PEG 6000 
5% v/v MPD
20% v/v Jeffamine M-600 
1.6M Ammonium sulphate 




10% w/v PEG 8000
8% v/v Ethylene glycol
1.6M Magnesium sulphate heptahydrate
2.0M Sodium Chloride
0.1 M K phosphate monobasic
12% w/v PEG 20,000
10% v/v Dioxane
30% v/v Jeffamine M-600
1.8M Ammonium sulphate
30% w/v PEG monomethylether 5000 
25% v/v PEG monomethylether 550
20% w/v PEG 10,000 
2.0M Ammonium sulphate 
1.0M Lithium sulphate 
4% v/v polyethyleneimine 
35% v/v tert-butanol 



















Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
0.2M Sodium Chloride 
0.01 M Cobalt Chloride 
hexahydrate 
0.1 M Cadmium chloride 
0.2M Ammonium sulphate 
2.0M Sodium Chloride 
0.01 M Cetyl trimethyl 
ammoniumbromide
0.1M Sodium acetate pH 4.6 
0.1 M Sodium acetate pH 4.6
0.1 M Sodium acetate pH 4.6 
0.1 M Sodium acetate pH 4.6
2.0M Ammonium Sulphate




30% v/v MPD 
1.0M 1,6 Hexanediol
30% v/v PEG 400
30% w/v PEG monomethylether 2000
10% w/v PEG 6000
0.5M Sodium chloride
0.1 M Magnesium chloride hexahydrate
25% v/v Ethylene glycol
35% v/v Dioxane
5% v/v Isopropanol
1.0M Imidazole pH 7.0
10% w/v PEG 1000
10% w/v PEG 8000
10% v/v Ethanol
1.6M Sodium citrate pH 6.5
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PEGflon Screen Reagent Formulation
Tube Number Salt
1. 0.2 M Sodium Fluoride
2. 0.2 M Potassium Fluoride
3. 0.2 M Ammonium Fluoride
4. 0.2 M Lithium Chloride anhydrous
5. 0.2 M Magnesium Chloride hexahydrate
6. 0.2 M Sodium Chloride
7. 0.2 M Calicium Chloride dihydrate
8. 0.2 M Potassium Chloride
9. 0.2 M Ammonium Chloride
10. 0.2 M Sodium Iodide
11. 0.2 M Potassium Iodide
12. 0.2 M Ammonium Iodide
13. 0.2 M Sodium Thiocyanate
14. 0.2 M Potassium Thiocyanate
15. 0.2 M Lithium Nitrate
16. 0.2 M Magnesium Nitrate hexahydrate
17. 0.2 M Sodium Nitrate
18. 0.2 M Potassium Nitrate
19. 0.2 M Ammonium Nitrate
20. 0.2 M Magnesium Formate
21. 0.2 M Sodium Formate
22. 0.2 M Potassium Formate
23. 0.2 M Ammonium Formate
24. 0.2 M Lithium Acetate dihydrate
25. 0.2 M Magnesium Acetate tetrahydrate
26. 0.2 M Zinc Acetate dihydrate
27. 0.2 M Sodium Acetate trihydrate
28. 0.2 M Calcium Acetate hydrate
29. 0.2 M Potassium Acetate
30. 0.2 M Ammonium Acetate
31. 0.2 M Lithium Sulfate monohydrate
32. 0.2 M Magnesium Sulfate heptahydrate
33. 0.2 M Sodium Sulfate decahydrate
34. 0.2 M Potassium Sulfate
35. 0.2 M Ammonium Sulfate
36. 0.2 M di-Sodium Tartrate dihydrate
37. 0.2 M Potassium Sodium Tartrate tetrahydrate
38. 0.2 M di-Ammonium Tartrate
39. 0.2 M Sodium dihydrogen Phosphate monohydrate
40. 0.2 M di-Sodium hydrogen Phosphate dihydrate
41. 0.2 M Potassium dihydrogen Phosphate
42. 0.2 M di-Potassium hydrogen Phosphate
43. 0.2 M Ammonium dihydrogen Phosphate
44. 0.2 M di-Ammonium hydrogen Phosphate
45. 0.2 M tri-Lithium Citrate tetrahydrate
46. 0.2 M tri-Sodium Citrate dihydrate
47. 0.2 M tri-Potassium Citrate monohydrate










Tube Number Polyethylene Glycol 3350 Tube Number pH
1. 20% w/v Polyethylene Glycol 3350 1.
2. 20% w/v Polyethylene Glycol 3350 2.
3. 20% w/v Polyethylene Glycol 3350 3.
4. 20% w/v Polyethylene Glycol 3350 4.
5. 20% w/v Polyethylene Glycol 3350 5.
6. 20% w/v Polyethylene Glycol 3350 6.
7. 20% w/v Polyethylene Glycol 3350 7.
8. 20% w/v Polyethylene Glycol 3350 8.
9. 20% w/v Polyethylene Glycol 3350 9.
10. 20% w/v Polyethylene Glycol 3350 10. 6.9
11. 20% w/v Polyethylene Glycol 3350 11. 6.8
12. 20% w/v Polyethylene Glycol 3350 12. 6.2
13. 20% w/v Polyethylene Glycol 3350 13. 6.9
14. 20% w/v Polyethylene Glycol 3350 14. 7.0
15. 20% w/v Polyethylene Glycol 3350 15. 7.1
16. 20% w/v Polyethylene Glycol 3350 16. 5.8
17. 20% w/v Polyethylene Glycol 3350 17. 6.8
18. 20% w/v Polyethylene Glycol 3350 18. 6.9
19. 20% w/v Polyethylene Glycol 3350 19. 6.3
20. 20% w/v Polyethylene Glycol 3350 20. 5.9
21. 20% w/v Polyethylene Glycol 3350 21. 7.2
22. 20% w/v Polyethylene Glycol 3350 22. 7.3
23. 20% w/v Polyethylene Glycol 3350 23. 6.6
24. 20% w/v Polyethylene Glycol 3350 24. 7.8
25. 20% w/v Polyethylene Glycol 3350 25. 7.7
26. 20% w/v Polyethylene Glycol 3350 26. 6.3
27. 20% w/v Polyethylene Glycol 3350 27. 7.9
28. 20% wAf Polyethylene Glycol 3350 28. 7.3
29. 20% w/v Polyethylene Glycol 3350 29. 7.8
30. 20% w/v Polyethylene Glycol 3350 30. 7.1
31. 20% w/v Polyethylene Glycol 3350 31. 6.4
32. 20% w/v Polyethylene Glycol 3350 32. 5.9
33. 20% w/v Polyethylene Glycol 3350 33. 6.6
34. 20% w/v Polyethylene Glycol 3350 34. 6.7
35. 20% w/v Polyethylene Glycol 3350 35. 6.0
36. 20% w/v Polyethylene Glycol 3350 36. 7.2
37. 20% w/v Polyethylene Glycol 3350 37. 7.2
38. 20% w/v Polyethylene Glycol 3350 38. 6.6
39. 20% w/v Polyethylene Glycol 3350 39. 4.5
40. 20% w/v Polyethylene Glycol 3350 40. 9.1
41. 20% w/v Polyethylene Glycol 3350 41. 4.7
42. 20% w/v Polyethylene Glycol 3350 42. 9.2
43. 20% w/v Polyethylene Glycol 3350 43. 4.6
44. 20% w/v Polyethylene Glycol 3350 44. 7.9
45. 20% w/v Polyethylene Glycol 3350 45. 8.1
46. 20% w/v Polyethylene Glycol 3350 46. 8.2
47. 20% w/v Polyethylene Glycol 3350 47. 8.3
48. 20% w/v Polyethylene Glycol 3350 48. 5.0
F Cl I
Fluoride Chloride Iodide
N —  o ' Nitrate
0
’ S —  C s s N
Thiocyanate
/ \
' 0  c h 3
Acetate














I /c— c— c— c
•07  10  H OH u
Tartrate
\  1 \ \ /c— c— c— c— c
-  /  I
H OH H
Citrate
PEG/lon Screen contains forty-eight unique reagents. To determine the formulation of each reagent, simply read across the page.
34 Journey Solutions for Crystal Growth
Aliso Viejo, CA 92656-3317 U.S.A.
Tel: (949) 425-1321 • Fax: (949) 425-1611
e-mail: tech@hrmail.com 0  2000-2003 H am pton  R esearch Corp. all rights reserved
. . . . .  , , P rin ted  in th e  U n ited  S tates o f  America. T h is  gu ide or
Website. WWW.hamptOnrcsearch.com parts th e re o f m ay n o t b e  reproduced in any form  w ithout





A1 10% MPD, 0.1 M Na HEPES pH 7.5, 0.1 M Na Citrate
A2 12% MPD, 0.1 M TRIS HCI pH 8.5, 0.05 M Mg Chloride
A3 15% MPD, 0.1 M Na Acetate pH 4.6, 0.02 M Ca Chloride
A4 15% MPD, 5% PEG 4000, 0.1 M Imidazole HCI pH 8.0
A5 15% MPD, 0.1 M Na Citrate pH 5.6, 0.2 M Ammonium Acetate
A6 15% MPD, 0.1 M Na MES pH 6.5, 0.2 M Mg Acetate
B1 15% MPD, 0.1 M Na HEPES pH 7.5, 0.2 M Na Citrate
B2 20% MPD, 0.1 M Na HEPES pH 7.5, 0.1 M Na Citrate
B3 20% MPD, 0.1 M Imidazole HCI pH 8.0
B4 20% MPD, 4% Glycerol, 0.2 M Na Chloride
B5 30% MPD, 0.1 M Na Acetate pH 4.6, 0.02 M Ca Chloride
B6 30% MPD, 0.1 M Na Citrate pH 5.6, 0.2 M Ammonium Acetate
C1 30% MPD, 0.1 M Na MES pH 6.5, 0.2 M Mg Acetate
C2 30% MPD, 0.5 M Ammonium Sulfate, 0.1 M Na HEPES pH 7.5
C3 30% MPD, 0.1 M Na HEPES pH 7.5, 0.2 M Na Citrate
C4 30% MPD, 5% PEG 4000, 0.1 M Na HEPES pH 7.5
C5 30% MPD, 10% PEG 4000, 0.1 M Imidazole HCI pH 8.0
C6 30% MPD, 20% Ethanol
D1 35% MPD
D2 35% MPD, 0.1 M Imidazole HCI pH 8.0
D3 40% MPD, 0.1 M TRIS HCI pH 8.5
D4 47% MPD, 0.1 M Na HEPES pH 7.5
D5 47% MPD, 2% tert.-Butanol
D6 50% MPD
► ► ►  JENA BIOSCIENCE
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A1 50% MPD, 15% Ethanol, 0.01 M Na Acetate
A2 50% MPD, 20% iso-Propanol, 0.05 M Na Acetate, 0.05 M Na Chloride
A3 50% MPD, 0.1 M TRIS HCI pH 8.5, 0.2 M Ammonium Dihydrogen Phosphate
A4 55% MPD
A5 60% MPD, 0.1 M Na Acetate pH 4.6, 0.01 M Ca Chloride
A6 60% MPD, 0.02 M Na Acetate
B1 70% MPD, 0.1 M Na MES pH 6.5
B2 70% MPD, 0.1 M TRIS HCI pH 8.5
B3 20% Methanol, 0.1 M TRIS HCI pH 8.5, 0.01 M Ca Chloride
B4 2% Ethanol, 0.1 M TRIS HCI pH 8.5
B5 5% Ethanol, 5% MPD, 0.1 M Na HEPES pH 7.5
B6 5% Ethanol, 5% MPD, 0.1 M TRIS HCI pH 8.5, 0.2 M Na Chloride
C1 10% Ethanol, 0.1 M TRIS HCI pH 8.5
C2 12% Ethanol, 4% PEG 400, 0.1 M Na Acetate pH 4.6
C3 14% Ethanol, 5% Glycerol, 0.1 M TRIS HCI pH 8.5
C4 18% Ethanol, 0.1 M TRIS HCI pH 8.5
C5 20% Ethanol
C6 20% Ethanol, 10% Glycerol
D1 30% Ethanol, 10% PEG 6000, 0.1 M Na Acetate
D2 45% Ethanol
D3 50% Ethanol, 0.01 M Na Acetate
D4 60% Ethanol, 1.5% PEG 6000, 0.05 M Na Acetate
D5 60% Ethanol, 0.1 M Na Chloride
D6 2% /so-Propanol, 0.1 M TRIS HCI pH 8.5, 0.01 M Mg Sulfate
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A1 5% iso-Propanol, 0.1 M Na HEPES pH 7.5
A2 10% iso-Propanol, 0.1 M Na Acetate pH 4.6, 0.2 M Ca Chloride
A3 10% iso-Propanol, 0.1 M Na HEPES pH 7.5, 0.2 M Na Citrate
A4 10% iso-Propanol, 0.1 M TRIS HCI pH 8.5, 0.01 M Mg Chloride
A5 12% iso-Propanol, 0.1 M TRIS HCI pH 8.5, 0.05 Na Chloride
A6 15% iso-Propanol, 0.1 M Na MES pH 6.5, 0.2 M Na Citrate
B1 15% iso-Propanol, 0.1 M Na HEPES pH 7.5, 0.2 M Na Citrate
B2 15% iso-P ropanol, 0.1 M Na HEPES pH 7.5, 0.2 M Mg Chloride
B3 15% iso-Propanol, 0.1 M TRIS HCI pH 8.5, 0.2 M Ammonium Acetate
B4 20% iso-Propanol, 0.1 M Na Acetate pH 4.6, 0.2 M Ca Chloride
B5 20% /so-Propanol, 0.1 M Na HEPES pH 7.5, 0.2 M Na Citrate
B6 25% iso-Propanol, 0.1 M Na HEPES pH 7.5, 0.1 M Mg Chloride
C1 30% iso-Propanol, 0.1 M Na MES pH 6.5, 0.2 M Na Citrate
C2 30% iso-Propanol, 0.1 M Na HEPES pH 7.5, 0.2 M Mg Chloride
C3 30% iso-Propanol, 0.1 M TRIS HCI pH 8.5, 0.2 M Ammonium Acetate
C4 25% tert.-Butanol, 0.1 M TRIS HCI pH 8.5, 0.1 M Ca Chloride
C5 35% tert.-Butanol, 0.1 M Na Citrate pH 5.6
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Crystal Screen Reagent Formulation
Tube Number Salt Tube Number Bufferf Tube Number Precipitant
1. 0.02 M Calcium Chloride dihydrate 1. 0.1 M Sodium Acetate trihydrate pH 4.6 1. 30% v/v 2-Methyl-2,4-pentanediol
2. None 2. None 2. 0.4 M Potassium Sodium Tartrate tetrahydrate
3. None 3. None 3. 0.4 M mono-Ammonium dihydrogen Phosphate
4. None 4. 0.1 M Tris Hydrochloride pH 8.5 4. 2.0 M Ammonium Sulfate
5. 0.2 M tri-Sodium Citrate dihydrate 5. 0.1 M HEPES -N a pH 7.5 5. 30% v/v 2-Methyl-2,4-pentanediol
6. 0.2 M Magnesium Chloride hexahydrate 6. 0.1 M Tris Hydrochloride pH 8.5 6. 30% w/v Polyethylene Glycol 4000
7. None 7. 0.1 M Sodium Cacodylate pH 6.5 7. 1.4 M Sodium Acetate trihydrate
8. 0.2 M tri-Sodium Citrate dihydrate 8. 0.1 M Sodium Cacodylate pH 6.5 8. 30% v/v iso-Propanol
9. 0.2 M Ammonium Acetate 9. 0.1 M tri-Sodium Citrate dihydrate pH 5.6 9. 30% w/v Polyethylene Glycol 4000
10. 0.2 M Ammonium Acetate 10. 0.1 M Sodium Acetate trihydrate pH 4.6 10. 30% w/v Polyethylene Glycol 4000
11. None 11. 0.1 M tri-Sodium Citrate dihydrate pH 5.6 11. 1.0 M mono-Ammonium dihydrogen Phosphate
12. 0.2 M Magnesium Chloride hexahydrate 12. 0.1 M HEPES - Na pH 7.5 12. 30% v/v iso-Propanol
13. 0.2 M tri-Sodium Citrate dihydrate 13. 0.1 M Tris Hydrochloride pH 8.5 13. 30% v/v Polyethylene Glycol 400
14. 0.2 M Calcium Chloride dihydrate 14. 0.1 M HEPES - Na pH 7.5 14. 28% v/v Polyethylene Glycol 400
15. 0.2 M Ammonium Sulfate 15. 0.1 M Sodium Cacodylate pH 6.5 15. 30% w/v Polyethylene Glycol 8000
16. None 16. 0.1 M HEPES - Na pH 7.5 16. 1.5 M Lithium Sulfate monohydrate
17. 0.2 M Lithium Sulfate monohydrate 17. 0.1 M Tris Hydrochloride pH 8.5 17. 30% Polyethylene Glycol 4000
18. 0.2 M Magnesium Acetate tetrahydrate 18. 0.1 M Sodium Cacodylate pH 6.5 18. 20% Polyethylene Glycol 8000
19. 0.2 M Ammonium Acetate 19. 0.1 M Tris Hydrochloride pH 8.5 19. 30% v/v iso-Propanol
20. 0.2 M Ammonium Sulfate 20. 0.1 M Sodium Acetate trihydrate pH 4.6 20. 25% w/v Polyethylene Glycol 4000
21. 0.2 M Magnesium Acetate tetrahydrate 21. 0.1 M Sodium Cacodylate pH 6.5 21. 30% v/v 2-Methyl-2,4-pentanediol
22. 0.2 M Sodium Acetate trihydrate 22. 0.1 M Tris Hydrochloride pH 8.5 22. 30% w/v Polyethylene Glycol 4000
23. 0.2 M Magnesium chloride hexahydrate 23. 0.1 M HEPES - Na pH 7.5 23. 30% v/v Polyethylene Glycol 400
24. 0.2 M Calcium Chloride dihydrate 24. 0.1 M Sodium Acetate trihydrate pH 4.6 24. 20% v/v iso-Propanol
25. None 25. 0.1 M Imidazole pH 6.5 25. 1.0 M Sodium Acetate trihydrate
26. 0.2 M Ammonium Acetate 26. 0.1 M tri-Sodium Citrate dihydrate pH 5.6 26. 30 % v/v 2-Methyl-2,4-pentanediol
27. 0.2 M tri-Sodium Citrate dihydrate 27. 0.1 M HEPES • Na pH 7.5 27. 20% v/v iso-Propanol
28. 0.2 M Sodium Acetate trihydrate 28. 0.1 M Sodium Cacoidylate pH 6.5 28. 30% wAr Polyethylene Glycol 8000
29. None 29. 0.1 M HEPES - Na pH 7.5 29. 0.8 M Potassium Sodium Tartrate tetrahydrate
30. 0.2 M Ammonium Sulfate 30. None 30. 30% w/v Polyethylene Glycol 8000
31. 0.2 M Ammonium Sulfate 31. None 31. 30% w/v Polyethylene Glycol 4000
32. None 32. None 32. 2.0 M Ammonium Sulfate
33. None 33. None 33. 4.0 M Sodium Formate
34. None 34. 0.1 M Sodium Acetate trihydrate pH 4.6 34. 2.0 M Sodium Formate
35. None 35. 0.1 M HEPES - Na pH 7.5 35. 0.8 M mono-Sodium dihydrogen phosphate 
0.8 M mono-Potassium dihydrogen phosphate
36. None 36. 0.1 M Tris Hydrochloride pH 8.5 36. 8% w/v Polyethylene Glycol 8000
37. None 37. 0.1 M Sodium Acetate trihydrate pH 4.6 37. 8% w/v Polyethylene Glycol 4000
38. None 38. 0.1 M HEPES - Na pH 7.5 38. 1.4 M tri-Sodium Citrate dihydrate
39. None 39. 0.1 M HEPES - Na pH 7.5 39. 2% v/v Polyethylene Glycol 400,2.0 M Ammonium Sulfate
40. None 40. 0.1 M tri-Sodium Citrate dihydrate pH 5.6 40. 20% v/v iso-Propanol, 20% w/v Polyethylene Glycol 4000
41. None 41. 0.1 M HEPES • Na pH 7.5 41. 10% v/v iso-Propanol, 20% w/v Polyethylene Glycol 4000
42. 0.05 M mono-Potassium dihydrogen Phosphate 42. None 42. 20% w/v Polyethylene Glycol 8000
43. None 43. None 43. 30% w/v Polyethylene Glycol 1500
44. None 44. None 44. 0.2 M Magnesium Formate
45. 0.2 M Zinc Acetate dihydrate 45. 0.1 M Sodium Cacodylate pH 6.5 45. 18% w/v Polyethylene Glycol 8000
46. 0.2 M Calcium Acetate hydrate 46. 0.1 M Sodium Cacodylate pH 6.5 46. 18% w/v Polyethylene Glycol 8000
47. None 47. 0.1 M Sodium Acetate trihydrate pH 4.6 47. 2.0 M Ammonium Sulfate
48. None 48. 0.1 M Tris Hydrochloride pH 8.5 48. 2.0 M mono-Ammonium dihydrogen Phosphate
49. 1.0 M Lithium Sulfate monohydrate 49. None 49. 2% w/v Polyethylene Glycol 8000
50. 0.5 M Lithium Sulfate monohydrate 50. None 50. 15% w/v Polyethylene Glycol 8000
t  Butfer pH is that of a 1.0 M stock prior to dilution with 
other reagent components. pH with HCI or NaOH.
Crystal Screen contains fifty unique reagents. To determine the formulation of each reagent, simply read across the page.
H a m p t o n
R K S K a r c : h
Solutions fo r  Crystal Growth
O  2000-2003 H am pton Research Corp. all rights reserved 
Printed in the U nited States o f America. T h is  guide or 
parts thereo f may not be reproduced in any form without 
the w ritten permission o f the publishers.
34 Journey
Aliso Viejo, CA 92656-3317 U.S.A.
Tel: (949) 425-1321 • Fax: (949) 425-1611
e-mail: tech@hrmail.com
Website: www.hamptonrescarch.com
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
APPENDIX THREE 
CLOSTRIDIAL NEUROTOXINS
BOTULINUM AND TETANUS NEUROTOXINS: STRUCTURE, FUNCTION AND 
THERAPEUTIC UTILITY
TURTON, K., CHADDOCK, J.A. & ACHARYA, K.R. (2002)
TRENDS BIOCHEM SCI, 27, 552-558
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Botulinum and tetanus neurotoxins 
structure, function and therapeutic 
utility
Kathryn Turton, John A. Chaddock and K. Ravi Acharya
The toxic products of the anaerobic bacteria Clostridium botulinum, 
Clostridium butyricum, Clostridium baratiand Clostridium tetaniare the 
causative agents of botulism and tetanus. The ability of botulinum neurotoxins 
to disrupt neurotransmission, often for prolonged periods, has been exploited 
for use in several medical applications and the toxins, as licensed 
pharmaceutical products, now represent the therapeutics of choice for the 
treatment for several neuromuscular conditions. Research into the structures 
and activities of botulinum and tetanus toxins has revealed features of these 
proteins that might be useful in the design of improved vaccines, effective 
inhibitors and novel biopharmaceuticals. Here, we discuss the relationships 
between structure, mechanism of action and therapeutic use.
DOI: 10.1016/S0968-0004(02)02177-1
Botulism results from intoxication by botulinum 
neurotoxin (BoNT) and is characterized by 
descending flaccid paralysis as a result of inhibition of 
acetylcholine release at the neuromuscular junction. 
There are seven botulinum neurotoxin serotypes 
(A-G) produced by bacteria of the genus Clostridium, 
and one of the factors in recovery from botulism 
depends on the BoNT serotype involved. Together 
with tetanus neurotoxin (TeNT) produced by 
Clostridium tetani, the BoNTs make up the clostridial 
neurotoxin (CNT) family. TeNT exhibits a high degree 
of sequence and structural homology to the BoNTfe, in 
particular to BoNT/B, and is the causative agent of 
tetanus, which is characterized by spastic paralysis.
Although differing in clinical manifestation, the 
fundamental mode of action -  inhibition of 
neurotransmission—is common to all CNTs. 
Inhibition of neurotransmitter release by the CNT9 is 
caused by the specific cleavage of a group of proteins 
integral to the exocytotic process, the SNARE 
proteins (soluble NSF-attachment protein receptors). 
Cleavage of one or more of the SNARE proteins leads 
to a block in the release of vesicular contents to the 
extracellular environment. Therefore, in the case of 
BoNT action on the motomeuron, release of 
acetylcholine is prevented. Neither the duration of 
action, nor the electrophysiology of the effects of 
BoNT in the neuromuscular junction are equivalent 
across the different serotypes [1].
This article reviews the most recent interpretations 
of BoNT structure and mechanism of action with 
respect to the therapeutic use of the toxins, and draws 
comparisons with the data on TeNT.
Kathryn liirton 
K. Ravi Acharya*
Dept of Biology and 
Biochemistry, University 
of Bath, Claverton Down, 




Centre for Applied 
Microbiology and 
Research, Porton Down, 
Salisbury, UK SP40JG.
CNT structure
Td understand the components of BoNT responsible 
for its mechanism of action, it is necessary to introduce 
the basic CNT structure. CNTs are synthesized as 
single-chain polypeptides of ~150 kDa and are 
subsequently cleaved to form di-chain molecules 
(Fig. 1), in which the light (LC) and heavy chains (HC) 
are linked by a single disulfide bond. The 50-kDa LC 
acts as a zinc-dependent endopeptidase. The heavy 
chain contains two functional domains, each of 
-50 kDa. The N-terminal half (HN) is the translocation 
domain, known to form ion channels in lipid bilayers, 
and the C-terminal half (Hc) is the ganglioside- 
binding domain, which has a key role in binding to the 
target cell membrane and internalization of the toxin 
molecules into cholinergic neurons. The three 
functional domains are structurally distinct and 
arranged in a linear fashion, such that there is no 
contact between the LC and Hc domains. Overall, 
BoNTs and TeNT share ~35% sequence identity [2]. 
The BoNT catalytic LC domains share up to 36% 
sequence identity [2], and the LC domains of BoNT/B 
and TeNT have over 50% identity [3].
Ciystal structures of BoNT/A [4] (Fig. 2a),
BoNT/B [5] and the Hc domain of TeNT [6] (Fig. 2b) 
have been determined. The ganglioside-binding(Hc) 
domain of BoNT/A is made up of two sub-domains of 
roughly equal size. Both subdomains are composed of 
mainly Jl-sheet topology, joined by an a-helix (Fig. 2b). 
Hc tilts away from the central translocation (HN) 
domain such that its surface loops are accessible for 
binding. The HN domain has two unique structural 
features: a pair of long (105 A) amphipathic helices, 
which resemble the coiled-coils of some viral proteins, 
and a long loop, known as the ‘translocation belt’, that 
wraps around the LC. The function of the HN domain 
is believed to be formation of pores and translocation 
of the catalytic domain into the neuron cytosol. 
However, the details of this are poorly understood and 
the pore-forming segment of HN remains to be 
identified. The catalytic domain (LC) contains the 
catalytic zinc atom and a conserved zinc-binding 
HExxH motif characteristic of zinc proteases. The 
catalytic site is located in a deep cleft on the protein 
surface, accessible by a channel. The translocation 
belt of the HN domain occludes the active site in 
BoNT/A, preventing access to the zinc atom, but is
http://tibs.trends.com 0968-0004/02/$- see front matter© 2002 Elsevier Science Ltd. All rights reserved. Pil: S0968-0004(02)02177-1
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Fig . 1. The di-chain structure of a Clostridial neurotoxin -  botulinum neurotoxin A (BoNT/A).
Clostridial neurotoxins are-150-kDa proteins, synthesized as single-chain polypeptides and 
post-translationally nicked to form di-chain molecules. They share the same domain architecture and 
overall structure. The light and heavy chains of BoNT/A are linked by a single disulfide bond, 
Cys430-Cys454. The light chain (LC), shown in red, functions as zinc-dependent endopeptidase and 
contains the catalytic zinc atom and HExxH motif associated with zinc-dependent proteases. The 
heavy chain comprises two functional domains of roughly equal size. The N-terminal section (HN), 
shown in blue, is the translocation domain, which forms ion channels spanning endosomal 
membranes and is thought to be involved in translocation and activation of the LC. The C-terminal 
section (Hc), shown in green, is the binding domain.
less effective in BoNT/B partly because the belt is 
shorter in BoNT/B than BoNT/A.
Although the crystal structure of holo-TeNT has 
not yet been reported, similarities have been observed 
between the Hc domains of BoNT serotypes A and B 
and that ofTeNT (Fig. 2b). Like BoNT-Hc, the Hc 
domain ofTeNT is divided into two subdomains. It 
appears, from deletion mutagenesis studies [7] and 
structure-based sequence alignment [8], that the 
C-terminal subdomain is also involved in ganglioside 
binding. The jelly-roll topology of the N-terminal 
subdomain is similar to the structures of many lectins 
(carbohydrate-binding proteins) and might contain 
the ganglioside-binding motif. The crystal structures 
ofTeNT in complex with a synthetic ganglioside 
analogue [9] and with carbohydrates [10] have 
provided insight into the ganglioside binding process, 
as discussed later.
Mechanism of action
BoNT intoxication (summarized in Fig. 3) occurs 
through a multi-step process involving each of the 
toxin functional domains, and can be described as the 
outcome of three discrete stages.
Binding to target cell and internalization 
BoNTs bind to cholinergic nerve terminals by their 
Hc domains and are subsequently internalized, 
possibly by receptor-mediated endocytosis. Binding is 
thought to require the presence of gangliosides 
(in particular GDlb, GTlb and GQlb) [11]. However, 
as a result of ganglioside distribution studies and 
affinity binding studies, we know that gangliosides 
are not the sole molecule to facilitate BoNT binding. A 
‘double-receptor’model has been proposed [11] 
whereby BoNTs must also bind to a protein receptor 
before internalization can occur. The precise identity 
of the receptor for each member of the CNT family has 
remained elusive, although there is some evidence to
suggest that synaptotagmin could be involved in the 
internalization of serotypes A, B and E [12-14]. 
Internalization ofTeNT is known to be protease- 
sensitive and the requirement for lipid raffs and one 
or more GPI-anchored protein has now been 
confirmed [15] to be important in the 
TeNT-intoxication process. Once bound to the surface 
of the neuron, CNTs are internalized into acidic 
compartments through an endocytic process that is 
temperature and energy-dependent. At this stage, the 
toxins can no longer be neutralized by antisera.
Translocation
In common with several other bacterial toxins, it is 
proposed that there is a pH-dependent structural 
rearrangement of the toxin inside an acidic 
compartment within the cell [16]. The identity of the 
intracellular compartment from which BoNTs 
translocate has not been categorically determined, 
although recycling synaptic vesicles and the endosomal 
compartment are obvious candidates. The reduction in 
pH is believed to trigger a structural change in BoNT, 
leading to greater hydrophobicity in the molecule and 
facilitating penetration of the lipid bilayer. It has been 
shown that BoNT serotypes A and E form ion channels 
in phospholipid bilayers [17] and PC 12 membranes [18] 
under conditions similar to those believed to exist in 
vivo. Active LC is translocated into the cytosol, where it 
interacts with, and subsequently cleaves, SNAREs.
Inhibition o f neurotransmitter release 
SNARE proteins are involved in the fusion of synaptic 
vesicles with the plasma membrane [19] and thus the 
action of BoNT-LC is to prevent exocytosis. At a more 
specific level, cleavage of SNARE proteins by BoNT 
inhibits the release of acetylcholine (ACh) at the 
neuromuscular junction, leading to inhibition of 
neurotransmission. It has been shown that cleavage of 
individual SNARE proteins does not prevent SNARE 
complex formation, but results in a non-functional 
complex where the coupling between Ca2+ influx and 
fusion is disrupted (see [20] for discussion). The role of 
Ca2+ is fundamental to the process of CNT-dependent 
inhibition of neurotransmitter release as increasing 
the Ca2+ concentration in the synaptic terminal 
partially reverses the effect of BoNT/A [21].
TeNT binds to gangliosides on the motomeuron 
surface in a similar manner to the BoNTs but, once 
internalized, TeNT undergoes retrograde axonal 
transport to the central nervous system, 
transcytosing across the synapse to internalize into 
the interneurons that regulate motomeuron activity. 
The spastic paralysis that results from intoxication 
with TeNT arises from the loss of spinal inhibitory 
control of motomeuron activity [22,23].
Structural basis of BoNT activity
Binding and internalization
Data obtained for the structure of the Hc domains of 
BoNT/A [4], BoNT/B [5] and TeNT [6] reveals that the
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(a) Translocation domain
Binding domain Catalytic domain
(b ) TeNT BoNT/A
T/BS
Fig. 2 . (a) Crystal structure of botulinum neurotoxin A (BoNT/A). The three functional domains are 
structurally distinct and oriented such that there are no contacts between the catalytic and binding 
domains. The binding domain is made up of two subdomains of roughly equal size: the N-terminal 
subdomain comprises a jelly roll motif while the C-terminal subdomain (which is believed to contain 
the ganglioside-binding motif) adopts a (i-trefoil fold. The central translocation domain has two 
unique structural features -  a pair of long helices that are reminiscent of a viral coiled-coil motif and a 
long loop (translocation belt) that wraps around the catalytic domain and occludes the active site. The 
catalytic domain houses the catalytic zinc atom and the conserved HExxH motif characteristic of 
zinc-dependent endopeptidases. (b) Botulinum neurotoxin A and tetanus neurotoxin (TeNT) binding 
domains. Structural comparisons drawn between the binding domains (Hc) of BoNT/A and TeNT 
reveal their overall architecture is similar. In both toxins the binding domain comprises two 
subdomains, the N-terminal of which has a jelly-roll, lectin-like fold and the C-terminal of which 
adopts a ^-trefoil fold. The subdomains are linked by a single a-helix. The C-terminal subdomain 
contains the ganglioside-binding site and the postulated five-residue ganglioside-binding motif.
binding domain is composed of two sub-domains.
The N-terminal half adopts a jelly-roll, lectin-like fold 
and the C-terminal half has a p-trefoil fold. The 
binding domain binds to gangliosides on the surface 
of motomeurons. As described previously, BoNTs bind 
to gangliosides of the GTlb and GDlb classes with 
low affinity [24]. Gangliosides consist of sialic 
acid-containing oligosaccharide linked to ceramide.
Sequence-to-structure alignment of the CNTs 
reveals a set of five conserved residues (in BoNT/A, 
these are Glul202, Serl263, Trpl265, Tyrl266 and 
Gly1278) within the C-terminal subdomain of Hc that 
are postulated to form a ganglioside-binding motif [8]. 
Neutralizing antibody data have also implicated the 
stretch of amino acids 1266-1272 in BoNT/A in 
ganglioside binding [10]. This motif lies close to a 
shallow cleft on the surface of BoNT/A and could 
accommodate the proposed protein co-receptor.
Since initial structural analysis of TeNT-Hc, 
binding studies and cocrystallisation experiments 
have been performed on this fragment [9,10,25] that 
have revealed clues to the mechanism of toxin 
internalization into cholinergic neurons. The five 
residues of the proposed CNT ganglioside binding 
motif (TVpl289, Hisl271, Hisl293, Tyrl290 and 
Phel218) have been implicated in ganglioside- 
binding in TeNT [9] and Tyrl290 has been shown, by 
site-directed mutagenesis, to be a key residue in 
ganglioside binding [7]. In addition, Argl226, 
Asnl216, Asp 1214, Asp 1147 and iyrl229 have been 
shown to line pockets on the surface ofTeNT where 
gangliosides bind. Binding studies with TeNT have 
identified a carbohydrate moiety essential for TeNT 
(or TeNT-Hc) binding, and crystallographic studies 
have revealed two carbohydrate-binding areas on the 
surface on the C-terminal domain of TeNT-Hc [10]. 
These two binding sites can interact with two 
separate ganglioside molecules, hence crosslinking 
could occur on the motomeuron surface. The crystal 
structure of TeNT-Hc bound to lactose reveals that 
the lactose binding site appears to be composed of 
residues of the proposed CNT ganglioside-binding 
motif and that the lactose residue is bound in an 
orientation consistent with that for ganglioside- 
binding [10]. Superposition of the Hc C-terminal 
sub-domains of BoNT/A, BoNT/B and TeNT reveals 
that they have similar binding clefts to accommodate 
sialic acid [5]. This has led to the proposition of a 
common model of interaction of GTlb gangliosides 
with these toxins.
CNTs are structurally homologous with respect to 
their Hc domains but sequence identity is low, which 
could be important in determining the specificity of 
each toxin for its protein co-receptor. Structural 
features of BoNT/B in complex with sialyllactose [5] 
are similar to that of apo-BoNT/B, suggesting a 
‘lock-and-key’ mechanism of binding between 
neurotoxin and ganglioside. This observation 
supports the idea that ganglioside-binding brings 
BoNTs into close proximity with a protein receptor, 
facilitating toxin recognition and internalization.
Once the CNT has bound to its receptor(s) on the 
motomeuron, it is internalized inside a vesicle, which 
the LC must ultimately leave to exert effects on the 
nervous system. In the case of BoNTs, exit from the 
vesicular compartment or endosome is the only 
means of accessing cytosolic protein targets (the 
SNARE proteins). By contrast, TeNT must be
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Fig. 3 . Mechanism of action of botulinum neurotoxin (BoNT). Each of the structural elements of 
botulinum neurotoxin, the light chain (LC) endopeptidase (yellow), the HN translocation domain 
(green) and the Hc cell-binding domain (blue) have a role in the mechanism of action of neurotoxin. 
The first stage in the intoxication process (interaction with gangliosides and an, as yet unidentified, 
protein receptor) (1) is followed by stage two, internalization of the toxin-receptor complex into an 
intracellular vesicle (2). The third stage (translocation) is characterized by release of the light chain 
endopeptidase from an acidic intracellular compartment into the cytosol (3). Once liberated from the 
vesicle, the light chain performs the final stage of intoxication; highly specific proteolytic cleavage of 
one of the proteins of the SNARE complex (4). BoNTs B, D, F and G cleave proteins of the VAMP family 
(purple) and BoNTs A, C and E cleave SNAP-25 (light blue). BoNT/C also has the capacity to cleave 
syntaxin (orange). Cleaved SNARE proteins are competent for facilitating docking of the secretory 
vesicle with the synaptic membrane, but fusion of the vesicle is compromised. Thus neurotransmitter 
release is inhibited. Abbreviations: HN, heavy chain N-terminal subdomain; Hc, heavy chain C-terminal 
subdomain; SNARE, soluble NSF-attachment protein receptors; VAMP, vesicle-associated membrane 
protein; SNAP-25, synaptosomal-associated protein of 25 kDa; ACh, acetylcholine; AChR, 
acetylcholine receptor.
retrogradely transported to the motomeuron cell 
body, from which it can access the inhibitory neurons 
of the spinal cord.
Pore formation
A candidate transmembrane region identified in 
BoNT/A increases the permeability of lipid 
bilayers [4]. Analysis of the crystal structure reveals 
that this region does not form a helix at neutral pH, 
although it may undergo structural rearrangement at 
low (i.e. endosomal) pH. The BoNT/A residues most 
likely to titrate at low pH, His551 and His560, are 
located in a loop connecting the translocation belt to 
the main body of the HN domain, which might 
rearrange exposing hydrophobic residues. There are 
several clusters of negative charge on the surface of 
the Hn domain that could be involved in belt 
movement and which could contribute to the 
structural changes that lead to pore formation [2].
BoNT/A and BoNT/B HN domains undergo 
conformational changes at low pH values, 
culminating in the formation of ion channels 
spanning artificial membranes, and the activity of the 
channels formed is maximal at endosomal pH [17]. 
Channels formed by BoNT/C in lipid membranes are
similar to those formed by diphtheria toxin and also 
only form at low pH [26]. BoNT channels are specific 
for cations (although not as highly specific as 
voltage-gated ion channels) but can be blocked 
in vitro by chloroquine.
However, it is not yet clear whether the channels 
formed by BoNTs are also the route by which the toxin 
LC enters the cytosol, because of the small pore size of 
the ion channels studied [18]. Data indicating that 
there is a dramatic change in LC structure at low 
pH [27] suggest that these conformational changes 
may lead to creation of an alternative LC structure 
that is more suited to translocation. Although this has 
not been determined in  vivo, the structural changes 
induced in BoNT/A-LC by low pH are completely 
reversible [27].
Unfortunately, pore formation is currently the 
least well understood step in the mechanism of BoNT 
action and further investigation is required to 
uncover the extent and implication of the structural 
changes that occur at low pH.
LC release and neurotoxin activation 
For BoNT to exert its effect on neurotransmission 
requires the activation of the inactive single-chain 
150-kDa toxin by proteolytic nicking within a 
surface-exposed loop at the LC-HN junction. Several 
bacterial and tissue proteases are able to perform this 
cleavage reaction to generate the active di-chain 
neurotoxin. Following nicking, the LC and HC remain 
associated through non-covalent interactions and a 
single disulfide bond. Reduction of this interchain 
disulfide bond (Cys430-Cys454 in BoNT/A) is the 
second stage of LC activation, and is necessary to 
render the LC free to enter the motomeuron cytosol 
and interact with substrate. As mentioned previously, 
there is a dramatic change in LC structure at low 
pH [27]. Such structural changes could contribute to 
the rearrangement of the translocation belt (if indeed 
the Hn domain is still in close proximity to the LC at 
the point of translocation) and lead to final activation 
oftheLC.
Interestingly, both the HC and LC ofTeNT and 
BoNT serotypes A, B and E are phosphorylated 
in  vitro by Src, leading to a marked increase in 
catalytic activity [28] and increased structural 
stability [29]. It has also been demonstrated that the 
more phosphorylation sites that are phosphorylated, 
the greater the increase in SNARE cleavage. These 
data indicate that neuronal signaling pathways could 
be intimately connected with BoNT-LC activity. It is, 
therefore, possible that completion of LC activation 
ultimately occurs in the cytosol following 
translocation from the low-pH compartment.
SNARE-protein cleavage and the catalytic mechanism 
BoNTs disrupt neurotransmission by cleaving 
SNARE proteins in a highly specific manner, no two 
serotypes cleave the same SNARE protein at the 
same peptide bond. In general terms, BoNTs A and E
http://tibs.trends.com
Review TRENDS in Biochemical Sciences 5
act on SNAP-25 (synaptosomal-associated protein of 
25 kDa); B0NT3 B, D, F and G cleave synaptobrevin 
(also known as vesicle-associated membrane protein, 
or VAMP); and BoNT Cx can act on both SNAP-25 and 
syntaxin. However, it has recently become clear that 
some SNARE proteins are insensitive to cleavage by 
specific BoNTs and that the above general statement 
can be misleading (reviewed in Ref. [20]). For 
example, the presence of TeNT-insensitive VAMP7 
(TI-VAMP) and BoNT B-, D-, F- and G-insensitive 
YAMP8 (endobrevin) [30] and SNAP-23 in a range of 
cells and their proposed roles in endocytosis and 
exocytosis does not support the simple interpretation 
of the relationship between SNAREs and CNTs. In  
several cases, for example human SNAP-23, 
resistance to cleavage by BoNT is determined by a 
single amino add substitution [31].
The specificity of BoNTs for their SNARE-protein 
substrate has been suggested to be because of their 
ability to recognize and interact with a nine-residue 
motif (the SNARE secondary recognition motif; SSR 
motif) within the SNARE protein. Indeed, there is 
evidence [31-34] for a requirement for all the 
BoNT LC domains to interact with one or more SSR 
motifs distant from the site of endopeptidase activity. 
The SSR motif occurs twice in synaptobrevin, twice in 
syntaxin and at four positions in SNAP-25, and these 
motifs are predicted to form amphipathic a-helices. 
The SSR motif is conserved throughout several 
spedes, which suggests that it is probably an essential 
part of SNARE function. Peptides corresponding to 
the nine-residue SSR motif have been shown to inhibit 
CNT action [32], indicating that these motifs are 
involved in substrate recognition by CNTs despite 
being distinct from the cleavage sites of the different 
toxins. The crystal structure of BoNT/B in complex 
with synaptobrevin 2 [35] also reveals the involvement 
of surface loops on the LC domain in binding the SSR 
motif at a site distal to the catalytic site.
The BoNT active site is buried (~20 A deep) in the 
LC, has negative surface charge and is accessible by a 
channel. The CNT active site contains a single zinc 
atom which has historically been proposed to have a 
functional, but not structural role, as the zinc can be 
removed by the use of metal chelators but reacquired 
by addition of free zinc without significant effects on 
the secondary structure [36]. However, recent studies 
investigating the potential structural role of the zinc 
atom in BoNT activity have been inconclusive [37-39]. 
TeNT would appear to be less restricted as the active 
site zinc atom can be exchanged with other divalent 
transition metals to form active toxin [40].
Residues His 222, Glu223 and His226 of 
BoNT/A form part of the conserved HExxH motif 
characteristic of zinc proteases and contribute 
directly to the reaction mechanism through 
co-ordination of the active site zinc (His 222 and 
His226) and a water molecule (Glu223). Glu261 is the 
third ligand to co-ordinate the zinc [4,41]. The 
catalytic mechanism of BoNT/A is proposed to be
similar to that of thermolysin [42] based on structural 
and sequence similarities between their active sites. 
Mutation of Glu223 to Asp leads to almost total loss of 
activity [43] and removal of His226 abolishes the 
catalytic activity of BoNT/A [44]. Analysis of the 
structure of BoNT/B has confirmed that the key 
residues involved in the mechanism of action are 
identical to those observed in BoNT/A. The crystal 
structure of BoNT/B bound to synaptobrevin 2 reveals 
that residues Arg369 and Tyr372 are located in the 
proximity of the peptide bond cleaved by the toxin [35]. 
These residues are strictly conserved throughout all 
CNTs, and the equivalent residues in TeNT (Glu271 
and Tyr375) have been shown, by site-directed 
mutagenesis, to be involved in protease activity [45]. 
Mutation of the corresponding residues in BoNT/A 
(Arg362 and Tyr365 to alanine and phenylalanine, 
respectively) dramatically reduces k ^ , but does not 
affect zinc binding or substrate binding [46], and it 
has been proposed that these residues are involved in 
transition state stabilization.
At the presynaptic nerve terminal, the core of the 
SNARE complex is stabilized by a bundle of four 
tightly packed helices [47], one from SNAP-25, one 
from syntaxin and two from synaptobrevin. The 
hydrophobic residues within these helices are 
conserved in the SNARE proteins and are known as 
the SNARE motif (this is distinct from the SSR motif 
mentioned previously). The SNARE complex is 
extremely stable and must be actively disassembled 
following neurotransmitter release. The structure of 
BoNT/B in complex with synaptobrevin 2 [35] 
revealed that the SNARE motif fits into the active site 
in a random coil conformation. In the SNARE 
complex, this motif is helical and cannot enter the 
active site. This explains why BoNTs can only act on 
free SNAREs and suggests a role for BoNTs in 
mopping up free SNAREs in solution (see Ref. [48] for 
a discussion on the action of clostridial neurotoxins on 
SNARE assembly).
Duration o f activity
The extended duration of BoNT effects at the 
neuromuscular junction is one of the key features that 
has driven the widespread use of BoNT as a 
therapeutic agent. However, there are significant 
differences in the in vivo duration of effect between 
the different BoNTs. This has been most fully studied 
through a comparison of the effects of BoNT/A and 
BoNT/E. BoNT/A induces long-term inhibition 
(months) whereas recovery from BoNT/E effects is 
rapid (weeks) [1]. The debate as to the reason for the 
disparity between BoNTs has centered around two 
hypotheses: first, that the BoNT/A-truncated 
SNAP-25 product persists in the SNARE complex and 
interferes with neuro transmitter release; second, 
there is a difference in the life-time of the LC in the 
cytosol, with BoNT/A persisting for longer than 
BoNT/E. These two hypotheses are not mutually 
exclusive, and recent findings support the view that
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both persistence of the LC and effects of the truncated 
product have a role [49]. However, it is important to 
note that the biochemistry of BoNT action is not the 
only factor that determines longevity of effect. There 
is a significant contribution from the biology of the 
system in which the rate, frequency and success of 
nerve sprouting have a role to play in determining the 
rate of recovery (reviewed in Ref. [21]).
Medical applications of BoNTs
Despite being extremely poisonous to humans,
BoNTs are highly effective therapeutic agents and 
accomplished research tools. It  was observed at the 
beginning of the 20th century that, by injection of 
botulinum toxin, localized paralysis of individual 
muscle groups could be achieved without causing 
botulism in the recipient (reviewed in Ref. [50]). 
Preparations of BoNT/A have been approved by 
the US Food and DrugAdministration as a 
biopharmaceutical for use in treating strabismus, 
blepharospasm and hemifacial spasm. However, the 
use of BoNT has now extended to cover a wide variety 
of disorders [51], including those that do not have a 
neuromuscular basis. For example, the effects of 
BoNT on the autonomic nervous system have resulted 
in its use as an effective treatment for axillary 
hyperhidrosis [52] (sweating), and some success has 
been reported for the treatment of myofascial 
pain [53] and tension and migraine headaches [54].
However, as with any therapeutic agent, there 
are some side effects associated with the use of 
BoNT/A [50,51] such as dysphagia (following 
injections into the neck muscles), although 
weakening of surrounding muscles is rare. Inherent 
in the use of a protein-based therapeutic is the 
potential for antibody formation leading to a decrease 
in effectiveness of the treatment. Such secondary 
non-responders are seen in a relatively low 
percentage of patients, most commonly with patients 
requiring large doses of BoNT, often on repeated 
occasions. Patients immune to BoNT/A might benefit 
from injection with serotypes B and F, although this 
has yet to be proven and, as discussed previously, the 
duration of effect of each serotype differs. BoNT/C, 
shown to induce paralysis as long-lasting as that 
caused by BoNT/A [55], might be developed into a 
valid alternative therapy. Since the majority of the 
immune response is generated toward the Hc 
fragment, future protein engineering of hybrid toxins 
could provide one route to prolong the therapeutic 
efficacy of BoNT treatment.
Future directions
Although some progress has been made in recent 
years, identification and characterization of the 
protein receptors for the BoNTs and determination of 
the mechanism of specificity of CNT binding domains 
for their receptors is an outstanding problem. 
Furthermore, understanding the mechanism of LC 
translocation and activation within the motomeuron, 
including the effects of pH on the tertiary structures 
of BoNTs, will be crucial for rationed design of 
engineered BoNT therapeutics. Further structural 
studies on the endopeptidase domains of BoNTs and 
TeNT, including the structural basis behind BoNT 
substrate specificity, might lead to the development of 
serotype-specific inhibitors. It  is clear that the 
headway made in the structural knowledge of BoNT 
and TeNT has already paid dividends in the 
understanding of these complex proteins, and it is 
essential that future assessment of the mechanism of 
BoNT action take into account functionally relevant 
domains of the toxins, in functionally relevant 
physiological conditions.
Use of fragments of BoNT for the therapeutics of 
the future is also exciting. For example, harnessing 
the properties of the BoNT LC endopeptidase 
fragments for the creation of a range of‘designer’ 
therapeutics is a reeil possibility following the 
successful retargeting of the LC/A domain to cells of 
neuronal [56] and non-neuronal [57] origin. 
Additionally, the ability of BoNTs to transport large 
polypeptides across the membranes could be 
harnessed for the delivery of biopharmaceuticals to 
cytosolic targets [58]. TeNT conjugates have been 
used to transport DNA [59] and enzymes [60] 
into neurons, and derivatives of BoNT/A and 
BoNT/B can target compounds specifically to 
human neuroblastoma cells [61]. The bacterium 
C. botulinum itself might also be useful in treating 
cancer -  apathogenic Clostridia specifically colonize 
hypoxic areas of tumors [62] and might be useful for 
transporting anti-cancer drugs specifically into 
tumor cells [63].
It  can be seen that the botulinum neurotoxins are 
of great interest to the medical and scientific 
communities. Despite causing disease, they have 
become valuable research tools and have wide- 
ranging applications as pharmaceuticals. As the 
structure and mechanism of action of the toxins are 
further dissected, the development of vaccines, 
serotype-specific inhibitors and novel therapeutics 
will undoubtedly follow.
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APPENDIX FOUR 
FRAGMENTS OF BOTULINUM NEUROTOXIN A
SEQUENCE ALIGNMENT OF CLOSTRIDIAL NEUROTOXINS 
EXPRESSION AND PURIFICATION OF LHN/A 
CRYSTALLIZATION CONDITIONS REPORTED FOR CNTs 
CRYSTALLIZATION CONDITIONS REPORTED FOR Zn2+ PROTEASES 
ANALYSIS OF CD SPECTRA
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Sequence Alignment of the Eight Clostridial Neurotoxins
The amino acid sequences of botulinum neurotoxins A-G and tetanus neurotoxin were obtained from the Entrez SeqSearch database, 
(www.ncbi.nim.nih.gov:80/entrez) and aligned using clustalw 1.8 (Thompson et al. 2003).
There is 30-40% sequence similarity among the clostridial neurotoxins. The three functional domains of BoNT/A have been coloured separately - 
the catalytic domain in red; the translocation domain in blue; and binding domain in green. Residues that are completely conserved among all the 
sequences are highlighted in yellow and conservatively substituted residues are indicated in bold type. The majority of conserved residues are 












































































































































































































BoNT/A ITSKTKSLDK G--- YNKAL NDLCIKVNNW DLFFSPSEDN
BoNT/B AP-------- -GICIDVDNE DLFFIADKNS
BoNT/Cl DGRSL---- ---- YNKTL DCRELLVKNT DLPFIGDISD
BoNT/D K--------- ----- NSRD DSTCIKVKNN RLPYVADKDS
BoNT/E SVKG------ ------IRKS --ICIEINNG ELFFVASENS
BoNT/F PRKG------ ------TKAP PRLCIRVNNS ELFFVASESS
BoNT/G YKN------- -------TGK SEQCIIVNNE DLFFIANKDS
TeNT PPTNIRENLY NRTASLTDLG GELCIKIKNE DLTFIAEKNS
BoNT/A SSDIIGQLEL MPNIERFPNG KKYELDKYTM FHYLRAQEFE
BoNT/B DFN-V--DVP VYEKQ--PAI KKIFTDENTI FQYLYSQTFP
BoNT/Cl SES--- EIL PGENQVFYDN RTQNVDYLNS YYYLESQKLS
BoNT/D MEP--- LNL PGEEIVFYDD ITKYVDYLNS YYYLESQKLS
BoNT/E QND-A--YIP KYDSNGTSDI EQHDVNELNV FFYLDAQKVP
BoNT/F QDN-S--YVP RYDSNGTSEI EEYDWDFNV FFYLHAQKVP
BoNT/G NFDDI--DIP VYIKQ--SAL KKIFVDGDSL FEYLHAQTFP
TeNT KGIP-- YAP EYKSNAASTI EIHNIDDNTI YQYLYAQKSP
BoNT/A VYDFTDETSE VSTTDKIADI TIIIPYIGPA LNIGNMLYKD
BoNT/B VNDFVIEANK SNTMDKIADI SLIVPYIGLA LNVGNETAKG
BoNT/Cl VEDFTTNILR KDTLDKISDV SAIIPYIGPA LNISNSVRRG
BoNT/D VEDFTTNIMK KDTLDKISDV SVIIPYIGPA LNIGNSALRG
BoNT/E LVDFTTEANQ KSTVDKIADI SIWPYIGLA LNIGNEAQKG
BoNT/F IRDFTTEATQ KSTVDKIADI SLIVPYVGLA LNIIIEAEKG
BoNT/G IDDFTSESTQ KSTIDKVSDV SIIIPYIGPA LNVGNETAKE
TeNT IDDFTNESSQ KTTIDKISDV STIVPYIGPA LNIVKQGYEG
FTNDLNKGEE ITSDTNIEAA EENISLDLIQ QYYLTFNFDN EPENISIENL 
FSDDLSKNER IEYNTQSNYI ENDFPINELI LDTDLISKIE LPSENTESLT 
VKTDIFLRKD INEETEVIYY PDNVSVDQVI LS-KNTSEHG QLDLLYPSID 
ISQEIFENKI ITDETNVQNY SDKFSLDESI LDGQVPINPE IVDPLLPNVN 
YNDDNINTPK EIDDTVTSNN NYENDLDQVI LNFNSESAPG LSDEKLNLTI 
YNENDINTPK EIDDTTNLNN NYRNNLDEVI LDYNSQTIPQ ISNRTLNTLV 
FSKDLAKAET IAYNTQNNTI ENNFSIDQLI LDNDLSSGID LPNENTEPFT 
FSEEPFQDEI VSYNTKNKPL NFNYSLDKII VDYNLQSKIT LPNDRTTPVT
HGKSRIALTN SVNEALLNPS RVYTFFSSDY VKKVNKATEA AMFLGWVEQL 
LDIRDISLTS SFDDALLFSN KVYSFFSMDY IKTANKWEA GLFAGWVKQI 
DNVEDFTFTR SIEEALDNSA KVYTYFPTLA NKVN-AGVQG GLFLMWANDV 
NNVENITLTT SVEEALGYSN KIYTFLPSLA EKVN-KGVQA GLFLNWANEV 
EGENNVNLTS SIDTALLEQP KIYTFFSSEF INNVNKPVQA ALFVSWIQQV 
EGETNISLTS SIDTALLEES -KDIFFSSEF IDTINKPVNA ALFIDWISKV 
SNIENLQLTN SLNDALRNNN KVYTFFSTNL VEKANTWGA SLFVNWVKGV 
TTLQRITMTN SVDDALINST KIYSYFPSVI SKVN-QGAQG ILFLQWVRDI
DFVGALIFSG AVILLEFIPE IAIPVLGTFA LVSYIAN  KVLTVQTIDN
NFENAFEIAG ASILLEFIPE LLIPWGAFL LESYID--N KNKIIKTIDN
NFTEAFAVTG VTILLEAFPE FTIPALGAFV IYSKVQ-- E RNEIIKTIDN
NFNQAFATAG VAFLLEGFPE FTIPALGVFT FYSSIQ--E REKIIKTIEN
NFKDALELLG AGILLEFEPE LLIPTILVFT IKSFLGSSDN KNKVIKAINN 
NFEEAFELLG VGILLEFVPE LTIPVILVFT IKSYIDSYEN KNKAIKAINN
NFKNAFEIGG AAILMEFIPE LIVPIVGFFT LESYVG--N KGHIIMTISN



























































































































BoNT/A HEYTIINCME ---- NNSGW KVSLNYG-- EIIWTLQDTQ
BoNT/B NEYTIINCMK ---- NNSGW KISIRGN-- RIIWTLIDIN
BoNT/Cl -GYTIIDSVK ---- NNSGW SIGIISN-- FLVFTLKQNE
BoNT/D -EYTIINSIE ---- QNSGW KLCIRNG-- NIEWILQDVN
BoNT/E NEYTIINCMR D--- NNSGW KVSLNHN-- EIIWTFEDNR
BoNT/F REYTIINCMG N--- NNSGW KISLRTVRDC EIIWTLQDTS
BoNT/G NEYTIISCIK ---- NDSGW KVSIKGN-- RIIWTLIDVN
TeNT NEYSIISSMK KHSLSIGSGW SVSLKGN-- NLIWTLKDSA
BoNT/A SNLGNIHASN NIMFKLDGCR DT-------- HRYIWIKYFN
BoNT/B KDIREVIANG EIIFKLDGDI DR-------- TQFIWMKYFS
BoNT/Cl KELTGINFSK TITFEINKIP DTGLITSDSD NINMWIRDFY
BoNT/D EDLDEVKLDK TIVFGIDENI DE-------- NQMLWIRDFN
BoNT/E LNLGNIHVSD NILFKIVNCS Y--------- TRYIGIRYFN
BoNT/F SNLGDIHVSD NILFKIVGCD D--------- ETYVGIRYFK
BoNT/G LNLDRINSSN DIDFKLINCT DT-------- TKFVWIKDFN
TeNT TGLGAIREDN NITLKLDRCN NN-------- NQYVSIDKFR
BoNT/A DVNNVGIRGY MYLKGPRGSV MTTNIYLNSS LYRGTKFIIK
BoNT/B KLKKDSPV-- GEILTRSKYN QNSKYINYRD LYIGEKFIIR
BoNT/Cl YANSRQIV-- FNTRRNNNDF NEGYKIIIKR IRG--NTNDT
BoNT/D APESNVLV-- LVQYPDRSKL YTGNPITIKS VSD--KNPYS
BoNT/E DRRK------ --DSTLSINN IRSTILLANR LYSGIKVKIQ
BoNT/F TLNSGI--- -LNINQQRGV TEGSVFLNYK LYEGVEVIIR
BoNT/G KYFSKASM-- GETAPRTNFN --NAAINYQN LYLGLRFIIK
TeNT QLKNITDY-- MYLTNAPSYT NGKLNIYYRR LYNGLKFIIK
EIKQRWFKY SQMINISDYI NRWIFVTITN NRLNNSKIYI NGRLIDQKPI 
GKTKSVFFEY NIREDISEYI NRWFFVTITN N-LNNAKIYI NGKLESNTDI 
DSEQSINFSY DISNNAPGYN -KWFFVTVTN NMMGNMKIYI NGKLIDTIKV 
RKYKSLIFDY SESLSHTGYT NKWFFVTITN NIMGYMKLYI NGELKQSQKI 
GINQKLAFNY GNANGISDYI NKWIFVTITN DRLGDSKLYI NGNLIDQKSI 
GNKENLIFRY EELNRISNYI NKWIFVTITN NRLGNSRIYI NGNLIVEKSI 
AKSKSIFFEY SIKDNISDYI NKWFSITITN DRLGNANIYI NGSLKKSEKI 
GEVRQITFRD LPDKFNAYLA NKWVFITITN DRLSSANLYI NGVLMGSAEI
LFDKELNEKE IKDLYDNQSN SGILKDFWGD YLQYDKPYYM LNLYDPNKYV 
IFNTELSQSN IEERYKIQSY SEYLKDFWGN PLMYNKEYYM FNAGNKNSYI 
IFAKELDGKD INILFNSLQY TNWKDYWGN DLRYNKEYYM VNIDYLNRYM 
IFSKELSNED INIVYEGQIL RNVIKDYWGN PLKFDTEYYI INDNYIDRYI 
IFDKELDETE IQTLYSNEPN TNILKDFWGN YLLYDKEYYL LNVLKPNNFI 
VFNTELDKTE IETLYSNEPD PSILKNYWGN YLLYNKKYYL FNLLRKDKYI 
IFGRELNATE VSSLYWIQSS TNTLKDFWGN PLRYDTQYYL FNQGMQNIYI 
IFCKALNPKE IEKLYTSYLS ITFLRDFWGN PLRYDTEYYL IPVASSSKDV
KYAS GNK DNIVRNNDRV YINVWKNKE YRLATNASQA GVEKILSALE
RKSNSQSIN- DDIVRKEDYI YLDFFNLN-Q EWRVYTYKYF KKEEEKLFLA 
RVRGGDILYF DMTINNKAYN LFMKNETMYA DNHSTEDIYA IGLREQTKDI 
RILNGDNIIL HMLYNSRKYM IIRDTDTIYA TQGGECSQNC VYALKLQSNL 
RVN--NSSTN DNLVRKNDQV YINFVASKTH LFPLYADTAT TNKEKTIKIS 
KNGPIDISNT DNFVRKNDLA YINWDRGVE YR-LYADTKS E-KEKIIRTS 
KASNSRNINN DNIVREGDYI YLNIDNISDE SYRVYVLVNS KEIQTQLFLA 
RYTPNNEIDS FVKSGDFIKL YVSYNNNEHI VGYPKDGNAF NNLDRILRVG
IV)O
BoNT/A IPDVGNLSQV WMKSKNDQG ITNKCKMNLQ DNNGNDIGFI G  -FHQFNNIAK LVASNWYNRQ IERSSR--TL GCSWEFIPVD
BoNT/B PISDSDEFYN TIQIKEYDEQ PTYSCQLLFK KDEESTDEIG LIGIHRFYES GIVFEEYKDY FCISKWYLKE VKRKPYNLKL GCNWQFIPKD
BoNT/Cl NDN--IIFQI QPMNNTYYYA SQIFKSNFNG ENISGIC  ----------  --SIGTYRFR LGGDWYRHNY LVPTVKQGNY ASLLESTSTH
BoNT/D GNYGIGIFSI KNIVSKNKYC SQIFSS-FRE NTMLLAD  ---------- --IYKPWRFS FKNAYTPVAV TNYETKLLST SSFWKFISRD
BoNT/E SSGNR--FNQ WVMNSVG-N CTMNFKNNNG NNIG------ ---------- --LLGFKADT WASTWYYTH MRDHTN--SN GCFWNFISEE
BoNT/F NLNDS--LGQ IIVMDSIGNN CTMNFQNNNG SNIG------ ---------- --LLGFHSNN LVASSWYYNN IRRNTS--SN GCFWSSISKE
BoNT/G PINDDPTFYD VLQIKKYYEK TTYNCQILCE KDTKTFGLFG IG--KFVKDY GYVWDTYDNY FCISQWYLRR ISENINKLRL GCNWQFIPVD










Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
Flowchart Outlining the Steps Involved in the Recombinant Expression and
Purification of LHN/A
(as described in Chaddock et al, 2002)
The pGEX-4T-2 expression vector was modified to incorporate strong rrnB 
transcriptional terminators downstream of the cloning site and the strong trc promoter.
4
The expression cassette was constructed using three sources of DNA:
Bases 1-913 -  synthetic DNA exhibiting an E.coli codon bias;
Bases 914-1138 and 1977-2616 -  derived from PCR amplification from clostridial DNA; 
Bases 1139-1976 -  obtained by direct cloning of chromosomal DNA.
4,
pGSTLHN/A was transformed into E.coli TG1 cells, which were grown in Terrific broth 
at 30°C to an OD6oo of 8.0. Expression of recGSTLHN/A was induced by the addition of 
0.5mM IPTG and a reduction in temperature to 25°C.
4
After 4 hours, the cells were harvested by centrifugation. Purification of recLHN/A from 
the cell paste utilised ion-exchange and affinity FPLC separation techniques.
4
The initial capture step consisted of a glutathione-Sepharose 4B column immediately 
preceded by a Q-Sepharose-FF column connected in tandem. The glutathione- 
Sepharose 4B column was eluted with 10mM reduced glutathione and the resulting 
fractions were pooled and dialysed against 25mM Bis-Tris, pH 6.0.
4
The dialysed material was treated with 0.1 mg trypsin/mg protein for 30 mins at 37°C to 
remove the GST expression tag and cleave the LC-HN junction (thus activating LHN/A).
4
Trypsin-treated material was purified using a Q-Sepharose 4B column in tandem with a 
glutathione-Sepharose 4B column. The material was passed through the glutathione- 
Sepharose column first to remove the GST tag and uncleaved, GST-tagged protein. 
recLHN/A-containing fractions were pooled, concentrated and stored at -20°C.
203
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
Conditions Reported for the Crystallization of a Variety of Clostridial 
Neurotoxins and Clostridial Neurotoxin Fragments
B oN T /A 1 .5M  sod ium  fo rm a te S tevens  e t a l. 1991
B oN T /A 10%  PE G  4000
0.2M  m agnes ium  ch lo ride
S tevens  e t a l. 1991
B oN T /A 0 .8M  sod ium  p o tass ium  ta rtra te  
0.1 M H epes, pH 8 .5
S tevens  e t a l. 1991
B oN T /A 0 .1 5M  m agnes ium  ace ta te  
11%  PE G  4000  
0 .1M  T ris , pH  7.0
Lacy e t a l. 1998
B oN T /A 30%  PE G  600 
0.1 M T ris , pH  7.0
Lacy and  S te ve n s  1999
Bo N T /A -H n 0.1 M T ris , pH 8 .5
0.1 M m agnes ium  fo rm a te
1m M  sod ium  azide
Lacy and  S tevens  1997
B oN T /A -LC  m in im a l 
e sse n tia l dom a in
25%  PEG  4000
0.1 M sod ium  ace ta te , pH 4 .6
3%  xy lito l
K a dkhodayan  e t al. 2000
B oN T/B 5m M  c itr ic  ac id , pH 5.6 
10m M  sod ium  phospha te
F licke r e t a l. 1999
B oN T /B PE G  6000 
0.1 M M ES pH 6.0
S w am ina than  and E sw a ra m o o rth y  
2 000a
B oN T /B 10%  PE G  4000  
0.1 M M ES, pH 6.0
S w am in a th an  and E sw a ra m o o rth y  
2 0 0 0b
B oN T /B -syn ap to b rev in  II 0.1 M H epes, pH 7 .0 -7 .5  
15-25%  P E G  4000
H anson  and S tevens  20 0 0
T eN T -H c 0.2M  am m on ium  su lpha te  
40%  PE G  4000  
1% M PD
E m sley  e t a l. 2000
T eN T -H c 20%  PEG  4000
0.2M  im idazo le -m a la te , pH 7.0
F o tinou  e t al. 2001
T eN T -H c 20%  PEG  8000
0.2M  sod ium  po tass ium  phospha te  
0.1 M T ris , pH 8.5
F o tinou  e t a l. 2001
These conditions, reported for several clostridial neurotoxins and clostridial neurotoxin 
fragments, were used in crystallization experiments on LHN/A and LHN/A(H227Y).
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Conditions Reported for the Crystallization of Zinc Proteases
0.1 M H epes, pH 7.0
0.1 M p o tass ium  th io cya n a te
4.5M  sod ium  ch lo ride
A m in o p e p tid a se C h e vrie r e t al (1994 ) S tru c tre , 2, 
283-291
0.1 -3 .0M  so d iu m  ch lo ride  
10m M  im id a zo le  pH 7 .0
A spz inc in Hori e t a l (2001 ) A c ta  C rys ta llog r, 
D 57, 3 6 1 -368
22%  PEG  40 0 0  
5 -10%  g lyce ro l 
5-1 OmM ca lc iu m  ch lo ride
D N A  po lym e ra se  I I I B a rnes e t al (1998 ) B iochem is try , 
37, 15254 -15260
0.1 M im idazo le , pH 6 .8  
10m M  ca lc iu m  ch lo ride  
2 .4M  a m m on ium  su lp h a te
A tro lys in  C Z hang  e t al (1994) P N A S , 91, 
8447-8451
5-12%  PEG  4000  
10% g lyce ro l 
20m M  z inc  su lp h a te
D N A  po lym e ra se  I I I B a rnes e t al (1998 ) B iochem is try , 
37, 15254 -15260
20%  PEG 8000  
0.1 M z inc  a ce ta te  
0.1 M P ipes, pH 6.1
N erve  g row th  fa c to r H o lland  e t a l (1994 ) J M ol B iol, 
239 , 385 -4 0 0
30%  PEG 8000
0.1 M am m on ium  su lp h a te
0.1 M sod ium  c itra te , pH 6 .3
5 0kD a  m e ta llo p ro tea se B aum ann  (1994 ) J M ol B io l, 242, 
244-251
20-24%  P E G  8000  
2 .5%  isop ropano l 
10m M  ca lc iu m  ch lo ride  
0.1M  T ris -H C I, pH 7 .5 -8 .5
S tro m e lys in  ca ta ly tic  dom a in C hen e t a l (1999 ) J M ol B io l, 293, 
545 -557
0.2M  am m on ium  su lp h a te  
0.1 M sod ium  ca co d y la te , pH 
6.5
15-30%  PE G  8000
C o lla g e n ase  ca ta ly tic  dom a in Love joy  e t a l (1994 ) S c ie n ce , 263, 
3 7 5 -377
0.1 M H epes, pH 7 .5  o r  8.2 
0.3M  sod ium  ch lo ride  
22%  PEG  5000  M M E
H um an th ro m b in  com p le xe s B rad ley  e t al (2001 ) J M ol B iol, 
301, 1451-1486
0.1 M sod ium  ace ta te , pH 4 .6  
2.0M  sod ium  fo rm a te
P ep tide  de fo rm y la se C han e t a l (1997 ) B iochem is try , 
36, 13904 -13909
50m M  M ES, pH 5 .5  
0 .5M  a m m on ium  su lp h a te  
1% tr ifluo ro e tha n o l
S trom e lys in -3  ca ta ly tic  dom a in G all e t al (2001 ) J M ol B io l, 307, 
5 7 7 -586
1.3M a m m on ium  su lp h a te  
0.1 M T ris -H C I, pH 7 .5
6 -pyruvo l te tra h yd ro p te rin  syn thase N ar e t a l (19 9 4 ) E M B O  J, 13, 
1255-1262
2.0M  sod ium  fo rm a te  
1mM ca lc ium  ch lo ride
C o llagenase  19kD a ca ta ly tic  dom a in Love joy  e t al (1994 ) B iochem is try , 
33, 8 2 0 7 -8 2 1 7
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50mM zinc chloride 
0.1 M Tris, pH 8
20% PEG 8000
25mM sodium citrate, pH 5.6
0.1 M zinc acetate
P-lactamase Carfi et al (1998) Acta Crystallogr, 
D54, 313-323
20% PEG 400 
10% isopropanol




0.1 M sodium citrate, pH 5.4
Catalytic domain of TNFa- 
converting enzyme




0.1 M sodium citrate, pH 6.5
Human uPA complexes Bradley et al (2001) J Mol Biol, 
301,1451-1486
20% PEG 4000 
Tris-HCI, pH 7.5
Acutolysin Zhu et al, (1999) Acta Crystallogr, 
D55, 1834
20% PEG 6000 
0.5M sodium chloride 
0.1 M calcium chloride 
0.2M MES, ph 6.0 
0.02% sodium azide
Collagenase catalytic domain Bode et al (1994) EMBO J, 13, 
1263-1269
In addition, two drops were set up with mother liquor comprising 50mM sodium acetate, 
pH 4.6, 10mM zinc sulphate and 15% PEG 4000, as this had previously been used by 
another member of the lab to crystallize a zinc-containing protein.
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Secondary Structure Compositions of LHN/A and LHN/A(H227Y) at pH 7.0
l h n/a CDSSTR 3 34 19 19 28
CONTINLL 3 32.6 19.9 18.5 29.1
SELCON3 3 32.5 16.8 21.2 30.5
CDSSTR 6 34 16 18 32
CONTINLL 6 30.3 16.9 16.1 36.8
SELCON3 6 32.4 16.9 21.1 30.5
LHn/A(H227Y) CDSSTR 3 35 20 18 26
CONTINLL 3 34.3 20 17.3 28.4
SELCON3 3 33 16.8 20.2 31.1
CDSSTR 6 35 19 18 29
CONTINLL 6 30.8 19 16.7 33.5
SELCON3 6 33.1 16.7 20 31.3
The percentage of residues involved in each of the four secondary structural elements 
(a-helix, p-strand, p-turn and random coil), as analysed by the programs CDSSTR, 
CONTINLL and SELCON3 with protein reference sets 3 and 6, are presented.
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Analysis of Far-UV CD Spectra Recorded for LHN/A
expermental data 
reconstructed data 
difference (exp - recon)
experimental data 
reconstructed data 












difference (exp - recon)
SELCON3
Graphical analyses of the CD spectra recorded for LHN/A using CDSSTR, CONTINLL
and SELCON3. The panels on the left represent spectra analysed using protein
reference set 3 and those on the right with reference set 6..
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difference (exp - recon)
expertdental data 
reconstructed data 
difference (exp - recon)





Graphical analyses of the CD spectra recorded for LHN/A(H227Y) using CDSSTR,
CONTINLL and SELCON3. The panels on the left represent spectra analysed with
protein reference set 3 and those on the right were analysed with reference set 6..
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Secondary Structure of LHN/A(H227Y) at pH 7.0 and pH 5.0
CDSSTR 3 7 35 17 19 29
CONTINLL 3 7 34.4 16 19.7 30.3
SELCON3 3 7 32.8 17.6 20.5 29.2
CDSSTR 6 7 35 15 18 31
CONTINLL 6 7 32.1 12.4 15.8 39.8
SELCON3 6 7 32.9 17.6 20.3 29.2
CDSSTR 3 5 34 17 19 29
CONTINLL 3 5 29.9 19.8 18.7 31.6
SELCON3 3 5 33.3 16.1 20.9 30.7
CDSSTR 6 5 35 16 17 34
CONTINLL 6 5 29 16.4 14.3 40.3
SELCON3 6 5 33.3 16.1 20.9 30.7
The percentage of residues involved in secondary structural elements (helix, strand, 
turn and random coil), as analysed using the programs CDSSTR, CONTINLL and 
SELCON3 with protein reference sets 3 and 6, are presented.
212
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A










100 190 203 210 213 220 223 230 235 240200 210 220 230 240 190 195 200
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230 240100 190 200 210 220 230 240 100 190 200 220
Graphical analyses of the CD spectra recorded for LHN/A(H227Y) at pH 5.0 using
CDSSTR, CONTINLL and SELCON3. Panels on the left represent those analysed with
protein reference set 3 and those on the right with reference set 6.
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210 220 229 230 240220 230 240 190 199 200 209180 190 200
SELCON3
o 10000
Graphical analyses of the CD spectra recorded for LHN/A(H227Y) at pH 7.0 using
CDSSTR, CONTINLL and SELCON3. The panels on the left represent those spectra
analysed with protein reference set 3 and those on the right with reference set 6.
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APPENDIX FIVE 
BRIEF DESCRIPTION OF COMPUTER PROGRAMS
PROGRAMS FOR SEQUENCE ANALYSIS
PROGRAMS FOR PROCESSING X-RAY DIFFRACTION DATA
PROGRAMS FOR MOLECULAR REPLACEMENT
PROGRAMS FOR MODEL BUILDING AND REFINEMENT
IMAGING PROGRAMS
PROGRAMS FOR STRUCTURAL ANALYSIS
PROGRAMS FOR CD SPECTRUM ANALYSIS
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PROGRAMS FOR SEQUENCE ANALYSIS:
CLUSTAL W (version 1.8) (Thompson et al. 1994)
www.ebi.ac.uk/clustalw/
This is a web-based, general purpose multiple alignment program for proteins 
or DNA. Clustal W can perform multiple sequence alignments and profile alignments 
and can also be used to produce phylogenetic trees.
PROTPARAM (Gill and von Hippel 1989)
http://ca.expasy.Org/tools/#protparam.html
A web-based tool for the computation of various physical and chemical 
parameters (including molecular weight, theoretical pi, amino acid composition, atomic 
composition, extinction coefficient, estimated half-life, instability index and grand 
average of hydropathicity) for a given protein sequence.
PROGRAMS FOR PROCESSING X-RAY DIFFRACTION DATA:
HKL2000 (Otwinowski and Minor 1997)
The HKL Suite is a package of programs intended for the analysis of X-ray 
diffraction data collected from single crystals. It consists of three programs: XDisplayF 
for visualisation of the diffraction pattern; Denzo for data reduction and integration; and 
Scalepack for merging and scaling of the intensities.
DENZO and XDISPLAYF (Otwinowski and Minor 1997)
These are programs for the visualisation and preliminary analysis of original, 
unprocessed diffraction data. Diffraction patterns are indexed, crystal and detector 
parameters are refined and diffraction maxima are integrated. Denzo takes raw X-ray 
diffraction data and reduces them to a file containing the h,k,l indexes and background 
and L-P corrected intensity of the spots on the image, and an estimate of the error.
SCALEPACK (Otwinowski and Minor 1997)
Scalepack finds the relative scale factors between measurements, precisely 
refines crystal parameters using the entire data set and performs merging and 
statistical analysis of measurements related by space group symmetry.
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SCALEPACK2MTZ and TRUNCATE
This program (part of the CCP4 Suite) converts the merged data output from 
Scalepack into MTZ format. After the conversion, the Truncate program (also part of 
the CCP4 program suite) is used to convert the intensities to structure factor 
amplitudes. Truncate obtains structure factor amplitudes and/or generates useful 
intensity statistics. Truncate is normally used to read a file of averaged intensities and 
write a file containing mean amplitudes and the original intensities. The amplitudes are 
put on an approximate absolute scale using the scale factor taken from a Wilson plot.
MTZ2XPLOR
The Mtz2various program is part of the CCP4 Suite and is used to convert the 
output from Scalepack2mtz into a variety of other formats. Mtz2xplor reads the MTZ 
file and produces an ASCII file in a suitable form for X-PLOR/CNS. The ASCII file may 
contain amplitudes, intensities or differences.
PROGRAMS FOR MOLECULAR REPLACEMENT 
6D.MOLEMAN
A program for manipulation and analysis of PDB files. Applications include 
chain renumbering (two digits) and truncation of amino acid side chains to alanine and 
glycine.
MATTHEWS_COEF
Part of the CCP4 Suite, this program calculates the Matthews coefficient (Vm) 
and solvent content of the crystal from the unit cell dimensions (in Angstroms) and the 
molecular weight (in Daltons) of the molecules in the unit cell.
AMORE (Navaza 1994)
AMoRe contains a set of programs for molecular replacement: ROTING 
determines the rotations that superimpose a search molecule upon the homologous 
ones within the target crystal by calculating the overlap within a conveniently chosen 
region of volume of the observed Patterson function and a rotated version of the 
Patterson function corresponding to the isolated search molecule. TRAING selects the 
possible translations of an oriented model. FITING performs rigid-body refinement.
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Other programs reformat the observed data from the new crystal form, and generate 
and tabulate structure factors from the model in a large P1 cell.
PROGRAMS FOR MODEL BUILDING AND REFINEMENT
MAKE_CV (Brunger 1992)
Part of the CNS Suite of programs, make_cv sets up a test array for cross- 
validation (Rfree) using a random selection of data (usually 5-10% of the recorded data).
GENERATE and GENERATE_EASY
These programs are both part of the CNS Suite. Generate_easy generates 
coordinate and structure files for simple, commonly encountered protein models 
(disulphide bonds are automatically determined by distance). Generate can be used to 
generate a structure file for a model containing protein, DNA/RNA, water, ligands 
and/or carbohydrate (i.e. more complex than models that can be handled by 
generate_easy).
RIGID (Brunger 1992; Pannu and Read 1996; Adams et al. 1997)
Part of the CNS Suite of programs, rigid performs crystallographic rigid body 
refinement, which is usually the first step in the refinement procedure. A rigid geometry 
is assigned to parts of the structure (or to the whole molecule) and the parameters of 
these regions are refined as a rigid group (instead of refining the individual atomic 
parameters).
MINIMIZE (Brunger 1992; Pannu and Read 1996; Adams et al. 1997)
Part of the CNS Suite, the minimize program performs crystallographic 
conjugate gradient minimization refinement to reduce differences between calculated 
and observed reflection amplitudes.
BIN DIVIDUAL (Brunger 1992; Pannu and Read 1996)
Part of the CNS Suite of programs, bindividual performs restrained, individual 
B-factor refinement to assign a temperature factor to each atom in the model.
ANNEAL (Brunger et al. 1987; Brunger et al. 1990; Brunger 1992; Rice and 
Brunger 1994; Pannu and Read; Adams et al. 1997)
218
Structural Studies on Erythrina cristagalli Lectin and Botulinum Neurotoxin A
Part of the CNS Suite, this program performs crystallographic simulated 
annealing refinement. Anneal computes a cross-validated estimate of a-A, determines 
the weighting scheme between the X-ray refinement target function and the geometric 
energy function, refines a flat bulk solvent model and an overall anisotropic B value of 
the model by least-squares minimisation and subsequently refines the atomic positions 
by simulated annealing. The refinement can be run as either slow-cooling or constant- 
temperature simulated annealing refinement.
MODEL-MAP (Read 1986; Kleywegt and Brunger 1996; Brunger et al. 1997)
Part of the CNS Suite, the modeljnap programs prepares electron density 
maps using phase information from a model. The program includes a choice of 
coefficients and the option to average the structure factors from several models.
CIS_PEPTIDE
Part of the CNS Suite of programs this program can be used to identify cis- 
peptides in a protein structure. The program writes out an appropriate parameter file to 
maintain cis-peptide geometry during refinement.
WATER_PICK (Read 1986; Kleywegt and Brunger 1996)
Part of the CNS Suite, the water_pick program picks water molecules in an 
electron density map.
MAPMAN (Kleywegt and Jones 1996)
This is a program for manipulation and analysis of electron density maps. 
Applications within Mapman include conversion of maps produced by different 
programs; producing DSN6 map files for O; and simple mathematics on maps.
O (version 8.0) (Jones et al. 1991)
O is a general purpose macromolecular modelling environment in which the 
electron density maps can be displayed and the structural model viewed and edited. 
Amino acid residues can repositioned, mutated or rebuilt to fit the observed electron 
density, bonds can be drawn and distances between pairs of atoms determined. The 
model can also be displayed in several ways (e.g. ball-and stick).
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IMAGING PROGRAMS
MOLSCRIPT (Kraulis 1991)
A program for creating schematic or detailed molecular graphics images from 
molecular 3D coordinates. The program reads a PDB file and displays the structure in 
terms of its secondary structural elements, which can then be edited and specifically 
coloured to produce a molecular image. Specific atoms and/or amino acid side chains 
can be selected and displayed.
POVRAY
http://www. povray.org/
The “Persistence of Vision Raytracer” is a high-quality tool for creating three- 
dimensional graphics. It can display a Molscript file and allow manipulation of the data 




The “GNU Image Manipulation Program” can be used for image authoring and 
composition. GIMP can be used to edit and label images rendered using Povray. The 
edited images can then be output in a number of formats.
GRASP (Nicholls et al. 1991)
“Graphical Representation and Analysis of Surface Properties”
GRASP is a graphics program written for Silicon Graphics computers that is 
used to visualise macromolecules. Its strength compared to other such programs is its 
facility with surfaces and electrostatics.
PROGRAMS FOR STRUCTURAL ANALYSIS
PROCHECK (Laskowski et al. 1993)
Part of the CCP4 Suite, Procheck contains a set of programs that check the 
stereochemical quality of a protein structure and produce a number of Postscript plots 
analysing its overall and residue-by-residue geometry. CLEAN produces a “cleaned- 
up" version of the coordinates file. SECSTR calculates all the required torsion angles,
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main-chain hydrogen-bond energies and secondary structure assignments. The NB 
program identifies non-bonded interactions between different pairs of residues in the 
protein structure. ANGLEN calculates all main-chain bond lengths and bond angles in 
the structure and the root mean squared distances from a best-fit plane for all planar 
side chain groups. Finally, the TPLOT, PPLOT and BPLOT programs create the plots 
and residue-by-residue listing for the structure. The plots created include a 
Ramachandran plot; chil and chi2 plot; rmsd from planarity; and distorted geometry.
CONTACT and H-BONDS
This program (part of the CCP4 Suite) computes various types of contacts in 
protein structures and can also analyse water hydrogen bonding.
MODEL_STATS
Part of the CNS Suite of programs, model_stats produces a list of statistics 
about a crystallographic model. This includes R factors, B factors, deviation from ideal 
bond lengths and bond angles, solvent content and Luzzati coordinate error.
LSQKAB (superpose)
Part of the CCP4 Suite, Lsqkab is used to work out and apply various 
transformations to coordinate files. The program optimises the fit of a subset of atomic 
coordinates from one file to the same subset of another file and assumes both sets of 
coordinates are in the PDB format. Lsqkab can be used to calculate the root mean 
square coordinate difference between two structures.
PROGRAMS FOR CD SPECTRUM ANALYSIS
CONTINLL (Provencher and Glockner 1981; Van Stokkum et al. 1990)
CONTIN analyses the conformations of proteins from far-UV CD spectra using 
ridge regression analysis. The contribution of each reference spectrum to the analysis 
is kept small unless it contributes to a good agreement between the theoretical best-fit 
curve and the raw data. The fit depends upon the choice of proteins in the reference 
set and an estimate of secondary structural composition may be improved by including 
denatured proteins in the reference set for the random conformation.
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SELCON3 (Sreerama and Woody 1993; Sreerama et al. 1999)
SELCON uses a self-consistent method to deconvolute protein CD spectra. 
Proteins in the reference set are arranged in order of increasing rmsd from the CD 
spectrum to be analysed and those that are least like the spectrum of interest are 
deleted. Structural prediction improves when the protein analysed is included in the 
basis set because the solution is biased toward the test protein structure. An initial 
estimate of protein structure is included in the database and the secondary structure of 
the protein of interest is then determined. The solution replaces the initial estimate and 
the process is repeated until self-consistency is attained.
CDSSTR (Compton and Johnson 1986; Manavalan and Johnson 1987; 
Sreerama and Woody 2000)
CDSSTR implements the variable selection method by performing all possible 
calculations using a fixed number of proteins from the reference set. The algorithm 
recognises proteins possessing characteristics not reflected by the test protein or 
proteins not reflecting the characteristics of the test protein and removes them from the 
basis set. This method probably produces the most accurate analysis results and will 
produce results where other methods fail to analyse proteins.
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